Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-butyl-2-[[(4-oxo-3,4-dihydroquinazolin-2-yl)methyl]sulfanyl]-1H-benzimidazole-5-sulfonamide
classical competitive mechanism. No significant influence on 11beta-HSD activities
2-[(4-fluorobenzyl)[(2-fluorophenyl)sulfonyl]amino]-N-[2-(3-fluorophenyl)ethyl]acetamide
-
methyl 3-methyl-2-([2-nitro-4-(trifluoromethyl)phenyl]amino)butanoate
-
N-tert-butyl-2-(2-chloro-6-methoxy-4-([(3-methyl-5-sulfanyl-4H-1,2,4-triazol-4-yl)amino]methyl)phenoxy)acetamide
-
((3aR,4R,6S,6aR)-6-((Z)-(((4-hydroperoxybenzyl)oxy)imino)methyl)-4-hydroxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 3-chlorobenzoate
83% inhibition at 0.1 mM, oxyimino derivative, obtained by reaction of a 1,5-dicarbonyl substrate with O-(arylmethyl)hydroxylamine. Inhibitor reduces both cell death and the apoptotic process when tested in an in vitro model of diabetic retinopathy
(1H-indol-1-yl)acetic acid
-
(2,3-dihydrocyclopenta[b]indol-4(1H)-yl)acetic acid
-
(2-carbamoyl-5-fluorophenoxy)acetic acid
the carboxamide nitrogen can undergo a further H-bond to the additionally recruited water molecule W2 that in turn mediates H-bonded contacts involving the additional water molecule W3 to the amide bonds next to Leu300. Using water molecules W2 and W3 as mediating partners, the compound forms additional polar contacts to the protein
(2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
7fold selectivity for ALR2 over ALR1
(2-oxo-8-phenyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
-
(2-oxo-8-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
24fold selectivity for ALR2 over ALR1
(2-[(4-bromo-2-fluorobenzyl)carbamoyl]-5-chlorophenoxy)acetic acid
thermodynamic binding data for isoform ALR2 and mutants
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2R)-1-[(benzyloxy)carbonyl]-2,3-dihydro-1H-indole-2-carboxylic acid
CC-13401
(2S)-3beta,7,4'-trihydroxy-5-methoxy-8-(gamma,gamma-dimethylallyl)-flavanone
-
-
(2S)-7,4'-dihydroxy-5-methoxy-8-(gamma,gamma-dimethylallyl)-flavanone
-
potent inhibitor of recombinant human aldose reductase
(3-benzothiazol-2-yl-pyrrol-1-yl)acetic acid
-
50% inhibition at 49 nM
(3-methyl-1-oxo-5-phenylpyrimido[4,5-c]quinolin-2(1H)-yl)acetic acid
14fold selectivity for isoform AKR1B1 over AKR1B10
(3-sulfanyl-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(3-sulfanyl[1,2,5]triazepino[4,3-b]indol-6(3H)-yl)acetic acid
-
(3-[(5-chloro-1,3-benzothiazol-2-yl)methyl]-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetic acid
thermodynamic binding data for isoform ALR2 and mutants
(3-[[(2-fluorophenyl)methyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(3-[[2-oxo-2-(2,4,6-trimethylanilino)ethyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(4-benzothiazol-2-yl-2-benzoylpyrrol-1-yl)acetic acid
-
50% inhibition at 45 nM
(4-hydroxy-3-methoxyphenyl)acetonitrile
-
IC50: 0.0244 mM
(4-hydroxy-3-methoxyphenyl)methamine
-
IC50: 0.0634 mM
(4-hydroxyphenyl)(6-hydroxypyrazin-2-yl)methanone
-
isolated from red ascidian Botryllus leachi, pyrazine derivative, IC50: 0.0414 mM
(4-hydroxyphenyl)[4-(4-hydroxyphenyl)-1H-imidazol-2-yl]methanone
-
isolated from red ascidian Botryllus leachi, imidazole derivative, IC50: 0.0214 mM
(4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indol-5-yl)acetic acid
-
(5-chloro-2-[(3-nitrobenzyl)carbamoyl]phenoxy)acetic acid
thermodynamic binding data for isoform ALR2 and mutants
(5-chloro-2-[(4-cyanobenzyl)carbamoyl]phenoxy)acetic acid
-
-
(5-methylIndoleDs)1-(3-(3,4,5-trimethoxyphenyl)-3-(5-methyl-1H-indol-3-yl)propanoyl)-4-(5-methyl-1H-indol-3-yl)piperidin-2-one
-
-
(5-methylIndoleMs)1-(3-(3,4,5-trimethoxyphenyl)-3-(5-methyl-1H-indol-3-yl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
(5Z)-3-chloro-4-(3,5-dibromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.019 mM
(5Z)-3-chloro-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-4-(4-hydroxyphenyl)furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.0008 mM
(5Z)-4-(3,5-dibromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.020 mM
(5Z)-4-(3-bromo-4-hydroxyphenyl)-3-chloro-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.013 mM
(5Z)-4-(3-bromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.048 mM
(5Z)-4-(3-bromo-4-hydroxyphenyl)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-chlorofuran-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.017 mM
(5Z)-5-(3-aminobenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.69
(5Z)-5-(3-fluorobenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.04
(5Z)-5-(3-hydroxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.97
(5Z)-5-(3-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.88
(5Z)-5-(3-methylbenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.03
(5Z)-5-(3-phenoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.21
(5Z)-5-(3-{(E)-[(4-hydroxyphenyl)imino]methyl}benzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.73
(5Z)-5-(4-fluorobenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.09
(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.93
(5Z)-5-(4-hydroxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 5.05
(5Z)-5-(4-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.39
(5Z)-5-(4-{(E)-[(4-hydroxyphenyl)imino]methyl}benzylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.64
(5Z)-5-(naphthalen-1-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.97
(5Z)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-4-(4-hydroxyphenyl)furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.057 mM
(5Z)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-chloro-4-(4-hydroxyphenyl)furan-2(5H)-one
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.046 mM
(5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.89
(5Z)-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.50
(6H-indolo[2,3-b]quinoxalin-6-yl)acetic acid
-
(7H-indolo[2',3':5,6][1,2,4]triazino[2,3-a]benzimidazol-7-yl)acetic acid
uncompetitive
(8-methyl-3-[[2-oxo-2-(propylamino)ethyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
-
(E)-1-(3-(1,3-diphenyl-1H-pyrazol-4-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(2,5-dimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)piperidin-2-one
-
-
(E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)pyrrolidin-2-one
-
-
(E)-1-(3-(3-(trifluoromethyl)phenyl)acryloyl)-5,6-dihydropyridin-2(1)-one
-
-
(E)-1-(3-(3-methyl-1-phenyl-1H-pyrazol-4-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(3-phenoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(4-bromophenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(4-chlorophenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(benzo[d][1,3]dioxol-5-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(furan-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(naphthalen-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(pyridin-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-(thiophen-2-yl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(3-mesitylacryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-1-(4-benzylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-1-(4-methylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-1-(4-phenylpiperazin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-1-(piperidin-1-yl)-3-(3,4,5-trimethoxyphenyl) prop-2-en-1-one
-
-
(E)-1-(pyrrolidin-1-yl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
-
-
(E)-2-(3-(3,4,5-trimethoxyphenyl)acryloyl)benzo[d]isothiazol-3(2H)-one
-
-
(E)-2-(3-(3,4,5-trimethoxyphenyl)acryloyl)isoindolin-1-one
-
-
(E)-3-((4-chlorophenyl)(hydroxy)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-((4-fluorophenyl)(hydroxy)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(3-(3,4,5-trimethoxyphenyl)acryloyl)benzo[d]oxazol-2(3H)-one
-
-
(E)-3-(5-(3-nitrophenyl)furan-2-yl)acrylic acid
-
(E)-3-(hydroxy(2-nitrophenyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(4-nitrophenyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(naphthalen-2-yl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(p-tolyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(phenyl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(pyridin-2-yl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-3-(hydroxy(thiophen-2-yl)methyl)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one
-
-
(E)-4-(hydroxy(2-oxo-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-1,2,5,6-tetrahydropyridin-3-yl)methyl)benzonitrile
-
-
(E)-methyl 3-(3,4,5-trimethoxyphenyl)acrylate
-
-
(E)-N-ethanethioyl-3-(3,4,5-trimethoxyphenyl)acrylamide
-
-
(E,E)-5[2-methyl-3-phenyl-2-propenylidene-4-oxo-2-thioxo-3-thiazolidine]acetic acid
(NH4)2SO4
-
0.05 mM: slight inhibition, 400 mM: activation
(S)-6-fluorospiro[chroman-4,5'-imidazolidine]-2',4'-dione
(Z)-2-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-N-hydroxyacetamide
-
(Z)-2-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
18% inhibition at 0.0125 mM
(Z)-2-(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
32% inhibition at 0.0125 mM
(Z)-2-(5-naphthalen-2-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
3% inhibition at 0.0125 mM
(Z)-2-[2,4-dioxo-5-(3-phenoxybenzylidene)thiazolidin-3-yl]acetamide
8% inhibition at 0.0125 mM
(Z)-2-[5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
16% inhibition at 0.0125 mM
(Z)-2-[5-(3-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
10% inhibition at 0.0125 mM
(Z)-2-[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]-N-hydroxyacetamide
-
(Z)-2-[5-(4-hydroxy-3-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
-
(Z)-2-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
31% inhibition at 0.0125 mM
(Z)-N-hydroxy-2-(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
-
(Z)-N-hydroxy-2-(5-naphthalen-2-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
39% inhibition at 0.025 mM
(Z)-N-hydroxy-2-[2,4-dioxo-5-(3-phenoxybenzylidene)-thiazolidin-3-yl]acetamide
-
(Z)-N-hydroxy-2-[2,4-dioxo-5-(4-phenoxybenzylidene)-thiazolidin-3-yl]acetamide
-
(Z)-N-hydroxy-2-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
-
([2-[(4-methoxy-1-methyl-1H-indazol-3-yl)amino]-2-oxoethyl]sulfanyl)acetic acid
HTS-03834
([5-(5-nitrofuran-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl)acetic acid
crystallization data
1'-(4-fluorobenzene-1-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
no selectivity for ALR2 over ALR1
1'-(5-chlorothiophene-2-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
3.4fold selectivity for ALR2 over ALR1
1-((2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)penta-2,4-dienoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-((2E,4E,6E)-7-(3,4,5-trimethoxyphenyl)hepta-2,4,6-trienoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(2-chlorobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(2-iodobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(1-benzyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(1-benzyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(1-benzyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(1-methyl-1H-indol-3-yl)propanoyl)-4-(1-methyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(1-methyl-1H-indol-3-yl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(2-methyl-1H-indol-3-yl)propanoyl)-4-(2-methyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(2-phenyl-1H-indol-3-yl)propanoyl)-4-(2-phenyl-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(5-methoxy-1H-indol-3-yl)propanoyl)-4-(5-methoxy-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(5-nitro-1H-indol-3-yl)propanoyl)-4-(5-nitro-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(3,4,5-trimethoxyphenyl)-3-(5-nitro-1H-indol-3-yl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-bromo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(5-bromo-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(5-bromo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-fluoro-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(5-fluoro-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(5-fluoro-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-iodo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-4-(5-iodo-1H-indol-3-yl)piperidin-2-one
-
-
1-(3-(5-iodo-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(3-(5-methoxy-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(4-fluorobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(4-fluorophenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
2.1fold selectivity for ALR2 over ALR1
1-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
8.5fold selectivity for ALR2 over ALR1
1-(4-methylphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
1.5fold selectivity for ALR2 over ALR1
1-(4-nitrobenzoyl)-5,6-dihydropyridin-2(1H)-one
-
-
1-(5-chlorothiophen-2-yl)-1,3-diazaspiro[4.5]decane-2,4-dione
1.9fold selectivity for ALR2 over ALR1
1-cinnamoyl-5,6-dihydropyridin-2(1H)-one
-
-
1-O-Galloyl-beta-D-glucose
i.e. beta-glucogallin or BGG, a major component of the Emblica officinalis medicinal plant, and a stable, potent, and specific inhibitor of aldose reductase, noncompetitive inhibition through binding the active site of AKR1B1, occupying both the anionic and the specificity pockets
1-[3-(2-phenyl-1H-indol-3-yl)-3-(3,4,5-trimethoxyphenyl)propanoyl]-5,6-dihydropyridin-2(1H)-one
-
-
2,1,3-benzoxadiazol-5-yl 5-chlorothiophene-2-sulfonate
KM-07100
2,2'-[sulfonylbis(benzene-4,1-diyliminomethylylidene)]dipropanedinitrile
BTB-06667
2,2,2-trifluoro-1-[1-(1-hydroxy-1H-pyrazol-4-yl)-4-[4-(methylsulfanyl)benzoyl]-1H-pyrrol-2-yl]ethan-1-one
mixed-type inhibition
2,2,2-trifluoro-1-[4-(4-fluorobenzoyl)-1-(1-hydroxy-1H-pyrazol-4-yl)-1H-pyrrol-2-yl]ethan-1-one
mixed-type inhibition
2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione
-
2,6-dichlorophenylacetic acid
-
competitive
2-(3,4-dimethoxyphenyl)-ethanoic acid
-
IC50: 0.0303 mM
2-(4-hydroxy-3-methoxyphenyl)ethanoic acid
-
derived from ginger rhizom, Zingiber officinale, IC50: 0.0185 mM, suppresses nt only sorbitol accumulation in human erythrocytes
2-(4-hydroxy-3-methoxyphenyl)ethanol
-
derived from ginger rhizom, Zingiber officinale, IC50: 0.0192 mM, suppresses sorbitol accumulation in human erythrocytes
2-(carboxymethyl)-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide
crystallization data
2-amino-4-oxo-3,4-dihydropteridine-6-carboxylic acid
-
2-amino-4-oxo-3,4-dihydropteridine-7-carboxylic acid
-
2-bromophenylacetic acid
-
competitive
2-Chlorophenylacetic acid
-
competitive
2-hydroxyphenylacetic acid
-
competitive
2-naphthylacetic acid
-
competitive
2-oxo-3-(3,4,5-trihydroxyphenoxy)-1,8-naphthyridine-1(2H)-carboxylic acid
21.7fold selectivity for AKR1B1 over AKR1A1
2-oxo-3-(3,4,5-trimethoxyphenoxy)-1,8-naphthyridine-1(2H)-carboxylic acid
20.8fold selectivity for AKR1B1 over AKR1A1
2-oxo-3-phenoxy-1,8-naphthyridine-1(2H)-carboxylic acid
27fold selectivity for AKR1B1 over AKR1A1
2-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]-4-phenylbutanoic acid
-
2-[2-(carboxymethoxy)-2-oxoethyl]-1-oxo-1,2-dihydronaphtho[1,2-d]isothiazole-4-carboxylic acid 3,3-dioxide
crystallization data
3'-(4-fluorobenzene-1-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
10fold selectivity for ALR2 over ALR1
3'-(5-chlorothiophene-2-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
1.1fold selectivity for ALR2 over ALR1
3,3-Tetramethylene glutaric acid
-
-
3,4-dihydroxyphenylacetic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
3,4-dinitro-2,5-bis(phenylsulfanyl)thiophene
SEW-05367
3,5-dichlorosalicylic acid
uncompetitive inhibition
3-(1H-indol-1-yl)propanoic acid
-
3-(2,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
-
a gamma,gamma-dimethylallyl type prenylated isoflavonoid
3-(2-phenylthiazole-4-yl)propanoic acid
-
3-(3,4,5-trimethoxyphenyl)-3-(2-methyl-1H-indol-3-yl)propanoic acid
-
-
3-(3,4-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
16.9fold selectivity for AKR1B1 over AKR1A1
3-(3,4-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
17.6fold selectivity for AKR1B1 over AKR1A1
3-(3,5-dihydroxy-4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
25.8fold selectivity for AKR1B1 over AKR1A1
3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
20.8fold selectivity for AKR1B1 over AKR1A1
3-(3,5-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
21.5fold selectivity for AKR1B1 over AKR1A1
3-(3-hydroxy-4,5-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
31.6fold selectivity for AKR1B1 over AKR1A1
3-(3-hydroxy-4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
19.3fold selectivity for AKR1B1 over AKR1A1
3-(3-hydroxy-5-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
15.1fold selectivity for AKR1B1 over AKR1A1
3-(4-fluorophenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
2.3fold selectivity for ALR2 over ALR1
3-(4-hydroxy-3-methoxyphenyl)propanol
-
IC50: 0.283 mM
3-(4-hydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
15.9fold selectivity for AKR1B1 over AKR1A1
3-(4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
20fold selectivity for AKR1B1 over AKR1A1
3-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
1.2fold selectivity for ALR2 over ALR1
3-(4-methylphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
11fold selectivity for ALR2 over ALR1
3-(4-nitrophenyl)-2-[(phenylsulfonyl)amino]propanoic acid
SPB-08302
3-(5-(3-(trifluormethyl)phenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-acetylphenyl)furan-2-yl)propanoic acid
-
3-(5-(3-aminophenyl)furan-2-yl)propanoic acid
-
3-(5-(3-methoxyphenyl)furan-2-yl)propanoic acid
-
3-(5-(3-methoxyphenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-methylphenyl)furan-2-yl)propanoic acid
-
3-(5-(3-methylphenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-methylsulfonyl)phenylfuran-2-yl)propanoic acid
-
3-(5-(3-nitrophenyl)furan-2-yl)propanoic acid
-
3-(5-(3-nitrophenyl)thiophene-2-yl)propanoic acid
-
3-(5-(3-trifluormethyl)phenylfuran-2-yl)propanoic acid
-
3-(5-chlorothiophen-2-yl)-1,3-diazaspiro[4.5]decane-2,4-dione
127fold selectivity for ALR2 over ALR1, 79% reduction in blood glucose level
3-(5-phenylfuran-2-yl)propanoic acid
-
3-(5-phenylthiophene-2-yl)propanoic acid
-
3-(5-pyridine-2-yl-furan-2-yl)propanoic acid
-
3-(5-pyridine-3-yl-furan-2-yl)propanoic acid
-
3-benzyl-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-methylbenzenesulfonate
NRB-05245
3-hydroxy-4-methoxymandelic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
3-hydroxybutyric acid
-
-
3-nitro-L-tyrosine
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
3-[(4-bromo-2-fluorophenyl)methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
-
recombinant from baculovirus system in Spodoptera frugiperda cells
3-[2-(carboxymethoxy)-4-fluorobenzamido]benzoic acid
the ligand directs its acid group toward the surrounding solvent and accommodates the hydrophobic cleft adjacent to the sealed specificity pocket
3-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
-
a gamma,gamma-dimethylallyl type prenylated isoflavonoid
3-[3-[(diethylamino)methyl]-1H-indol-1-yl]propanoic acid
-
4-(4-hydroxy-3-methoxyphenyl)-2-butanone
-
IC50: 0.197 mM
4-(4-hydroxy-3-methoxyphenyl)butanol
-
IC50: 0.642 mM
4-(5-(3-methylphenyl)thiophene-2-yl)butanoic acid
-
4-(5-phenylthiophene-2-yl)butanoic acid
-
4-androsten-17alpha-ol-3-one
i.e. epitestosterone
4-androsten-17beta-ol-3-one
i.e. testosterone
4-androstene-3,17-dione
-
4-hydroxy-3-methoxymandelic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
4-hydroxy-3-methoxyphenol
-
IC50: 0.273 mM
4-hydroxy-3-methoxyphenyl methanol
-
IC50: 0.0244 mM
4-hydroxy-3-methoxyphenylacetic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
4-hydroxy-3-methoxyphenyllactic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
4-hydroxybenzoic acid
-
-
4-oxo-4-(5-(3-methylphenyl)thiophene-2-yl)butanoic acid
-
4-oxo-4-(5-phenylthiophen-2-yl)butanoic acid
-
4-pregenene-21-ol-3,20-dione
i.e. 11-deoxycorticosterone
4-pregnene-11beta,17alpha,21-triol-3,20-dione
i.e. cortisol
4-pregnene-11beta,21-diol-3,20-dione
i.e. corticosterone
4-pregnene-17alpha,21-diol-3,11,20-trione
i.e. cortisone
4-pregnene-18-al-11beta,21-diol-3,20-dione
i.e. aldosteron
4-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]butanoic acid
-
4-[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid
crystallization data
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
4-[5,7-dimethoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl]benzene-1,3-diol
-
a gamma,gamma-dimethylallyl type prenylated isoflavonoid
4-[7-hydroxy-5-methoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl]benzene-1,3-diol
-
a gamma,gamma-dimethylallyl type prenylated isoflavonoid
5,5-diphenylhydantoin
-
-
5,6-dihydro-1-((E)-3-(3,4,5-trimethoxyphenyl)acryloyl)pyridin-2(1H)-one
-
-
5-(3-phenoxybenzyl)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.10
5-(4-phenoxybenzyl)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.39
5-(biphenyl-4-ylmethyl)-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.18
5-androsten-3beta-ol-17-one
i.e. dehydroepiandrosterone
5-cholenic acid-3beta-ol
-
5-oxo-3-phenyl-5-(quinolin-2-ylamino)pentanoic acid
HTS-06058
5-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]pentanoic acid
-
5-[4-(benzyloxy)benzyl]-1,3-thiazolidine-2,4-dione
-
pIC50 is 4.50
5alpha-Androstan-17alpha-ol-3-one
-
5alpha-androstan-17beta-ol-3-one
i.e. 5alpha-dehydrotestosterone
5alpha-Androstan-3alpha-ol-17-one
-
5alpha-Androstan-3beta-ol-17-one
competitive inhibition with respect to geraniol
5alpha-androstane-3,17-dione
competitive inhibition with respect to geraniol
5alpha-androstane-3alpha,17beta-diol
-
5alpha-Androstane-3beta,17beta-diol
-
5alpha-cholanic acid-3beta-ol
-
5alpha-pregnan-3beta-ol-20-one
-
5alpha-pregnane-21-ol-3,20-dione
-
5alpha-pregnane-3,20-dione
competitive inhibition with respect to geraniol
5beta-androstan-17beta-ol-3-one
-
5beta-Androstan-3alpha-ol-17-one
-
5beta-androstan-3beta-ol-17-one
-
5beta-androstane-3,17-dione
-
5beta-androstane-3beta,17beta-diol
-
5beta-cholanic acid
competitive inhibition with respect to geraniol
5beta-cholanic acid methyl ester
-
5beta-cholanic acid-3-one
-
5beta-cholanic acid-3alpha,12alpha-diol
i.e. chenodeoxycholic acid
5beta-cholanic acid-3alpha,6alpha-diol
i.e. hyodeoxycholic acid
5beta-cholanic acid-3alpha,7alpha,12alpha-triol
i.e. cholic acid
5beta-cholanic acid-3alpha,7alpha-diol
i.e. deoxycholic acid
5beta-cholanic acid-3alpha,7beta-diol
i.e. ursodeoxycholic acid
5beta-cholanic acid-3alpha-ol
i.e. lithocholic acid
5beta-cholanic acid-3beta-ol
i.e. isolithocholic acid
5beta-Pregnan-3alpha-ol-20-one
-
5beta-Pregnan-3beta-ol-20-one
-
5beta-pregnane-3,20-dione
-
6',6''-dinitrorosmarinic acid
docking structure with ALR2, overview
6'-nitrorosmarinic acid
docking structure with ALR2, overview
6-bromo-3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
19.8fold selectivity for AKR1B1 over AKR1A1
6-chloro-3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
18.4fold selectivity for AKR1B1 over AKR1A1
6-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]hexanoic acid
-
6-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]pyridazin-3(2H)-one
binding structure, inhibition mechanism, residues Trp111, His110, Thr113, Tyr48, Trp20, and Phe122, and the residues of the C-terminal loop Ala299, Leu300, Leu301, Ser302, Cys303 are involved, overview
6-[[(di(2,4-dimethoxyphenyl)methylidene)amino]oxy]hexanoic acid
-
-
6-[[(di(3,5-dimethoxyphenyl)methylidene)amino]oxy]hexanoic acid
-
-
6-[[(di(4-methoxy-3-methylphenyl)methylidene)amino]oxy]hexanoic acid
-
-
7-Hydroxy-4-oxo-4H-chromen-2-carboxylic acid
-
-
8-lavandulylkaempferol
-
potent inhibitor of recombinant human aldose reductase
8-methoxy-N-[(1S)-2-methyl-1-(5-phenyl-1H-imidazol-2-yl)propyl]-2H-1-benzopyran-3-carboxamide
-
8-methoxy-N-[(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
-
8-methoxy-N-[[5-(4-methoxyphenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
bezafibrate
-
noncompetitive, IC50: 0.003 mM, recombinant enzyme
butein
-
89.9% inhibition at 0.002 mM
Cibacron blue F3GA
competitive inhibition with respect to NADP+, noncompetitive inhibition with respect to geraniol
ciprofibrate
-
competitive, IC50: 0.00086 mM, recombinant enzyme
citrate
-
inhibition is pH-dependent
Clofibric acid
-
noncompetitive, IC50: 0.0012 mM, recombinant enzyme
coptisine
-
53.85-61.54% inhibition at 0.075 mg/ml
CuCl2
-
0.007 mM, 20% residual activity, addition of dithiothreitol recovers activity
curcumin
inhibits ALR2 in a non-competitive manner, also inhibits AKR1B10, docking analysis and kinetics, overview. Curcumin is able to suppress sorbitol accumulation in human erythrocytes under high glucose conditions
desmethylanhydroicaritin
-
potent inhibitor of recombinant human aldose reductase
dithiothreitol
-
increased inhibitory effect of sorbinil
DL-dihydrolipoic acid
-
binds very tight to the enzyme, best inhibitor of the investigated, competitive
DL-lipoamide
-
binds three-fold more weakly than D,L-lipoic acid, competitive
DL-lipoic acid
-
is effective in the treatment of diabetic complications, binds tightly to the enzyme, competitive
epiberberine
-
69.23-76.92% inhibition at 0.075 mg/ml
estriol
i.e. 16alpha-hydroxyestradiol
ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate
-
an AR inhibitor, abolishes the accumulation of TPA-treated cells in S phase was almost completely
fenofibrate
-
competitive, IC50: 0.00056 mM, recombinant enzyme
fisetin
-
31.1% inhibition at 0.002 mM
fustin
-
20.1% inhibition at 0.002 mM
gemfibrozil
-
noncompetitive, IC50: 0.0065 mM, recombinant enzyme
glycochenodeoxycholic acid
-
groenlandicine
-
69.23-76.92% inhibition at 0.075 mg/ml
hexanoic acid
-
competitive
isolithocholic acid
uncompetitive inhibition with respect to NADP+, competitive inhibition with respect to geraniol
kushenol E
-
potent inhibitor of recombinant human aldose reductase
L-tyrosine
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
Li2SO4
-
0.4 M: essential for full activity
lithocholic acid
competitive inhibition with respect to geraniol
lukianol B
-
IC50: 0.0006 mM
Mandelic acid
-
competitive
methyl [(5Z)-2,4-dioxo-5-(3-phenoxybenzylidene)-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.88
methyl [(5Z)-5-(3-aminobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 4.41
methyl [(5Z)-5-(3-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.05
methyl [(5Z)-5-(3-methylbenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.00
methyl [(5Z)-5-(4-fluorobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 4.89
methyl [(5Z)-5-(4-hydroxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 5.21
methyl [5-(3-methoxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetate
-
pIC50 is 4.68
methyl {(5Z)-2,4-dioxo-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetate
-
pIC50 is 4.54
methyl {(5Z)-2,4-dioxo-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetate
-
pIC50 is 5.46
Morin hydrate
-
14.1% inhibition at 0.002 mM
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-beta-alanine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-alanine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-isoleucine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-leucine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-phenylalanine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-serine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-tyrosine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-valine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycine
-
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycyl-L-phenylalanine
9% inhibition at 10.5 mM
N-(2-phenylethyl)-N-{[4-(trifluoromethyl)phenyl]sulfonyl}glycine
-
-
N-cyclopropyl-N-[cyclopropyl(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
-
N-cyclopropyl-N-[cyclopropyl(5-phenyl-1H-imidazol-2-yl)methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-cyclopropyl-N-[cyclopropyl[5-(pyridin-3-yl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-cyclopropyl-N-[cyclopropyl[5-(pyridin-3-yl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-galloyl beta-D-glucopyranosylamine
-
N-[(1S)-1-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-methylpropyl]-2H-1-benzopyran-3-carboxamide
-
N-[(1S)-1-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-methylpropyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[(1S)-2-methyl-1-(5-phenyl-1H-imidazol-2-yl)propyl]-2H-1-benzopyran-3-carboxamide
-
N-[(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-bromophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-bromophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl](cyclopropyl)methyl]-N-cyclopropyl-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl](cyclopropyl)methyl]-N-cyclopropyl-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
-
N-[[5-(4-methoxyphenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
-
N-[[6-methoxy-5(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine
N2-(2-methylaminobenzoyl)tetrahydro-1H-pyrido[3,4-b]indol-1-one
-
i.e. rhetsinine, from Evodia rutaecarpa hot water extract. Rhetsinine inhibits sorbitol accumulation by 79.3% at 0.1 mM in erythrocytes
naringenin
uncompetitive. The interaction is enthalpy driven and the microenvironment of aromatic residues is also altered. Naringenin inhibits fructosamine content by approximately 31.6% at 0.01 mM, and more than 93% inhibition of fluorescent advanced glycation end-products is achieved. Naringenin forms hydrogen bonds (Asn160 and Ile260), and two Pi-Pi interactions with Trp20 and one with His110
nitric oxide
-
from NO donors S-nitroso-N-acetylpenicillamine or S-nitrosoglutathione in vivo and in vitro, leads to increased S-glutathiolation of the enzyme
p-hydroxymercuribenzoate
-
-
pentagalloyl glucose
-
46.6% inhibition at 0.002 mM
phenylacetic acid
-
competitive
protocatechuic acid
-
12.6% inhibition at 0.002 mM
pyrazolo[5,1-c][1,2,4]benzotriazin-8-yl dimethylcarbamate
EN-00263
rosmarinic acid
docking structure with ALR2, overview
S-nitrosoglutathione
-
0.05 mM, up to 40% inhibition, possibly due to selctive formation of a single mixed disulfide between glutathione and Cys298
semilicoisoflavone B
-
contains a gamma,gamma-dimethylchromene ring on the aromatic ring
Statil
molecular modeling redicts an enhancement of net binding energy of the complex by 33% through replacement of the fluorine atom of statil by a carboxylate group
sulfuretin
-
69.8% inhibition at 0.002 mM
sulindac
exhibits both the highest inhibitory activity towards human aldose reductase among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes, uncompetitive inhibition, enzyme binding structure, overview
sulindac sulfide
enzyme binding structure, overview
sulindac sulfone
enzyme binding structure, overview
Tolmetin
enzyme binding structure, overview
[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino](phenyl)acetic acid
-
[(3-[[(3-nitrophenyl)methyl]carbamoyl][1,1'-biphenyl]-4-yl)oxy]acetic acid
-
[(5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]acetic acid
-
[(5Z)-2,4-dioxo-5-(3-phenoxybenzylidene)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.89
[(5Z)-2,4-dioxo-5-(4-phenoxybenzylidene)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.09
[(5Z)-5-(3-fluorobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.13
[(5Z)-5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.25
[(5Z)-5-(3-hydroxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.18
[(5Z)-5-(3-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.32
[(5Z)-5-(3-methylbenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.19
[(5Z)-5-(3-nitrobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.31
[(5Z)-5-(4-fluorobenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.94
[(5Z)-5-(4-hydroxy-3-methoxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.15
[(5Z)-5-(4-hydroxybenzylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.82
[(5Z)-5-(biphenyl-4-ylmethylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.59
[(5Z)-5-(naphthalen-1-ylmethylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.77
[2,4-dioxo-5-(3-phenoxybenzyl)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 6.00
[2,4-dioxo-5-(4-phenoxybenzyl)-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.55
[2-(ethynylcarbamoyl)-5-fluorophenoxy]acetic acid
the ligand exhibits a terminal pi-electron rich substituent at the amide function, which fills the cleft between Leu300 and Trp219 next to the sealed specificity pocket
[2-oxo-8-[(E)-2-phenylethenyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
9fold selectivity for ALR2 over ALR1
[2-[(1,3-benzothiazol-2-yl)carbamoyl]-5-fluorophenoxy]acetic acid
an H-bond is formed between the backbone Leu300NH group and the nitrogen atom of the benzothiazolyl moiety
[3-(2,2-dimethylpropanoyl)-1H-indol-1-yl]acetic acid
-
[3-(2,4-dihydroxyphenyl)-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-(2,5-dihydroxyphenyl)-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
-
-
[3-[(diethylamino)methyl]-1H-indol-1-yl]acetic acid
-
[3-[(dimethylamino)methyl]-2-methyl-1H-indol-1-yl]acetic acid
-
[3-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
most potent activity
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
most active inhibitor evaluated
[3-[(morpholin-4-yl)methyl]-1H-indol-1-yl]acetic acid
-
[3-[(propan-2-yl)sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl]acetic acid
-
[3-[(pyrrolidin-1-yl)methyl]-1H-indol-1-yl]acetic acid
-
[3-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[3-[2-(4-hydroxyphenyl)ethyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
-
[5-(3-carboxymethoxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
i.e. CMD, a potent inhibitor of ALR2, but not for ALR1, structure molecular modelling, overview. The non-conserved C-terminal residue Leu300 in ALR2, which is Pro301 in ALR1, contributes to inhibitor selectivity
[5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
i.e. HMD, modelling of inhibitor-enzyme active site complex
[5-(3-methoxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.53
[5-(4-bromophenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
-
[5-(4-chlorophenyl)-1-oxo-3-propylpyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
18fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-3-ethyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
39fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-3-ethyl-9-fluoro-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
9fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
37fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-chlorophenyl)-9-fluoro-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
3fold selectivity for isoform AKR1B1 over AKR1B10
[5-(4-hydroxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.68
[5-(4-methoxybenzyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.97
[5-(biphenyl-4-ylmethyl)-2,4-dioxo-1,3-thiazolidin-3-yl]acetic acid
-
pIC50 is 5.77
[5-fluoro-2-(phenylcarbamoyl)phenoxy]acetic acid
ligand is among the weakest of the known ALR2 binders that open the specificity pocket
[5-fluoro-2-[(3-nitrophenyl)carbamoyl]phenoxy]acetic acid
the ligand opens the specificity pocket with its terminal benzyl moiety and places the meta attached nitro group deeply in the transient pocket
[5-fluoro-2-[(4,5,7-trifluoro-1,3-benzothiazol-2-yl)carbamoyl]phenoxy]acetic acid
-
[5-fluoro-2-[[[(4,5,7-trifluoro-2-benzothiazolyl)methyl]amino]carbonyl]phenoxy]acetic acid
-
[6-ethyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
-
-
[6-hydroxy-3-(4-hydroxyphenoxy)pyrazin-2-yl](4-hydroxyphenyl)methanone
-
isolated from red ascidian Botryllus leachi, pyrazine derivative, IC50: 0.0194 mM
[6-methoxy-2-oxo-3-(2,4,6-trihydroxyphenyl)quinoxalin-1(2H)-yl]acetic acid
-
[6-methyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
-
-
[7-methoxy-2-oxo-3-(2,4,6-trihydroxyphenyl)quinoxalin-1(2H)-yl]acetic acid
-
[7-methoxy-2-oxo-3-[(E)-2-phenylethenyl]quinoxalin-1(2H)-yl]acetic acid
-
[8-(4-formylphenyl)-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-(4-methoxyphenyl)-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-fluorophenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
25.7fold selectivity for ALR2 over ALR1
[8-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
24fold selectivity for ALR2 over ALR1
[8-[(E)-2-(4-hydroxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
60fold selectivity for ALR2 over ALR1
[8-[(E)-2-(4-methoxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-methylphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-nitrophenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[8-[(E)-2-(4-tert-butylphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
4fold selectivity for ALR2 over ALR1
[8-[(E)-2-([1,1'-biphenyl]-4-yl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
-
[9-fluoro-5-(4-methoxyphenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
9fold selectivity for isoform AKR1B1 over AKR1B10
[[(4-methylphenyl)sulfonyl](2-thiophen-2-ylethyl)amino]acetic acid
S-12728
{(5Z)-2,4-dioxo-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.33
{(5Z)-2,4-dioxo-5-[4-(trifluoromethyl)benzylidene]-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.34
{(5Z)-5-[3-(carboxymethoxy)-4-ethoxybenzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 5.85
{(5Z)-5-[3-(carboxymethoxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.64
{(5Z)-5-[4-(benzyloxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.55
{(5Z)-5-[4-(carboxymethoxy)-3-methoxybenzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.59
{(5Z)-5-[4-(carboxymethoxy)benzylidene]-2,4-dioxo-1,3-thiazolidin-3-yl}acetic acid
-
pIC50 is 6.22
(E,E)-5[2-methyl-3-phenyl-2-propenylidene-4-oxo-2-thioxo-3-thiazolidine]acetic acid
-
-
(E,E)-5[2-methyl-3-phenyl-2-propenylidene-4-oxo-2-thioxo-3-thiazolidine]acetic acid
-
recombinant from baculovirus system in Spodoptera frugiperda cells
(S)-6-fluorospiro[chroman-4,5'-imidazolidine]-2',4'-dione
-
-
(S)-6-fluorospiro[chroman-4,5'-imidazolidine]-2',4'-dione
-
wild type and recombinant from E. coli
(S)-6-fluorospiro[chroman-4,5'-imidazolidine]-2',4'-dione
-
recombinant from baculovirus system in Spodoptera frugiperda cells
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
SB-02066
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
SEW-01456
Alrestatin
-
-
Alrestatin
-
1,3-dioxo-1H-benz[de]isoquinoline-2-(3H)acetic acid
Alrestatin
-
inhibits aldose reductase, does not appear to affect RUNX2 activation in cells exposed to euglycemia
Cl-
-
-
Cl-
-
0.2 M, wild type and recombinant from E. coli
epalrestat
-
-
epalrestat
-
orally active inhibitor
epalrestat
-
85.8% inhibition at 0.0025 mM
epalrestat
26.7fold selectivity for ALR2 over ALR1
epalrestat
55.7fold selectivity for isoform AKR1B1 over AKR1A1
fidarestat
-
-
fidarestat
complex formation with the enzyme
fidarestat
-
i.e. inhibitor F, inhibition in vivo and in vitro
fidarestat
thermodynamic binding data for isoform ALR2 and mutants
fidarestat
-
aldose reductase inhibitor, attenuates the increase in growth, but in the absence of angiogenic factors, such as VEGF- and FGF, fidarestat alone does not affect the HUVEC growth
fidarestat
an inhibitor highly selective for aldose reductase (AKR1B1, EC 1.1.1.21) versus aldehyde reductase (AKR1A1, EC 1.1.1.2). Inhibitor binding site and structure comparisons of enzymes AKR1B1 and AKR1B10, overview. Fidarestat is specific for aldose reductase AKR1B1 versus aldose reductae-like AKR1B10
fidarestat
significantly inhibits the enzyme activity as well as the enzyme expression
glycolithocholic acid
-
glycolithocholic acid
competitive inhibition with respect to geraniol
IDD 594
-
IDD 594
binding structure, inhibition mechanism, overview
IDD594
-
-
kuraridin
-
-
kuraridin
-
potent inhibitor of recombinant human aldose reductase
lidorestat
-
-
lidorestat
binding mode, overview
minalrestat
-
-
minalrestat
uncompetitive inhibition
minalrestat
complex formation with the enzyme
N-[[6-methoxy-5(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine
-
-
N-[[6-methoxy-5(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine
-
wild type and recombinant from E. coli
N-[[6-methoxy-5(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methylglycine
-
recombinant from baculovirus system in Spodoptera frugiperda cells
ponalrestat
-
-
ponalrestat
-
wild type and recombinant from E. coli
quercetin
-
-
quercetin
uncompetitive inhibition
quercetin
-
IC50: 0.027 mM
quercetin
-
39.1% inhibition at 0.002 mM
quercetin
-
potent inhibitor of recombinant human aldose reductase
sorbinil
-
-
sorbinil
-
inhibition of enzyme, preventing apotosis and activation of caspase-3, attenuation of TNF-alpha and hyperglykemia-induced activation of protein kinase C
sorbinil
-
competitive, IC50: 0.0021 mM, recombinant enzyme
sorbinil
complex formation with the enzyme
sorbinil
-
enzyme inhibition abolishes fibroblast growth factorinduced and platelet-derived growth factorinduced up-regulation of PGE2 synthesis and lipid-adehyde signaling, e.g. by 4-hydroxy-trans-2-nonenal, in Caco-2 cells, overview
sorbinil
-
in vivo inhibition potentiates apoptosis due to lipid aldehydes, overview
sorbinil
-
orally active inhibitor, IC50: 0.0036 mM
sorbinil
-
inhibition significantly prevents the tumor necrosis factor alpha-induced prostaglandin E2 production in Caco-2 cells
sorbinil
thermodynamic binding data for isoform ALR2 and mutants
Tolrestat
-
-
Tolrestat
uncompetitive inhibition
Tolrestat
-
0.001 mM, about 50% inhibition
Tolrestat
-
inhibition of enzyme, preventing apotosis and activation of caspase-3, attenuation of TNF-alpha and hyperglykemia-induced activation of protein kinase C
Tolrestat
-
orally active inhibitor
Tolrestat
-
inhibition significantly prevents the tumor necrosis factor alpha-induced prostaglandin E2 production in Caco-2 cells
Tolrestat
thermodynamic binding data for isoform ALR2 and mutants
Tolrestat
uncompetitive inhibition with respect to NADP+, competitive inhibition with respect to geraniol
vanillic acid
-
-
vanillic acid
able to prevent the formation of the tubulin/aldose reductase complex and the activation of aldose reductase by tubulin
Zenarestat
-
-
Zenarestat
-
orally active inhibitor
zopolrestat
-
-
zopolrestat
-
0.001 mM, about 30% inhibition
zopolrestat
-
competitive, IC50: 0.00006 mM, recombinant enzyme
zopolrestat
thermodynamic binding data for isoform ALR2 and mutants
additional information
-
aldose reductase inhibitors have considerable potential for the treatment of diabetes, without increased risk of hypoglycemia, structure-activity relationship study, the applicable side alkyl chain length and the presence of a OCH3 group at C3 in the aromatic ring are essential features for enzyme recognition and binding, no or poor inhibition by gingerol, shogaol, 2-(4-hydroxy-3-nitrophenyl)ethanoic acid, 2-(3,4-dihydroxyphenyl)ethanoic acid, and 2-(4-hydroxyphenyl)ethanoic acid
-
additional information
-
enzyme inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in high-glucose exposed mesengial cells
-
additional information
-
enzyme-inhibitor complex structures, the hydrophobic nature of the enzyme active site makes significant contributions to inhibitor binding rather than a reliance on pi-pi orbital interactions with Trp 20, overview
-
additional information
-
inhibition of AR protects the ischemic myocardium and is associated with improved energy metabolism
-
additional information
Arg312 in ALR1 contributes favourably to the binding of 3,5-dichlorosalicylic acid through an electrostatic interaction with the inhibitor's electronegative halide atom and undergoes a conformational change upon tolrestat binding. Tyr116 in ALR1 forms electrostatic interactions with the fluorobenzyl moiety of minalrestat and the 3- and 4-hydroxy groups on the phenyl ring of quercetin.
-
additional information
not inhibited by (Z)-2-[2,4-dioxo-5-(4-phenoxybenzylidene)thiazolidin-3-yl]acetamide, (Z)-2-[5-(4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide, and (Z)-2-[5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
-
additional information
-
development of series of highly potent and selective [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid aldose reductase inhibitors. The compounds inhibit aldose reductase, but are inactive against aldehyde reductase
-
additional information
enzyme active site interactions with the 3-carboxymethoxy-4-methoxy-phenyl moiety of the inhibitor, binding structure, overview
-
additional information
-
identification of inhibitory compounds from Glycyrrhiza uralensis, overview
-
additional information
-
inhibition of the enzyme activity also inhibits the expression of the enzyme protein in xenograft tissue
-
additional information
-
structure analysis of a series of 2,4-thiazolidinediones derivative ALR2 inhibitors, 3D-QSAR molcular modeling, detailed overview. A large volume group next to the R-substituent will increase the ALR2 inhibitory activity, and adding a -CH2COOH substituent at the R-position can generate a compound with higher predicted activity
-
additional information
-
inhibitor molecular docking study with ALR2, overview
-
additional information
analysis of pterin-7-carboxamides as aldose reductase inhibitors, evaluation of the inhibitory activity of the compounds
-
additional information
-
analysis of pterin-7-carboxamides as aldose reductase inhibitors, evaluation of the inhibitory activity of the compounds
-
additional information
design and synthesis of chiral 2H-chromene-N-imidazolo-imino acid conjugates as aldose reductase inhibitors, identification by NMR and mass spectrometry, in vitro inhibition screening, molecular docking study, overview
-
additional information
identification of aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold, structure-activity relationships, overview
-
additional information
no inhibition by the triazole 1-(beta-D-glucopyranosyl)-4-(3,4,5-trihydroxyphenyl)-1,2,3-triazole, the amide N-phenylacetyl beta-D-glucopyranosylamine, and the glycosides of beta-glucogallin, 2-(3,4,5-trihydroxyphenyl)ethyl beta-D-glucopyranoside, [1-(3,4,5-trihydroxybenzyl)-1,2,3-triazole-4-yl]methyl beta-D-glucopyranoside, and 3-(3,4,5-trihydroxyphenyl)propyl beta-D-glucopyranoside, synthesis and evaluation, overview
-
additional information
partial nonclassical competitive inhibition is exerted by the aldose hemiacetal on the reduction of the free aldehyde, aldose reductase modulation by hemiacetals, negative cooperative behavior of AR acting on L-idose, mechanism of inhibition, kinetic modelling, nonclassical competitive model, detailed overview
-
additional information
-
partial nonclassical competitive inhibition is exerted by the aldose hemiacetal on the reduction of the free aldehyde, aldose reductase modulation by hemiacetals, negative cooperative behavior of AR acting on L-idose, mechanism of inhibition, kinetic modelling, nonclassical competitive model, detailed overview
-
additional information
contruction of two explicit models to correlate the binding energies with the inhibitory activities. Flavonoids tend to bind aldose reductase in E and EC states, while sulfonyl-pyridazinones prefer ES and ECS states. Van der Waals and electrostatic interactions always have positive contributions for stabilizing flavonoids and sulfonyl-pyridazinones. The conserved feature for the aldose reductase binding pocket and the aldose reductase inhibitors is the aromatic stacking and hydrogen bonding
-
additional information
phenolic hydroxyl groups are important both in C3 side chain and the core structure of quinoxalinone cores for constructing potent ALR2 inhibitors with antioxidant activity
-
additional information
synthesis of 2-phenoxypyrido[3,2-b]pyrazin-3(4H)-one derivatives.The combination of phenolic 3,5-dihydroxyl in the C2-phenoxy group and C7-halogen (Cl or Br) in the core structure largely increases the AKR1B1 inhibitory activity, and the 3,5-dihydroxyl substituent contributes greatly to the activity enhancement of antioxidation when comparing all the phenolic hydroxyl derivatives
-
additional information
synthesis of a series of 1-oxo-pyrimido[4,5-c]quinoline-2-acetic acid derivatives as inhibitors. The 2-amino compounds are unable to inhibit AKR1B1 while the 2-acetic acid derivatives are not cytotoxic against fibrosarcoma HT-1080 cells
-
additional information
-
synthesis of a series of 1-oxo-pyrimido[4,5-c]quinoline-2-acetic acid derivatives as inhibitors. The 2-amino compounds are unable to inhibit AKR1B1 while the 2-acetic acid derivatives are not cytotoxic against fibrosarcoma HT-1080 cells
-
additional information
synthesis of spiroimidazolidine-2,4-dione derivatives which preserve the minimum requirements of the proposed pharmacophoric models to enhance both activities. All compounds (except 1-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione) reduce the blood glucose level and all inhibit aldose reductase activity
-
additional information
use of dihydrobenzoxazinone derivatives as aldose reductase inhibitors. Most of the derivatives with styryl side chains exhibit good inhibitory activities and most of the compounds reveal powerful antioxidant activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Aberrant Crypt Foci
Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation.
Acute Kidney Injury
Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat.
Acute Kidney Injury
Temporal alterations in regional gene expression after nephrotoxic renal injury.
Acute Kidney Injury
The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice.
Adenocarcinoma
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Adenocarcinoma
Cancer biomarker AKR1B10 and carbonyl metabolism.
Adenocarcinoma
Fibrates in the chemical action of daunorubicin.
Adenocarcinoma
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Adenocarcinoma
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Adenocarcinoma
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Adenocarcinoma
Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice.
Adenocarcinoma
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Adenocarcinoma of Lung
Oxidation of PAH trans-Dihydrodiols by Human Aldo-Keto Reductase AKR1B10.
Adenocarcinoma of Lung
Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma.
Adenoma
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Adenoma
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Adrenocortical Carcinoma
Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Albuminuria
Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
Albuminuria
Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats.
Albuminuria
Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.
Albuminuria
Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency.
Albuminuria
Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies.
Albuminuria
Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
aldose reductase deficiency
Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
aldose reductase deficiency
Aldose reductase deficiency improves Wallerian degeneration and nerve regeneration in diabetic thy1-YFP mice.
aldose reductase deficiency
Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation.
aldose reductase deficiency
Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma.
aldose reductase deficiency
Aldose reductase deficiency inhibits LPS-induced M1 response in macrophages by activating autophagy.
aldose reductase deficiency
Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson's disease.
aldose reductase deficiency
Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice.
aldose reductase deficiency
Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.
aldose reductase deficiency
Aldose reductase deficiency protects sugar-induced lens opacification in rats.
aldose reductase deficiency
Aldose reductase deficiency reduced vascular changes in neonatal mouse retina in oxygen-induced retinopathy.
aldose reductase deficiency
Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgf?1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
aldose reductase deficiency
Correction to: Aldose reductase deficiency inhibits LPS-induced M1 response in macrophages by activating autophagy.
Alveolar Bone Loss
Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats.
Asthma
Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma.
Asthma
Aldose reductase inhibition for the treatment of asthma.
Asthma
Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice.
Asthma
Current Prospective of Aldose Reductase Inhibition in the Therapy of Allergic Airway Inflammation in Asthma.
Asthma
Novel aldose reductase inhibitors: a patent survey (2006--present).
Atherosclerosis
Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis.
Atherosclerosis
Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia.
Atherosclerosis
Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
Atherosclerosis
Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein e-/- mice.
Atherosclerosis
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice.
Atherosclerosis
Human Aldose Reductase Expression Prevents Atherosclerosis Regression in Diabetic Mice.
Atherosclerosis
Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
Bacterial Infections
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Blindness
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Blindness
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
Blindness
[Pathophysiology of diabetic retinopathy and nephropathy]
Bone Diseases
[Effect of aldose reductase on the abnormality of calcium metabolism in diabetic patients]
Bone Diseases, Metabolic
Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Brain Infarction
Pre-exposure of voglibose exerts cerebroprotective effects through attenuating activation of the polyol pathway and inflammation.
Brain Infarction
Promising Anti-stroke Signature of Voglibose: Investigation through In- Silico Molecular Docking and Virtual Screening in In-Vivo Animal Studies.
Breast Neoplasms
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Breast Neoplasms
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Breast Neoplasms
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Breast Neoplasms
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Breast Neoplasms
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
Breast Neoplasms
AKR1B10 protects against UVC-induced DNA damage in breast cancer cells.
Breast Neoplasms
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Breast Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Breast Neoplasms
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Breast Neoplasms
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Breast Neoplasms
[AKR1B10 promotes proliferation of breast cancer cells by activating Wnt/?-catenin pathway].
Brucellosis
Erythritol Availability in Bovine, Murine and Human Models Highlights a Potential Role for the Host Aldose Reductase during Brucella Infection.
Carcinogenesis
AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
Carcinogenesis
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Carcinogenesis
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Carcinogenesis
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Carcinogenesis
AKR1B10 protects against UVC-induced DNA damage in breast cancer cells.
Carcinogenesis
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Carcinogenesis
Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Carcinogenesis
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Carcinogenesis
Author's reply to: AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
Carcinogenesis
Diallyl sulfide protects against N-nitrosodiethylamine-induced liver tumorigenesis: role of aldose reductase.
Carcinogenesis
Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-?B signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.
Carcinogenesis
Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10.
Carcinogenesis
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Carcinogenesis
Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
Carcinogenesis
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Carcinogenesis
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Carcinogenesis
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Carcinogenesis
Oxidation of PAH trans-Dihydrodiols by Human Aldo-Keto Reductase AKR1B10.
Carcinogenesis
Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma.
Carcinogenesis
Smoking-induced Up-regulation of AKR1B10 Expression in the Airway Epithelium of Healthy Individuals.
Carcinogenesis
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Carcinogenesis
Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex.
Carcinoma
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Carcinoma
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
Carcinoma
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Carcinoma
AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers.
Carcinoma
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Carcinoma
Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Carcinoma
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Carcinoma
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Carcinoma
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Carcinoma
Fibrates in the chemical action of daunorubicin.
Carcinoma
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Carcinoma
Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Carcinoma
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Carcinoma
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Carcinoma
Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases.
Carcinoma
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Carcinoma
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Carcinoma
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Carcinoma
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Carcinoma
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Carcinoma
Oxidation of PAH trans-Dihydrodiols by Human Aldo-Keto Reductase AKR1B10.
Carcinoma
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Carcinoma
Regulation of aldo-keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2.
Carcinoma
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Carcinoma, Adenoid Cystic
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Carcinoma, Basal Cell
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Carcinoma, Ductal
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Carcinoma, Hepatocellular
A Large-Scale Multicenter Study Validates AKR1B10 as a New Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Carcinoma, Hepatocellular
AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Carcinoma, Hepatocellular
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Carcinoma, Hepatocellular
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Carcinoma, Hepatocellular
Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis.
Carcinoma, Hepatocellular
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Carcinoma, Hepatocellular
Biostatistics mining associated method identifies AKR1B10 enhancing hepatocellular carcinoma cell growth and degenerated by miR-383-5p.
Carcinoma, Hepatocellular
Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.
Carcinoma, Hepatocellular
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas.
Carcinoma, Hepatocellular
Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Carcinoma, Hepatocellular
Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes.
Carcinoma, Hepatocellular
Epidermal Growth Factor Induces Tumor Marker AKR1B10 Expression through Activator Protein-1 Signaling in Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Further characterization of a rat hepatoma-derived aldose-reductase-like protein--organ distribution and modulation in vitro.
Carcinoma, Hepatocellular
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Carcinoma, Hepatocellular
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hypoglycemic activity of C-glycosyl flavonoid from Enicostemma hyssopifolium.
Carcinoma, Hepatocellular
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Carcinoma, Hepatocellular
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Carcinoma, Hepatocellular
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Carcinoma, Hepatocellular
New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Carcinoma, Hepatocellular
Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.
Carcinoma, Hepatocellular
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Carcinoma, Hepatocellular
Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants.
Carcinoma, Hepatocellular
Pseudogene AKR1B10P1 enhances tumorigenicity and regulates epithelial-mesenchymal transition in hepatocellular carcinoma via stabilizing SOX4.
Carcinoma, Hepatocellular
Regulation of aldo-keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2.
Carcinoma, Hepatocellular
Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study.
Carcinoma, Hepatocellular
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Carcinoma, Hepatocellular
[AKR1B10 inhibitor enhances the inhibitory effect of sorafenib on liver cancer xenograft].
Carcinoma, Hepatocellular
[Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Carcinoma, Hepatocellular
[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)]
Carcinoma, Non-Small-Cell Lung
AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers.
Carcinoma, Non-Small-Cell Lung
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Carcinoma, Squamous Cell
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Carcinoma, Squamous Cell
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
Carcinoma, Squamous Cell
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Carcinoma, Squamous Cell
Fibrates in the chemical action of daunorubicin.
Carcinoma, Squamous Cell
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Cardiomegaly
Identification of a novel aldose reductase-like gene upregulated in the failing heart of cardiomyopathic hamster.
Cardiomyopathies
Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.
Cardiomyopathies
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
Cardiomyopathies
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
Cardiomyopathies
The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats.
Cardiotoxicity
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.
Cardiovascular Diseases
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Cardiovascular Diseases
Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-?B and MAPK pathways.
Cardiovascular Diseases
Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
Carotid Artery Diseases
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
Cataract
A mouse model of galactose-induced cataracts.
Cataract
A new approach against sugar cataract through aldose reductase inhibitors.
Cataract
A novel high resolution in vivo digital imaging system for the evaluation of experimental cataract in diabetic rats.
Cataract
A simple and stable galactosemic cataract model for rats.
Cataract
A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes.
Cataract
A thirty year journey in the polyol pathway.
Cataract
Abnormal expression of aldose reductase mRNA in fiber cells of cataractous rat lens. Analysis by in situ hybridization.
Cataract
Activation of aldose reductase by interaction with tubulin and involvement of this mechanism in diabetic cataract formation.
Cataract
Additive effect of aldose reductase Z-4 microsatellite polymorphism and glycaemic control on cataract development in type 2 diabetes.
Cataract
Age-dependent lens changes in galactose-fed dogs.
Cataract
Aldehyde dehydrogenase, aldose reductase, and free radical scavengers in cataract.
Cataract
Aldo-keto reductases in the eye.
Cataract
Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.
Cataract
Aldose reductase (EC 1.1.1.21) activity and reduced-glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose.
Cataract
Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.
Cataract
Aldose reductase and its inhibition in the control of diabetic complications.
Cataract
Aldose reductase and sorbitol dehydrogenase distribution in substructures of normal and diabetic rat lens.
Cataract
Aldose reductase and the etiology of diabetic cataracts.
Cataract
Aldose reductase expression as a risk factor for cataract.
Cataract
Aldose reductase expression in human diabetic retina and retinal pigment epithelium.
Cataract
Aldose reductase in diabetic cataracts.
Cataract
Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.
Cataract
Aldose Reductase Inhibition Prevents Development of Posterior Capsular Opacification in an In Vivo Model of Cataract Surgery.
Cataract
Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
Cataract
Aldose reductase inhibitors and cataract.
Cataract
Aldose reductase inhibitors and galactose toxicity in neonatal and maternal rat lenses.
Cataract
Aldose reductase inhibitors and prevention of galactose cataracts in rats.
Cataract
Aldose reductase inhibitors from Litchi chinensis Sonn.
Cataract
Aldose reductase inhibitory, anti-cataract and antioxidant potential of selected medicinal plants from the Marathwada region, India.
Cataract
Aldose reductase mRNA is an epithelial cell-specific gene transcript in both normal and cataractous rat lens.
Cataract
Aldose Reductase Polymorphisms, Fasting Blood Glucose, and Age-Related Cortical Cataract.
Cataract
Aldose reductase the major protein associated with naphthalene dihydrodiol dehydrogenase activity in rat lens.
Cataract
Aldose reductase, glucose and cataracts.
Cataract
Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Cataract
Aldose reductase-deficient mice develop nephrogenic diabetes insipidus.
Cataract
Aldose reductase-mediated induction of epithelium-to-mesenchymal transition (EMT) in lens.
Cataract
Analysis of sorbitol, galactitol, and myo-inositol in lens and sciatic nerve by high-performance liquid chromatography.
Cataract
Anticataract activity of analogs of a sorbitol dehydrogenase inhibitor.
Cataract
Anticataractogenesis and Antiretinopathy Effects of the Novel Protective Agent Containing the Combined Extract of Mango and Vietnamese Coriander in STZ-Diabetic Rats.
Cataract
Antioxidant status in an in vitro model for hyperglycemic lens cataract formation: effect of aldose reductase inhibitor statil.
Cataract
Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes.
Cataract
Attenuation of aldose reductase gene suppresses high-glucose-induced apoptosis and oxidative stress in rat lens epithelial cells.
Cataract
Bioactive fraction of Saraca indica prevents diabetes induced cataractogenesis: An aldose reductase inhibitory activity.
Cataract
Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats.
Cataract
Cataract prevention in diabetic Octodon degus with Pfizer's sorbinil.
Cataract
Cataracts in experimentally diabetic mouse: morphological and apoptotic changes.
Cataract
Changes of some biochemical parameters of the lens in galactose-treated weaned rats with and without vitamin E therapy.
Cataract
Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat.
Cataract
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
Cataract
Characterization of structural requirement for binding of gigantol and aldose reductase.
Cataract
Corneal endothelial morphology in the rat. Effects of aging, diabetes, and topical aldose reductase inhibitor treatment.
Cataract
Correlation between adult diabetic cataracts and red blood cell aldose reductase levels.
Cataract
CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
Cataract
Cytoprotective mechanism of action of curcumin against cataract.
Cataract
Delayed progression of diabetic cataractogenesis and retinopathy by Litchi chinensis in STZ-induced diabetic rats.
Cataract
Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens.
Cataract
Design, synthesis, in vitro and in silico investigation of aldose reductase inhibitory effects of new thiazole-based compounds.
Cataract
Determination of sorbitol and galactitol at the nanogram level in biological samples by high-performance liquid chromatography.
Cataract
Developmental and physiological pattern of aldose reductase mRNA expression in lens and retina.
Cataract
Diabetes can alter the signal transduction pathways in the lens of rats.
Cataract
Diabetes-Independent Retinal Phenotypes in an Aldose Reductase Transgenic Mouse Model.
Cataract
Diabetic and galactosaemic cataracts.
Cataract
Diabetic cataracts and flavonoids.
Cataract
Diabetic cataracts in animal models: prevention and reversibility with aldose reductase inhibitors.
Cataract
Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
Cataract
Dietary myo-inositol effect on sugar cataractogenesis.
Cataract
Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats.
Cataract
Discovery of New Selective Human Aldose Reductase Inhibitors through Virtual Screening Multiple Binding Pocket Conformations.
Cataract
Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation.
Cataract
Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175.
Cataract
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
Cataract
Dynamic phosphorus-31 NMR study of sugar cataract and its prevention in rat lenses with aldose reductase inhibitors.
Cataract
Effect of aldose reductase inhibitor on experimental diabetic cataract monitored by laser Raman spectroscopy.
Cataract
Effect of aldose reductase inhibitors on lenticular dulcitol level in galactose fed rats.
Cataract
Effect of aldose reductase inhibitors on naphthalene cataract formation in the rat.
Cataract
Effect of an aldose reductase inhibitor, AL-1576, on the development of UV-B and X-ray cataract.
Cataract
Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.
Cataract
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Cataract
Effect of D-myo-inositol on platelet function and composition and on cataract development in streptozotocin-induced diabetic rats.
Cataract
Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract.
Cataract
Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats.
Cataract
Effect of the isoflavone genistein against galactose-induced cataracts in rats.
Cataract
Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Cataract
Effects of an aldose reductase inhibitor, 1-[(p-bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats.
Cataract
Effects of galactose feeding on aldose reductase gene expression.
Cataract
Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats.
Cataract
Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.
Cataract
Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens.
Cataract
Effects of topical administration of an aldose reductase inhibitor on cataract formation in dogs fed a diet high in galactose.
Cataract
Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Cataract
Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats.
Cataract
Esculetin, a Coumarin Derivative, Inhibits Aldose Reductase Activity in vitro and Cataractogenesis in Galactose-Fed Rats.
Cataract
Establishment of mouse as an animal model for study of diabetic cataracts: biochemical studies.
Cataract
Establishment of the mouse as a model animal for the study of diabetic cataracts.
Cataract
Evaluation of in vitro aldose reductase inhibitory potential of different fraction of Hybanthus enneaspermus Linn F. Muell.
Cataract
Evolution of the aldose reductase-related gecko eye lens protein rhoB-crystallin: a sheep in wolf's clothing.
Cataract
Expression levels of aldose reductase enzyme, vascular endothelial growth factor, and intercellular adhesion molecule-1 in the anterior lens capsule of diabetic cataract patients.
Cataract
Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
Cataract
Galactose-induced retinal microangiopathy in rats.
Cataract
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells.
Cataract
GP-1447, an inhibitor of aldose reductase, prevents the progression of diabetic cataract in rats.
Cataract
Grape seed extract and Zinc containing nutritional food supplement delays onset and progression of Streptozocin-induced diabetic cataract in Wistar rats.
Cataract
Identification of new urinary metabolites of byakangelicin, a component of Angelicae dahuricae Radix, in rats.
Cataract
Idiopathic presenile cataract formation and galactosaemia.
Cataract
Implications of aldose reductase in cataracts in human diabetes.
Cataract
Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.
Cataract
In utero and milk-mediated effect of aldose reductase inhibitor on galactose cataracts.
Cataract
In Vitro and In Vivo Inhibitory Activities of Four Indian Medicinal Plant Extracts and their Major Components on Rat Aldose Reductase and Generation of Advanced Glycation Endproducts.
Cataract
In vitro expression of rat lens aldose reductase in Escherichia coli.
Cataract
Increased lenticular aldose reductase activity and high incidence of congenital cataract in the offspring of diabetic rats.
Cataract
Inhibition in rat of development of in utero galactose-induced cataract by an aldose reductase inhibitor--a light microscopic study.
Cataract
Inhibition of aldose reductase and xylose-induced lens opacity by puerariafuran from the roots of Pueraria lobata.
Cataract
Inhibition of aldose reductase by Aegle marmelos and its protective role in diabetic cataract.
Cataract
Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract.
Cataract
Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols.
Cataract
Inhibition of aldose reductases from rat and bovine lenses by flavonoids.
Cataract
Inhibition of C298S mutant of human aldose reductase for antidiabetic applications: Evidence from in silico elementary mode analysis of biological network model.
Cataract
Inhibition of glycation and aldose reductase activity using dietary flavonoids: A lens organ culture studies.
Cataract
Inhibition of in utero galactose-induced cataract development by an aldose reductase inhibitor in rat--electron microscopic study.
Cataract
Inhibition of lens aldose reductase by flavonoids--their possible role in the prevention of diabetic cataracts.
Cataract
Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: salicylate, indomethacin, oxyphenbutazone, sulindac.
Cataract
Inhibition of naphthalene cataract in rats by aldose reductase inhibitors.
Cataract
Inhibition of polyol formation in rat lens by verapamil.
Cataract
Inhibitory effect of lycopene on cataract development in galactosemic rats.
Cataract
Inhibitory effects of chlorogenic acid on aldose reductase activity in vitro and cataractogenesis in galactose-fed rats.
Cataract
Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships.
Cataract
Interaction of AR and iNOS in lens epithelial cell: A new pathogenesis and potential therapeutic targets of diabetic cataract.
Cataract
Intrinsic inhibition of aldose reductase.
Cataract
Investigation of synergistic mechanism and identification of interaction site of aldose reductase with the combination of gigantol and syringic acid for prevention of diabetic cataract.
Cataract
Involvement of aldose reductase in naphthalene cataract.
Cataract
In vitro and in vivo evaluation of pterostilbene for the management of diabetic complications.
Cataract
Isolation of an aldose reductase inhibitor from the fruits of Vitex rotundifolia Part 2 in the series "Studies on the inhibitory effects of medicinal plant constituents on cataract formation".
Cataract
Kinetic behaviour under defined assay conditions for bovine lens aldose reductase.
Cataract
Lens aldose reductase in diabetic and galactosemic cataracts.
Cataract
Lens aldose reductase inhibiting potential of some indigenous plants.
Cataract
Levels of expression of hexokinase, aldose reductase and sorbitol dehydrogenase genes in lens of mouse and rat.
Cataract
Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Cataract
Management of aldose reductase mRNA abundance in rat lens undergoing reversal of galactose induced cataracts. A model for gene response to changes in the environment.
Cataract
Medical therapy in the prevention of cataract.
Cataract
Melatonin Reduces Cataract Formation and Aldose Reductase Activity in Lenses of Streptozotocin-induced Diabetic Rat.
Cataract
Metabolic cataracts in newly diagnosed diabetes.
Cataract
Metabolic studies of galactosemic cataract.
Cataract
Method for isolating tight-binding inhibitors of rat lens aldose reductase.
Cataract
Methods for evaluation of medical therapy of senile and diabetic cataracts.
Cataract
Modelling cortical cataractogenesis VII: Effects of vitamin E treatment on galactose-induced cataracts.
Cataract
NADPH-oxidising activity in lens and erythrocytes in diabetic and nondiabetic patients with cataract.
Cataract
Naphthalene-induced cataract in the rat. II. Contrasting effects of two aldose reductase inhibitors on glutathione and glutathione redox enzymes.
Cataract
Natural therapies for ocular disorders, part two: cataracts and glaucoma.
Cataract
Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes.
Cataract
Nonosmotic diabetic cataracts.
Cataract
Nutritional supplementation to prevent cataract formation.
Cataract
Olive and ginkgo extracts as potential cataract therapy with differential inhibitory activity on aldose reductase.
Cataract
Osmotic stress, not aldose reductase activity, directly induces growth factors and MAPK signaling changes during sugar cataract formation.
Cataract
Overexpression of Na(+)-dependent myo-inositol transporter gene in mouse lens led to congenital cataract.
Cataract
Overview of the current attempts toward the medical treatment of cataract.
Cataract
Photographic and spectroscopic correlations of human cataracts.
Cataract
Polyol accumulation in cultured human lens epithelial cells.
Cataract
Polyol pathway-dependent osmotic and oxidative stresses in aldose reductase-mediated apoptosis in human lens epithelial cells: role of AOP2.
Cataract
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Cataract
Prefeeding of aldose reductase inhibitor and galactose cataractogenesis.
Cataract
Preventative Effects of Ginkgo biloba Extract (EGb761) on High Glucose-Cultured Opacity of Rat Lens.
Cataract
Prevention of cataract development in severely galactosemic rats by the aldose reductase inhibitor, tolrestat.
Cataract
Prevention of naphthalene-1,2-dihydrodiol-induced lens protein modifications by structurally diverse aldose reductase inhibitors.
Cataract
Preventive effect of chlorogenic acid on lens opacity and cytotoxicity in human lens epithelial cells.
Cataract
Profile of messenger RNA decay in the Emory mouse lens in cataractogenesis and in aging.
Cataract
Progression of sugar cataract in the dog.
Cataract
Properties of an aldose reductase from pig lens. Comparative studies of an aldehyde reductase from pig lens.
Cataract
Protective effect of glycine in streptozotocin-induced diabetic cataract through aldose reductase inhibitory activity.
Cataract
Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
Cataract
Pyruvate inhibits galactosemic changes in cultured cat lens epithelial cells.
Cataract
Rabbit corneal and conjunctival permeability of the novel aldose reductase inhibitors: N-[[4-(benzoylamino)phenyl] sulphonyl]glycines and N-benzoyl-N-phenylglycines.
Cataract
Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
Cataract
Reduction of oxidative-nitrosative stress underlies anticataract effect of topically applied tocotrienol in streptozotocin-induced diabetic rats.
Cataract
Relative abundance of aldose reductase mRNA in rat lens undergoing development of osmotic cataracts.
Cataract
Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
Cataract
Repression of Polyol Pathway Activity by Hemidesmus indicus var. pubescens R.Br. Linn Root Extract, an Aldose Reductase Inhibitor: An In Silico and Ex Vivo Study.
Cataract
Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
Cataract
Reversal of galactose cataract with Sorbinil in rats.
Cataract
Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
Cataract
Rho B-crystallin, an aldose reductase-like lens protein in the gecko Lepidodactylus lugubris.
Cataract
Risk factors for cataract in Chinese patients with type 2 diabetes: evidence for the influence of the aldose reductase gene.
Cataract
Role of aldose reductase in diabetes-induced retinal microglia activation.
Cataract
Role of aldose reductase in the development of diabetes-associated complications.
Cataract
Role of dietary flavonoids in amelioration of sugar induced cataractogenesis.
Cataract
Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract.
Cataract
Scanning electron microscopy of X-ray-induced cataract in mice on normal and galactose diet.
Cataract
Scopoletin Inhibits Rat Aldose Reductase Activity and Cataractogenesis in Galactose-Fed Rats.
Cataract
Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking.
Cataract
Sorbitol metabolism in inner medullary collecting duct cells of diabetic rats.
Cataract
Status of oxidative stress markers, advanced glycation index, and polyol pathway in age-related cataract subjects with and without diabetes.
Cataract
Structure-Activity Relationship Study Reveals Benzazepine Derivatives of Luteolin as New Aldose Reductase Inhibitors for Diabetic Cataract.
Cataract
Studies on cataractogenesis in humans and in rats with alloxan-induced diabetes. II. Histochemical evaluation of lenticular enzymes.
Cataract
Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
Cataract
Substituted 2-thioxothiazolidin-4-one derivatives showed protective effects against diabetic cataract via inhibition of aldose reductase.
Cataract
Sugar cataracts in vitro: implications of oxidative stress and aldose reductase I.
Cataract
Sugar metabolism in the crystalline lens.
Cataract
Synergism between phospholipase D2 and sorbitol accumulation in diabetic cataract formation through modulation of Na,K-ATPase activity and osmotic stress.
Cataract
Synergism of sorbinil and normal diet on reversal of stage-II sugar cataract.
Cataract
Synthesis and aldose reductase inhibitory activities of novel N-nitromethylsulfonanilide derivatives.
Cataract
Synthesis and Biological Evaluation of Novel Gigantol Derivatives as Potential Agents in Prevention of Diabetic Cataract.
Cataract
Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
Cataract
Syringic Acid Extracted from Herba dendrobii Prevents Diabetic Cataract Pathogenesis by Inhibiting Aldose Reductase Activity.
Cataract
Taxifolin Shows Anticataractogenesis and Attenuates Diabetic Retinopathy In STZ-Diabetic Rats via Suppression of Aldose Reductase, Oxidative Stress and MAPK Signaling Pathway.
Cataract
The aldose reductase inhibitor site.
Cataract
The effect of aldose reductase and its inhibition on sugar cataract formation.
Cataract
The effect of oxidation on sorbitol pathway kinetics.
Cataract
The efficacy of aldose reductase inhibitor, antioxidant butylated hydroxytoluene and cysteine protease inhibitor E64 on hyperglycemia-induced metabolic changes in the organ-cultured bovine lens.
Cataract
The efficacy of aldose reductase inhibitors on polyol accumulation in human lens and retinal pigment epithelium in tissue culture.
Cataract
The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity.
Cataract
The isolation and characterization of ?-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis.
Cataract
The penetration of Sorbinil, an aldose reductase inhibitor, into lens, aqueous humour and erythrocytes of patients undergoing cataract extraction.
Cataract
The possible mechanism of naphthalene cataract in rat and its prevention by an aldose reductase inhibitor (ALO1576).
Cataract
The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis).
Cataract
The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase.
Cataract
Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies.
Cataract
Therapies for galactosemia: a patent landscape.
Cataract
Thymol, a monoterpene, inhibits aldose reductase and high-glucose-induced cataract on isolated goat lens.
Cataract
Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts.
Cataract
Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1).
Cataract
Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.
Cataract
Transient elevation of aldose reductase mRNA in lens of rats developing galactose cataracts.
Cataract
Ultrastructural cytochemistry: effect of Sorbinil on arylsulfatases in cataractous lenses.
Cataract
Up-regulation of P-glycoprotein expression by osmotic stress in rat sugar cataract.
Cataract
Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Cataract
Upregulations of Clcn3 and P-Gp Provoked by Lens Osmotic Expansion in Rat Galactosemic Cataract.
Cataract
Vitamin K1 prevents diabetic cataract by inhibiting lens aldose reductase 2 (ALR2) activity.
Cataract
X-ray affinity and photoaffinity inhibitor of aldose reductase.
Cataract
[Aldose reductase: physiological role, properties and prospects for regulating activity]
Cataract
[Aldose-reductase inhibitors and cataract formation (author's transl)]
Cataract
[Biochemical changes in lens, aqueous humor and vitreous body and effects of aldose reductase inhibitor (TAT) on rats with experimental diabetes]
Cataract
[Effects of M79175, an aldose reductase inhibitor, on experimental sugar cataracts]
Cataract
[Magnetic resonance imaging study on rat sugar cataract]
Cataract
[Morphological classification of the prevention by aldose reductase inhibitor of rat galactosemic cataract]
Cataract
[Movement of regenerated lens epithelial cells in 50% galactose cataract and an aldose reductase inhibitor]
Cataract
[Outlook for the future in the treatment of diabetic retinopathy]
Cataract
[Prefeeding of aldose reductase inhibitor inhibits galactose cataract]
Cataract
[Prevention and reversal of rat galactosemic cataract with aldose reductase inhibitor--immunohistochemical study]
Cataract
[Prevention of galactose-induced cataractogenesis in rats by salvianolic acid A]
Cataract
[Prevention of rat galactose cataract with topical aldose reductase inhibitor, E-1008]
Cataract
[Preventional and therapeutic effects of aldose reductase inhibitor FR74366 on rat galactose cataract]
Cataract
[Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanisms]
Cataract
[Quantitative study of rat diabetic cataract, by the relaxation times of nuclear magnetic resonance]
Cataract
[The inhibitory effect of aldose reductase inhibitor for proliferation in the lens epithelial cells of rat sugar cataract]
Cataract
[The localization of aldose reductase mRNA in the rat lens]
Cataract
[The role of lens epithelium in cataract formation in diabetic rats]
Cataract
[What possibilities exist to modify cataract development on the basis of current biochemical knowledge? Where can drugs act?]
Central Nervous System Diseases
Defects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases.
Cholangiocarcinoma
Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Colitis, Ulcerative
Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice.
Colonic Neoplasms
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Colonic Neoplasms
AKR1B10 negatively regulates autophagy through reducing GAPDH upon glucose starvation in colon cancer.
Colonic Neoplasms
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Colonic Neoplasms
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Colonic Neoplasms
Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
Colonic Neoplasms
Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
Colonic Neoplasms
Aldose reductase inhibition prevents colon cancer growth by restoring PTEN through modulation of miR-21 and FOXO3a.
Colonic Neoplasms
Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells.
Colonic Neoplasms
Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression.
Colonic Neoplasms
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.
Colonic Neoplasms
Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction.
Colonic Neoplasms
Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO-1/AMPK pathway in colon cancer cells.
Colonic Neoplasms
Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells.
Colonic Neoplasms
Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells.
Colonic Neoplasms
Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Colonic Neoplasms
Expression of Concern: Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1 ? (HIF-1?) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells.
Colonic Neoplasms
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo.
Colonic Neoplasms
Inhibition of aldose reductase prevents colon cancer metastasis.
Colonic Neoplasms
Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
Colonic Neoplasms
Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Colonic Neoplasms
Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Colonic Neoplasms
Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Colonic Neoplasms
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Colonic Neoplasms
Treatment of cancer cells with chemotherapeutic drugs results in profound changes in expression of genes encoding aldehyde-metabolizing enzymes.
Colorectal Neoplasms
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Colorectal Neoplasms
Aldo-keto reductase 1B10 protects human colon cells from DNA damage induced by electrophilic carbonyl compounds.
Colorectal Neoplasms
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Colorectal Neoplasms
Aldose Reductase Inhibitor Fidarestat as a Promising Drug Targeting Autophagy in Colorectal Carcinoma: a Pilot Study.
Colorectal Neoplasms
Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO-1/AMPK pathway in colon cancer cells.
Colorectal Neoplasms
Altered Expression of Multiple Genes Involved in Retinoic Acid Biosynthesis in Human Colorectal Cancer.
Colorectal Neoplasms
Fibrates in the chemical action of daunorubicin.
Colorectal Neoplasms
Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway.
Colorectal Neoplasms
Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Colorectal Neoplasms
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Colorectal Neoplasms
Proteomics in human disease: cancer, heart and infectious diseases.
Colorectal Neoplasms
Treatment of cancer cells with chemotherapeutic drugs results in profound changes in expression of genes encoding aldehyde-metabolizing enzymes.
Colorectal Neoplasms
[Downregulation of AKR1B10 gene expression in colorectal cancer]
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Corneal Diseases
Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.
Corneal Diseases
Improvement of corneal sensation and tear dynamics in diabetic patients by oral aldose reductase inhibitor, ONO-2235: a preliminary study.
Corneal Injuries
Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats.
Coronary Artery Disease
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
Dehydration
Acute changes in intracellular ions or pH and regulation of aldose reductase activity.
Dehydration
An aldose reductase homolog from the resurrection plant Xerophyta viscosa Baker.
Dehydration
Estimated plasma osmolarity and risk of end-stage kidney disease in patients with IgA nephropathy.
Dehydration
Osmolyte regulation by TonEBP/NFAT5 during anoxia-recovery and dehydration-rehydration stresses in the freeze-tolerant wood frog (Rana sylvatica).
Dehydration
Rehydration with Soft Drink-like Beverages Exacerbates Dehydration and Worsens Dehydration-associated Renal Injury.
Demyelinating Diseases
Cellular pathology of the nerve microenvironment in galactose intoxication.
Diabetes Complications
(2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
Diabetes Complications
(5-Hydroxy-4-oxo-2-styryl-4H-pyridin-1-yl)-acetic Acid Derivatives as Multifunctional Aldose Reductase Inhibitors.
Diabetes Complications
1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase.
Diabetes Complications
1-Benzopyran-4-one antioxidants as aldose reductase inhibitors.
Diabetes Complications
1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.
Diabetes Complications
1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor.
Diabetes Complications
3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication.
Diabetes Complications
3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach.
Diabetes Complications
3D-QSAR studies on a series of 5-arylidine-2, 4-thiazolidinediones as aldose reductase inhibitors: a self-organizing molecular field analysis approach.
Diabetes Complications
A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Diabetes Complications
A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.
Diabetes Complications
A delayed-early gene activated by fibroblast growth factor-1 encodes a protein related to aldose reductase.
Diabetes Complications
A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners.
Diabetes Complications
A new approach against sugar cataract through aldose reductase inhibitors.
Diabetes Complications
A non-invasive, multi-target approach to treat diabetic retinopathy.
Diabetes Complications
A novel zwitterionic inhibitor of aldose reductase interferes with polyol pathway in ex vivo and in vivo models of diabetic complications.
Diabetes Complications
A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases.
Diabetes Complications
A series of pyrido[2,3-b]pyrazin-3(4H)-one derivatives as aldose reductase inhibitors with antioxidant activity.
Diabetes Complications
A thirty year journey in the polyol pathway.
Diabetes Complications
Aberrant mRNA splicing causes sorbitol dehydrogenase deficiency in C57BL/LiA mice.
Diabetes Complications
Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors.
Diabetes Complications
Active site modification of aldose reductase by nitric oxide donors.
Diabetes Complications
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Diabetes Complications
Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA.
Diabetes Complications
Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.
Diabetes Complications
Aldo-Keto Reductases 1B in Adrenal Cortex Physiology.
Diabetes Complications
Aldo-Keto Reductases 1B in Endocrinology and Metabolism.
Diabetes Complications
Aldo-keto reductases as modulators of stress response.
Diabetes Complications
Aldo-keto reductases in the eye.
Diabetes Complications
Aldose and aldehyde reductase in animal tissues.
Diabetes Complications
Aldose reductase and advanced glycation endproducts inhibitory effect of Phyllostachys nigra.
Diabetes Complications
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.
Diabetes Complications
Aldose reductase and its inhibition in the control of diabetic complications.
Diabetes Complications
Aldose reductase and p-crystallin belong to the same protein superfamily as aldehyde reductase.
Diabetes Complications
Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: in vivo kinetic studies using 19F 3-FDG NMR in rats.
Diabetes Complications
Aldose reductase deficiency protects sugar-induced lens opacification in rats.
Diabetes Complications
Aldose Reductase Differential Inhibitors in Green Tea.
Diabetes Complications
Aldose reductase enzyme and its implication to major health problems of the 21(st) century.
Diabetes Complications
Aldose reductase gene expression and osmotic dysregulation in cultured human retinal pigment epithelial cells.
Diabetes Complications
Aldose reductase in diabetic complications of the eye.
Diabetes Complications
Aldose reductase in diabetic microvascular complications.
Diabetes Complications
Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
Diabetes Complications
Aldose reductase in the etiology of diabetic complications. 3. Neuropathy.
Diabetes Complications
Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
Diabetes Complications
Aldose reductase in the etiology of diabetic complications: 4. Retinopathy.
Diabetes Complications
Aldose reductase in the etiology of diabetic complications: I. Introduction.
Diabetes Complications
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Diabetes Complications
Aldose reductase inhibitors and diabetic complications.
Diabetes Complications
Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics.
Diabetes Complications
Aldose reductase inhibitors and the complications of diabetes mellitus.
Diabetes Complications
Aldose reductase inhibitors and their potential for the treatment of diabetic complications.
Diabetes Complications
Aldose reductase inhibitors for diabetic complications: Receptor induced atom-based 3D-QSAR analysis, synthesis and biological evaluation.
Diabetes Complications
Aldose reductase inhibitors from Viola hondoensis W. Becker et H Boss.
Diabetes Complications
Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism.
Diabetes Complications
Aldose Reductase Inhibitors of Plant Origin.
Diabetes Complications
Aldose reductase inhibitors.
Diabetes Complications
Aldose reductase inhibitors: 2013-present.
Diabetes Complications
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Diabetes Complications
Aldose reductase inhibitors: an update.
Diabetes Complications
Aldose reductase inhibitors: therapeutic implications for diabetic complications.
Diabetes Complications
Aldose reductase inhibitory activity and antioxidant capacity of pomegranate extracts.
Diabetes Complications
Aldose reductase inhibitory activity of compounds from Zea mays L.
Diabetes Complications
Aldose reductase inhibitory compounds from Glycyrrhiza uralensis.
Diabetes Complications
Aldose Reductase Inhibitory Compounds from Xanthium strumarium.
Diabetes Complications
Aldose reductase inhibitory effect by tectorigenin derivatives from Viola hondoensis.
Diabetes Complications
Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages.
Diabetes Complications
Aldose reductase regulates hepatic peroxisome proliferator-activated receptor alpha phosphorylation and activity to impact lipid homeostasis.
Diabetes Complications
Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Diabetes Complications
Aldose reductase, oxidative stress and diabetic cardiovascular complications.
Diabetes Complications
Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
Diabetes Complications
ALDOSE REDUCTASE: New Insights for an Old Enzyme.
Diabetes Complications
Alkaloids as aldose reductase inhibitors, with special reference to berberine.
Diabetes Complications
All in the family: aldose reductase and closely related aldo-keto reductases.
Diabetes Complications
An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.
Diabetes Complications
An allied approach for in vitro modulation of aldose reductase, sorbitol accumulation and advanced glycation end products by flavonoid rich extract of Coriandrum sativum L. seeds.
Diabetes Complications
An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.
Diabetes Complications
Anti-hyperglycemic effect of Potentilla discolor decoction on obese-diabetic (Ob-db) mice and its chemical composition.
Diabetes Complications
Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice.
Diabetes Complications
Antidiabetic properties of dietary phenolic compounds: Inhibition effects on ?-amylase, aldose reductase, and ?-glycosidase.
Diabetes Complications
Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
Diabetes Complications
Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?
Diabetes Complications
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
Diabetes Complications
Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
Diabetes Complications
Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
Diabetes Complications
Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy.
Diabetes Complications
Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies.
Diabetes Complications
Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies.
Diabetes Complications
Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus.
Diabetes Complications
Bioavailability, multiple-dose pharmacokinetics, and biotransformation of the aldose reductase inhibitor zopolrestat in dogs.
Diabetes Complications
Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling.
Diabetes Complications
Carboxymethylated tetrahydropyridoindoles as aldose reductase inhibitors: in vitro selectivity study in intact rat erythrocytes in relation to glycolytic pathway.
Diabetes Complications
Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Diabetes Complications
Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Diabetes Complications
Characterization of genomic regions directing the cell-specific expression of the mouse aldose reductase gene.
Diabetes Complications
Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Diabetes Complications
Clinical significance of erythrocyte sorbitol-blood glucose ratios in type II diabetes mellitus.
Diabetes Complications
Clinical trials with aldose reductase inhibitors.
Diabetes Complications
Cloning and expression of human aldose reductase.
Diabetes Complications
Coconut phytocompounds inhibits polyol pathway enzymes: Implication in prevention of microvascular diabetic complications.
Diabetes Complications
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Diabetes Complications
Comparisons of genomic structures and chromosomal locations of the mouse aldose reductase and aldose reductase-like genes.
Diabetes Complications
Cooperative regulation of mouse aldose reductase (AKR1B3) gene transcription by Nrf2, TonEBP, and c-jun.
Diabetes Complications
CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
Diabetes Complications
Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily.
Diabetes Complications
Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.
Diabetes Complications
Deficiency of ascorbic acid in experimental diabetes. Relationship with collagen and polyol pathway abnormalities.
Diabetes Complications
Design and synthesis of chiral 2H-chromene-N-imidazolo-amino acid conjugates as aldose reductase inhibitors.
Diabetes Complications
Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
Diabetes Complications
Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.
Diabetes Complications
Design and synthesis of pyridazinone-substituted benzenesulphonylurea derivatives as anti-hyperglycaemic agents and inhibitors of aldose reductase - an enzyme embroiled in diabetic complications.
Diabetes Complications
Design, synthesis, in vitro and in silico investigation of aldose reductase inhibitory effects of new thiazole-based compounds.
Diabetes Complications
Determination of sorbitol and galactitol at the nanogram level in biological samples by high-performance liquid chromatography.
Diabetes Complications
Development and validation of a rapid high-performance liquid chromatography-tandem mass spectrometry method for the determination of WJ-38, a novel aldose reductase inhibitor, in rat plasma and its application to a pharmacokinetic study.
Diabetes Complications
Development of coumarin-thiosemicarbazone hybrids as aldose reductase inhibitors: Biological assays, molecular docking, simulation studies and ADME evaluation.
Diabetes Complications
Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.
Diabetes Complications
Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity.
Diabetes Complications
Development of novel pyrazolone derivatives as inhibitors of aldose reductase: An eco-friendly one-pot synthesis, experimental screening and in silico analysis.
Diabetes Complications
Development of potent aldose reductase inhibitors having a hydantoin structure.
Diabetes Complications
Developmental and physiological regulation of aldose reductase mRNA expression in renal medulla.
Diabetes Complications
Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
Diabetes Complications
Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
Diabetes Complications
Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
Diabetes Complications
Dihydroxanthyletin-type coumarins from Angelica decursiva that inhibits the formation of advanced glycation end products and human recombinant aldose reductase.
Diabetes Complications
Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Diabetes Complications
Discovery of new inhibitors of aldose reductase from molecular docking and database screening.
Diabetes Complications
Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis.
Diabetes Complications
Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
Diabetes Complications
Disruption of aldose reductase gene (Akr1b1) causes defect in urinary concentrating ability and divalent cation homeostasis.
Diabetes Complications
Does aldose reductase have a role in the development of the ocular complications of diabetes?
Diabetes Complications
Does sorbinil bind to the substrate binding site of aldose reductase?
Diabetes Complications
Downregulation of aldose reductase is responsible for developmental abnormalities of the silkworm purple quail-like mutant (q-lp).
Diabetes Complications
Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.
Diabetes Complications
DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGF?1 signaling.
Diabetes Complications
Early identification of promiscuous attributes of aldose reductase inhibitors using a DMSO-perturbation assay.
Diabetes Complications
Edible vegetables as a source of aldose reductase differential inhibitors.
Diabetes Complications
Effect of a novel mutation in 5'-regulatory region of aldose reductase gene on its expression.
Diabetes Complications
Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.
Diabetes Complications
Effects of a new aldose reductase inhibitor on diabetic complications in rats.
Diabetes Complications
Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats.
Diabetes Complications
Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
Diabetes Complications
Effects of galactose feeding on aldose reductase gene expression.
Diabetes Complications
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
Diabetes Complications
Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Diabetes Complications
Efficacy of aldose reductase inhibitors is affected by oxidative stress induced under X-ray irradiation.
Diabetes Complications
Efficacy of glucose, ouabain and an aldose reductase inhibitor on 2-[3H] myo-inositol uptake by human, rat and rabbit erythrocytes.
Diabetes Complications
Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
Diabetes Complications
Enzyme immunoassay for erythrocyte aldose reductase.
Diabetes Complications
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Diabetes Complications
Erythrocyte aldose reductase correlates with erectile dysfunction in diabetic patients.
Diabetes Complications
Evaluation of aldose reductase inhibition and docking studies of 6'-nitro and 6',6''-dinitrorosmarinic acids.
Diabetes Complications
Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study.
Diabetes Complications
Evaluation of in vitro aldose reductase inhibitory potential of alkaloidal fractions of Piper nigrum, Murraya koenigii, Argemone mexicana, and Nelumbo nucifera.
Diabetes Complications
Exploiting oxadiazole-sulfonamide hybrids as new structural leads to combat diabetic complications via aldose reductase inhibition.
Diabetes Complications
Exploring the interactional details between aldose reductase (AKR1B1) and 3-Mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid through molecular dynamics simulations.
Diabetes Complications
Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262.
Diabetes Complications
Extraction and identification of three major aldose reductase inhibitors from Artemisia montana.
Diabetes Complications
Fibrates inhibit aldose reductase activity in the forward and reverse reactions.
Diabetes Complications
Flavonol Glycosides: In Vitro Inhibition of DPPIV, Aldose Reductase and Combating Oxidative Stress are Potential Mechanisms for Mediating the Antidiabetic Activity of Cleome droserifolia.
Diabetes Complications
Functional genomic studies of aldo-keto reductases.
Diabetes Complications
Gedunin, A Neem Limonoid in Combination With Epalrestat Inhibits Cancer Hallmarks By Attenuating Aldose Reductase-Driven Oncogenic Signaling In SCC131 Oral Cancer Cells.
Diabetes Complications
Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus.
Diabetes Complications
Genetic analysis of aldose reductase in diabetic complications.
Diabetes Complications
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells.
Diabetes Complications
High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase.
Diabetes Complications
Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Diabetes Complications
Highly selective aldose reductase inhibitors. II. Optimization of the aryl part of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids.
Diabetes Complications
Hormonal regulation of aldose reductase in rat ovary during the estrous cycle.
Diabetes Complications
Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Diabetes Complications
Human liver 6-pyruvoyl tetrahydropterin reductase is biochemically and immunologically indistinguishable from aldose reductase.
Diabetes Complications
Identification and characterization of in vitro and in vivo fidarestat metabolites: Toxicity and efficacy evaluation of metabolites.
Diabetes Complications
Identification of 2-benzoxazolinone derivatives as lead against molecular targets of diabetic complications.
Diabetes Complications
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.
Diabetes Complications
Identification of a new class of potent aldose reductase inhibitors: Design, microwave-assisted synthesis, in vitro and in silico evaluation of 2-pyrazolines.
Diabetes Complications
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Diabetes Complications
Identification of an aldose reductase inhibitor site by affinity labeling.
Diabetes Complications
Identification of new potent inhibitor of aldose reductase from Ocimum basilicum.
Diabetes Complications
Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
Diabetes Complications
In Vitro and In Vivo Inhibitory Activities of Four Indian Medicinal Plant Extracts and their Major Components on Rat Aldose Reductase and Generation of Advanced Glycation Endproducts.
Diabetes Complications
In-vitro assessment of a hypersensitivity syndrome associated with sorbinil.
Diabetes Complications
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Diabetes Complications
Increased white cell aldose reductase mRNA levels in diabetic patients.
Diabetes Complications
Inhibition behaviours of some phenolic acids on rat kidney aldose reductase enzyme: an in vitro study.
Diabetes Complications
Inhibition of ?-glucosidase, ?-amylase, and aldose reductase by potato polyphenolic compounds.
Diabetes Complications
Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol.
Diabetes Complications
Inhibition of aldose reductase by flavonoids: possible attenuation of diabetic complications.
Diabetes Complications
Inhibition of aldose reductase by phenylethanoid glycoside isolated from the seeds of Paulownia coreana.
Diabetes Complications
Inhibition of aldose reductase from human retina.
Diabetes Complications
Inhibition of phosphatidylinositol synthase by glucose in human retinal pigment epithelial cells.
Diabetes Complications
Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts.
Diabetes Complications
Inhibitory activities of selected Kampo formulations on human aldose reductase.
Diabetes Complications
Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase.
Diabetes Complications
Inhibitory activity of Aralia continentalis roots on protein tyrosine phosphatase 1B and rat lens aldose reductase.
Diabetes Complications
Inhibitory constituents of aldose reductase in the fruiting body of Phellinus linteus.
Diabetes Complications
Inhibitory Effect of Chemical Constituents Isolated from Artemisia iwayomogi on Polyol Pathway and Simultaneous Quantification of Major Bioactive Compounds.
Diabetes Complications
Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity.
Diabetes Complications
Inhibitory effect of total lignan from Fructus Arctii on aldose reductase.
Diabetes Complications
Inhibitory effect of ursolic acid derivatives on recombinant human aldose reductase.
Diabetes Complications
Inhibitory effects of 2'-hydroxychalcones on rat lens aldose reductase and rat platelet aggregation.
Diabetes Complications
Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
Diabetes Complications
Inhibitory effects of Nelumbo nucifera leaves on rat lens aldose reductase, advanced glycation endproducts formation, and oxidative stress.
Diabetes Complications
Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships.
Diabetes Complications
Inhibitory effects of Zingiber officinale Roscoe derived components on aldose reductase activity in vitro and in vivo.
Diabetes Complications
Intrinsic inhibition of aldose reductase.
Diabetes Complications
Inventing and understanding catalytic, enantioselective reactions.
Diabetes Complications
In vitro and in vivo evaluation of pterostilbene for the management of diabetic complications.
Diabetes Complications
Is sorbitol dehydrogenase gene expression affected by streptozotocin-diabetes in the rat?
Diabetes Complications
Isoflavonoids from the rhizomes of Belamcanda chinensis and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues.
Diabetes Complications
Isolation and characterization of cDNA clones encoding aldose reductase.
Diabetes Complications
Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
Diabetes Complications
Kinetic and structural characterization of the glutathione-binding site of aldose reductase.
Diabetes Complications
Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase.
Diabetes Complications
Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
Diabetes Complications
Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
Diabetes Complications
Localization of aldose reductase in the human eye.
Diabetes Complications
Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
Diabetes Complications
Long-term induction of an aldose reductase protein by basic fibroblast growth factor in rat astrocytes in vitro.
Diabetes Complications
Mechanism of capsaicin inhibition of aldose reductase activity.
Diabetes Complications
Mechanistic inhibition of non-enzymatic glycation and aldose reductase activity by naringenin: Binding, enzyme kinetics and molecular docking analysis.
Diabetes Complications
Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.
Diabetes Complications
Method for isolating tight-binding inhibitors of rat lens aldose reductase.
Diabetes Complications
Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase.
Diabetes Complications
Methylglyoxal, glyoxalases and the development of diabetic complications.
Diabetes Complications
Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes.
Diabetes Complications
Minimal effects of two aldose reductase inhibitors, AL-1576 and AL-4114, after subacute topical-ocular dosing on xenobiotic biotransformation in rabbits.
Diabetes Complications
Modelling of aldose reductase inhibitory activity of pyrrol-1-yl-acetic acid derivatives by means of multivariate statistics.
Diabetes Complications
Modelling the catalytic reaction in human aldose reductase.
Diabetes Complications
Modulation of Advanced Glycation End Products, Sorbitol, and Aldose Reductase by Hydroalcohol Extract of Lagenaria siceraria Mol Standl in Diabetic Complications: An In Vitro Approach.
Diabetes Complications
Modulation of aldose reductase activity by aldose hemiacetals.
Diabetes Complications
Molecular cloning of testicular 20 alpha-hydroxysteroid dehydrogenase: identity with aldose reductase.
Diabetes Complications
Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
Diabetes Complications
N-(Aroyl)-N-(arylmethyloxy)-?-alanines: Selective inhibitors of aldose reductase.
Diabetes Complications
Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.
Diabetes Complications
Neuroprotective effects of oleuropein on retina photoreceptors cells primary culture and olive leaf extract and oleuropein inhibitory effects on aldose reductase in a diabetic model: Meriones shawi.
Diabetes Complications
New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition.
Diabetes Complications
Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes.
Diabetes Complications
Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells.
Diabetes Complications
Nitric oxide up-regulates aldose reductase expression in rat vascular smooth muscle cells: a potential role for aldose reductase in vascular remodeling.
Diabetes Complications
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Diabetes Complications
Noninvasive evaluation of effects of an aldose reductase inhibitor in rat brain by 19F FDG NMR spectroscopy.
Diabetes Complications
Novel aldose reductase inhibitors: a patent survey (2006--present).
Diabetes Complications
Novel quercetin derivatives: From redox properties to promising treatment of oxidative stress related diseases.
Diabetes Complications
Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors.
Diabetes Complications
Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.
Diabetes Complications
Novel sites of aldose reductase immunolocalization in normal and streptozotocin-diabetic rats.
Diabetes Complications
Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications.
Diabetes Complications
Oral baicalin and liquid extract of licorice reduce sorbitol levels in red blood cell of diabetic rats.
Diabetes Complications
Osmolarity and glucose differentially regulate aldose reductase activity in cultured mouse podocytes.
Diabetes Complications
Osteomeles schwerinae extracts inhibits the binding to receptors of advanced glycation end products and TGF-?1 expression in mesangial cells under diabetic conditions.
Diabetes Complications
Oxidized aldose reductase: in vivo factor not in vitro artifact.
Diabetes Complications
Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity.
Diabetes Complications
Parasitoid wasp venom elevates sorbitol and alters expression of metabolic genes in human kidney cells.
Diabetes Complications
Phospho-Site-Specific Antibody Microarray to Study the State of Protein Phosphorylation in the Retina.
Diabetes Complications
Plants used in the management of diabetic complications.
Diabetes Complications
Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.
Diabetes Complications
Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.
Diabetes Complications
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Diabetes Complications
Presence of a closely related subgroup in the aldo-ketoreductase family of the mouse.
Diabetes Complications
Presence of aldose reductase inhibitors in tea leaves.
Diabetes Complications
Prevention of Diabetic Complications by Walnut Leaf Extract via Changing Aldose Reductase Activity: An Experiment in Diabetic Rat Tissue.
Diabetes Complications
Prevention of tubulin/aldose reductase association delays the development of pathological complications in diabetic rats.
Diabetes Complications
Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.
Diabetes Complications
Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Diabetes Complications
Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry.
Diabetes Complications
Production of crystals of human aldose reductase with very high resolution diffraction.
Diabetes Complications
Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: an attempt to standardize the botanicals for amelioration of diabetes complications.
Diabetes Complications
Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
Diabetes Complications
Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat.
Diabetes Complications
Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
Diabetes Complications
Protein structure-based de novo design and synthesis of aldose reductase inhibitors.
Diabetes Complications
Pterin-7-carboxamides as a new class of aldose reductase inhibitors.
Diabetes Complications
Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
Diabetes Complications
QM/MM analysis, synthesis and biological evaluation of epalrestat based mutual-prodrugs for diabetic neuropathy and nephropathy.
Diabetes Complications
Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Immunoassay of human aldose reductase.
Diabetes Complications
Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
Diabetes Complications
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
Diabetes Complications
Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy.
Diabetes Complications
Rapid Identification and Isolation of Inhibitors of Rat Lens Aldose Reductase and Antioxidant in Maackia amurensis.
Diabetes Complications
Rat kidney aldose reductase and aldehyde reductase and polyol production in rat kidney.
Diabetes Complications
Rat lens aldose reductase: rapid purification and comparison with human placental aldose reductase.
Diabetes Complications
Recent clinical experience with aldose reductase inhibitors.
Diabetes Complications
Recent studies of aldose reductase enzyme inhibition for diabetic complications.
Diabetes Complications
Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications.
Diabetes Complications
Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Diabetes Complications
Regulation of plasma fructose and mortality in mice by the aldose reductase inhibitor lidorestat.
Diabetes Complications
Regulation of the human taurine transporter by oxidative stress in retinal pigment epithelial cells stably transformed to overexpress aldose reductase.
Diabetes Complications
Regulation on SIRT1-PGC-1?/Nrf2 pathway together with selective inhibition of aldose reductase makes compound hr5F a potential agent for the treatment of diabetic complications.
Diabetes Complications
Residues affecting the catalysis and inhibition of rat lens aldose reductase.
Diabetes Complications
Restriction fragment length polymorphisms of the human aldose reductase gene: a preliminary report.
Diabetes Complications
Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies.
Diabetes Complications
Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy.
Diabetes Complications
Role of polyol pathway in nonenzymatic glycation.
Diabetes Complications
Screening of Korean forest plants for rat lens aldose reductase inhibition.
Diabetes Complications
Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications.
Diabetes Complications
Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
Diabetes Complications
Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
Diabetes Complications
Sorbitol metabolism in inner medullary collecting duct cells of diabetic rats.
Diabetes Complications
Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.
Diabetes Complications
Spiro hydantoin aldose reductase inhibitors.
Diabetes Complications
Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
Diabetes Complications
Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes.
Diabetes Complications
Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
Diabetes Complications
Structural bases for the inhibition of aldose reductase by phenolic compounds.
Diabetes Complications
Structure based comprehensive modelling, spatial fingerprints mapping and ADME screening of curcumin analogues as novel ALR2 inhibitors.
Diabetes Complications
Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
Diabetes Complications
Study of aldose reductase inhibition in intact lenses by 13C nuclear magnetic resonance spectroscopy.
Diabetes Complications
Substituted derivatives of indole acetic acid as aldose reductase inhibitors with antioxidant activity: structure-activity relationship.
Diabetes Complications
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
Diabetes Complications
Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate.
Diabetes Complications
Sulfonyl group-containing compounds in the design of potential drugs for the treatment of diabetes and its complications.
Diabetes Complications
Symposium: Aldose reductase and the complications of diabetes mellitus: reviews of preclinical studies in eyes, nerves, and kidneys. London, September 1984. Proceedings.
Diabetes Complications
Synthesis and activity of a new series of (Z)-3-phenyl-2-benzoylpropenoic acid derivatives as aldose reductase inhibitors.
Diabetes Complications
Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives.
Diabetes Complications
Synthesis and Aldose Reductase Inhibitory Activity of Botryllazine A Derivatives.
Diabetes Complications
Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors Bearing a Spirobenzopyran Scaffold.
Diabetes Complications
Synthesis and structure-activity relationship studies of quinoxaline derivatives as aldose reductase inhibitors.
Diabetes Complications
Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
Diabetes Complications
Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors.
Diabetes Complications
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product.
Diabetes Complications
Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.
Diabetes Complications
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
Diabetes Complications
The activity of aldose reductase is elevated in diabetic mouse heart.
Diabetes Complications
The aldo-keto reductases (AKRs): Overview.
Diabetes Complications
The aldose reductase inhibitor site.
Diabetes Complications
The aldose reductase inhibitory capacity of Sorbus domestica fruit extracts depends on their phenolic content and may be useful for the control of diabetic complications.
Diabetes Complications
The combined extract of purple waxy corn and ginger prevents cataractogenesis and retinopathy in streptozotocin-diabetic rats.
Diabetes Complications
The crystal structure of the aldose reductase.NADPH binary complex.
Diabetes Complications
The effect of hypertonicity on aldose reductase, alpha B-crystallin, and organic osmolytes in the retinal pigment epithelium.
Diabetes Complications
The effect of non-enzymatic glycation on recombinant human aldose reductase.
Diabetes Complications
The Effect of Urinary pH and Flow Rate on the Renal Elimination of Zopolrestat and Zopolrestat Glucuronide in Humans.
Diabetes Complications
The effects of streptozotocin-induced diabetes and aldose reductase inhibition with sorbinil, on left and right atrial function in the rat.
Diabetes Complications
The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
Diabetes Complications
The Human Aldose Reductase AKR1B1 Qualifies as the Primary Prostaglandin F Synthase in the Endometrium.
Diabetes Complications
The identification of aldose reductase in the pathogenesis of diabetic complications: the background.
Diabetes Complications
The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity.
Diabetes Complications
The inhibitory effect of benzodiazepine derivatives on the bovine lens aldose reductase enzyme.
Diabetes Complications
The involvement of aldose reductase in diabetic complications.
Diabetes Complications
The relationship between aldose reductase gene C106T polymorphism and the severity of retinopathy in Type 2 diabetic patients: A case-control study.
Diabetes Complications
The role of aldose reductase in the development of diabetic complications.
Diabetes Complications
The role of aldose reductase inhibitors in diabetic complications: recent trends.
Diabetes Complications
The use of dimethylsulfoxide as a solvent in enzyme inhibition studies: the case of aldose reductase.
Diabetes Complications
Therapeutic potential of resveratrol in diabetic complications: In vitro and in vivo studies.
Diabetes Complications
Three-dimensional quantitative structure-activity relationships and docking studies of some structurally diverse flavonoids and design of new aldose reductase inhibitors.
Diabetes Complications
Thymol, a monoterpene, inhibits aldose reductase and high-glucose-induced cataract on isolated goat lens.
Diabetes Complications
Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats.
Diabetes Complications
Tissue-specific expression of two aldose reductase-like genes in mice: abundant expression of mouse vas deferens protein and fibroblast growth factor-regulated protein in the adrenal gland.
Diabetes Complications
Tracing changes in protonation: a prerequisite to factorize thermodynamic data of inhibitor binding to aldose reductase.
Diabetes Complications
Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Diabetes Complications
Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
Diabetes Complications
Zopolrestat as a human glyoxalase?i inhibitor and its structural basis.
Diabetes Complications
[Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications]
Diabetes Complications
[Ciliary body changes associate with aldose reductase in galactosemic rats (2)]
Diabetes Complications
[Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications]
Diabetes Complications
[Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients]
Diabetes Complications
[Effects of transgenic expression of human aldose reductase on diabetic complications]
Diabetes Complications
[Effects of transgenic human aldose reductase and sorbitol dehydrogenase deficiency on diabetes complications]
Diabetes Complications
[Progress in research of aldose reductase inhibitors in traditional medicinal herbs]
Diabetes Complications
[Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors]
Diabetes Complications
[Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors]
Diabetes Insipidus
Genetic restoration of aldose reductase to the collecting tubules restores maturation of the urine concentrating mechanism.
Diabetes Mellitus
(AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
Diabetes Mellitus
(CA)(n) dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1.
Diabetes Mellitus
31P NMR studies of the diabetic lens.
Diabetes Mellitus
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Diabetes Mellitus
Aldose reductase (AC)(n) microsatellite polymorphism and diabetic microvascular complications in Caucasian Type 1 diabetes mellitus.
Diabetes Mellitus
Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.
Diabetes Mellitus
Aldose reductase and IGF-I gene expression in aortic and arteriolar smooth muscle during hypo- and hyperinsulinemic diabetes.
Diabetes Mellitus
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
Diabetes Mellitus
Aldose reductase and sorbitol dehydrogenase activities in diabetic brain: in vivo kinetic studies using 19F 3-FDG NMR in rats.
Diabetes Mellitus
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
Diabetes Mellitus
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus.
Diabetes Mellitus
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Diabetes Mellitus
Aldose reductase inhibitors and diabetic complications.
Diabetes Mellitus
Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics.
Diabetes Mellitus
Aldose reductase inhibitors and the complications of diabetes mellitus.
Diabetes Mellitus
Aldose reductase inhibitors: an update.
Diabetes Mellitus
Aldose reductase messenger RNA in the lens epithelium in vivo: effects of diabetes mellitus and galactosaemia.
Diabetes Mellitus
Aldose reductase-deficient mice develop nephrogenic diabetes insipidus.
Diabetes Mellitus
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
Diabetes Mellitus
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
Diabetes Mellitus
Anti-hyperglycemic effect of Potentilla discolor decoction on obese-diabetic (Ob-db) mice and its chemical composition.
Diabetes Mellitus
Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
Diabetes Mellitus
Association of aldose reductase gene (AKR1B1) polymorphism with diabetic retinopathy.
Diabetes Mellitus
Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in chinese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
Diabetes Mellitus
Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies.
Diabetes Mellitus
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
Diabetes Mellitus
Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Diabetes Mellitus
Chlorophytum alismifolium mitigates microvascular complications of type 2 diabetes mellitus: the involvement of oxidative stress and aldose reductase.
Diabetes Mellitus
Clinical significance of erythrocyte sorbitol-blood glucose ratios in type II diabetes mellitus.
Diabetes Mellitus
Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose.
Diabetes Mellitus
Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Diabetes Mellitus
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Diabetes Mellitus
Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.
Diabetes Mellitus
Design, Synthesis and Evaluation of Rhodanine Derivatives as Aldose Reductase Inhibitors.
Diabetes Mellitus
Determinants of retinopathy progression in type 1 diabetes mellitus.
Diabetes Mellitus
Developmental and physiological regulation of aldose reductase mRNA expression in renal medulla.
Diabetes Mellitus
Diabetic neuropathy in elderly patients. What can be done?
Diabetes Mellitus
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Diabetes Mellitus
Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
Diabetes Mellitus
Effect of a novel mutation in 5'-regulatory region of aldose reductase gene on its expression.
Diabetes Mellitus
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy.
Diabetes Mellitus
Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model.
Diabetes Mellitus
Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
Diabetes Mellitus
Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
Diabetes Mellitus
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Diabetes Mellitus
Exploring antidiabetic potential of adamantyl-thiosemicarbazones via aldose reductase (ALR2) inhibition.
Diabetes Mellitus
Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship.
Diabetes Mellitus
Gene regulation of aldose-, aldehyde- and a renal specific oxido reductase (RSOR) in the pathobiology of diabetes mellitus.
Diabetes Mellitus
Impaired myelinated fiber regeneration following freeze-injury in rats with streptozotocin-induced diabetes: involvement of the polyol pathway.
Diabetes Mellitus
In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B.
Diabetes Mellitus
Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Diabetes Mellitus
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Diabetes Mellitus
Minalrestat and leukocyte migration in diabetes mellitus.
Diabetes Mellitus
Morphological and functional changes in the diabetic peripheral nerve: using diagnostic ultrasound and neurosensory testing to select candidates for nerve decompression.
Diabetes Mellitus
Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
Diabetes Mellitus
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
Diabetes Mellitus
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
Diabetes Mellitus
Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus.
Diabetes Mellitus
Polymorphisms of Aldose Reductase (ALR2) Regulatory Gene are Risk Factors for Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients in Bali, Indonesia.
Diabetes Mellitus
Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus.
Diabetes Mellitus
Preventing and treating actions of compound lian zhu capsule on micrangium lesions in diabetic rats.
Diabetes Mellitus
Prevention of tubulin/aldose reductase association delays the development of pathological complications in diabetic rats.
Diabetes Mellitus
Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.
Diabetes Mellitus
Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening.
Diabetes Mellitus
Retinal dystrophy: development retarded by galactose feeding in spontaneously hypertensive rats.
Diabetes Mellitus
Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats.
Diabetes Mellitus
Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group.
Diabetes Mellitus
Role of Cys-298 in specific recognition of glutathione by aldose reductase.
Diabetes Mellitus
Screening and Isolating Major Aldose Reductase Inhibitors from the Seeds of Evening Primrose (Oenothera biennis).
Diabetes Mellitus
Sorbinil does not prevent hyperfiltration, elevated ultrafiltration pressure and albuminuria in streptozotocin-diabetic rats.
Diabetes Mellitus
Spiro hydantoin aldose reductase inhibitors.
Diabetes Mellitus
Spirohydantoin inhibitors of aldose reductase inhibit iron- and copper-catalysed ascorbate oxidation in vitro.
Diabetes Mellitus
Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
Diabetes Mellitus
Substance P levels in peripheral nerve, skin, atrial myocardium and gastrointestinal tract of rats with long-term diabetes mellitus. Effects of aldose reductase inhibition.
Diabetes Mellitus
Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene.
Diabetes Mellitus
Symposium: Aldose reductase and the complications of diabetes mellitus: reviews of preclinical studies in eyes, nerves, and kidneys. London, September 1984. Proceedings.
Diabetes Mellitus
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
Diabetes Mellitus
The crystal structure of the aldose reductase.NADPH binary complex.
Diabetes Mellitus
The effect of aldose reductase inhibition with ponalrestat on the width of the capillary basement membrane in diabetes mellitus.
Diabetes Mellitus
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
Diabetes Mellitus
The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation.
Diabetes Mellitus
The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus.
Diabetes Mellitus
Topical KINOSTAT ameliorates the clinical development and progression of cataracts in dogs with diabetes mellitus.
Diabetes Mellitus
Vascular endothelium dysfunction: a conservative target in metabolic disorders.
Diabetes Mellitus
[Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy]
Diabetes Mellitus
[Polymorphism of aldose reductase gene and susceptibility to retinopathy and nephropathy in Caucasians with type 1 diabetes]
Diabetes Mellitus
[The role of methylglyoxal in the development of diabetic complications]
Diabetes Mellitus
[Treatment of chronic complications of diabetes mellitus with aldose reductase inhibitors]
Diabetes Mellitus
[Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors]
Diabetes Mellitus
[Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus]
Diabetes Mellitus, Experimental
Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
Diabetes Mellitus, Experimental
Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inositol supplementation and aldose reductase inhibition.
Diabetes Mellitus, Experimental
Control of sorbitol metabolism in renal inner medulla of diabetic rats: regulation by substrate, cosubstrate and products of the aldose reductase reaction.
Diabetes Mellitus, Experimental
Effect of streptozotocin diabetes on motor and inhibitory transmission in rat anococcygeus.
Diabetes Mellitus, Experimental
Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus.
Diabetes Mellitus, Experimental
Studies of sorbinil on axonal transport in streptozotocin-diabetic rats.
Diabetes Mellitus, Experimental
The effect of aldose reductase inhibition and dietary protein restriction on renal function in experimental diabetes mellitus.
Diabetes Mellitus, Experimental
The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus.
Diabetes Mellitus, Type 1
A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes.
Diabetes Mellitus, Type 1
AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Diabetes Mellitus, Type 1
Aldose reductase (AC)(n) microsatellite polymorphism and diabetic microvascular complications in Caucasian Type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Aldose reductase gene expression is increased in diabetic nephropathy.
Diabetes Mellitus, Type 1
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Determinants of retinopathy progression in type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Diabetic nephropathy is associated with the 5'-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes.
Diabetes Mellitus, Type 1
Diabetic neuropathy.
Diabetes Mellitus, Type 1
Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
Diabetes Mellitus, Type 1
Effect of an aldose reductase inhibiting agent on limited joint mobility in IDDM.
Diabetes Mellitus, Type 1
Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy.
Diabetes Mellitus, Type 1
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Diabetes Mellitus, Type 1
Neutrophil aldose reductase activity and its association with established diabetic microvascular complications.
Diabetes Mellitus, Type 1
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Diabetes Mellitus, Type 1
Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy.
Diabetes Mellitus, Type 1
Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by 6 mo of aldose reductase inhibition.
Diabetes Mellitus, Type 1
Risk factors for progression of distal symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research Group.
Diabetes Mellitus, Type 1
Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
Diabetes Mellitus, Type 1
The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.
Diabetes Mellitus, Type 1
Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
Diabetes Mellitus, Type 1
Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
[Polymorphism of aldose reductase gene and susceptibility to retinopathy and nephropathy in Caucasians with type 1 diabetes]
Diabetes Mellitus, Type 1
[Polymorphism of the dinucleotide repeat inside the aldose reductase gene in normal states and in patients with insulin-dependent diabetes mellitus with vascular complications]
Diabetes Mellitus, Type 1
[The pathogenetic characteristics and the possible ways for the pharmacological correction of insulin-dependent diabetes mellitus]
Diabetes Mellitus, Type 1
[Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus]
Diabetes Mellitus, Type 2
(AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Activities of aldose reductase, ATPases, and nucleotide concentrations of erythrocytes in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Diabetes Mellitus, Type 2
Adding value to polyvinylpolypyrrolidone winery residue: A resource of polyphenols with neuroprotective effects and ability to modulate type 2 diabetes-relevant enzymes.
Diabetes Mellitus, Type 2
Additive effect of aldose reductase Z-4 microsatellite polymorphism and glycaemic control on cataract development in type 2 diabetes.
Diabetes Mellitus, Type 2
Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians.
Diabetes Mellitus, Type 2
Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes.
Diabetes Mellitus, Type 2
Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Diabetes Mellitus, Type 2
An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.
Diabetes Mellitus, Type 2
An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.
Diabetes Mellitus, Type 2
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
Diabetes Mellitus, Type 2
Association of aldose reductase gene (AKR1B1) polymorphism with diabetic retinopathy.
Diabetes Mellitus, Type 2
Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in chinese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients.
Diabetes Mellitus, Type 2
Association of retinopathy with a microsatellite at 5' end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes.
Diabetes Mellitus, Type 2
Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy.
Diabetes Mellitus, Type 2
C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control.
Diabetes Mellitus, Type 2
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Chemometrics Optimized Extraction Procedures, Phytosynergistic Blending and in vitro Screening of Natural Enzyme Inhibitors Amongst Leaves of Tulsi, Banyan and Jamun.
Diabetes Mellitus, Type 2
Chlorophytum alismifolium mitigates microvascular complications of type 2 diabetes mellitus: the involvement of oxidative stress and aldose reductase.
Diabetes Mellitus, Type 2
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Diabetes Mellitus, Type 2
Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
Diabetes Mellitus, Type 2
Diabetic nephropathy is associated with the 5'-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes.
Diabetes Mellitus, Type 2
Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
Diabetes Mellitus, Type 2
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Diabetes Mellitus, Type 2
Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of a novel mutation in 5'-regulatory region of aldose reductase gene on its expression.
Diabetes Mellitus, Type 2
Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine.
Diabetes Mellitus, Type 2
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Diabetes Mellitus, Type 2
Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients.
Diabetes Mellitus, Type 2
Epithelial cell density in cataractous lenses of patients with diabetes: association with erythrocyte aldose reductase.
Diabetes Mellitus, Type 2
Flavonoids as promising lead compounds in type 2 diabetes mellitus: molecules of interest and structure-activity relationship.
Diabetes Mellitus, Type 2
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
Diabetes Mellitus, Type 2
High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
Diabetes Mellitus, Type 2
Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy.
Diabetes Mellitus, Type 2
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Diabetes Mellitus, Type 2
Neutrophil aldose reductase activity and its association with established diabetic microvascular complications.
Diabetes Mellitus, Type 2
Oxidative stress and male IGF-1, gonadotropin and related hormones in diabetic patients.
Diabetes Mellitus, Type 2
Pathological mechanisms involved in diabetic neuropathy: can we slow the process?
Diabetes Mellitus, Type 2
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.
Diabetes Mellitus, Type 2
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes: response to Wang et al.
Diabetes Mellitus, Type 2
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
Diabetes Mellitus, Type 2
Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients.
Diabetes Mellitus, Type 2
Risk factors for cataract in Chinese patients with type 2 diabetes: evidence for the influence of the aldose reductase gene.
Diabetes Mellitus, Type 2
The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes.
Diabetes Mellitus, Type 2
The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Diabetes Mellitus, Type 2
The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
Diabetes Mellitus, Type 2
The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
Diabetes Mellitus, Type 2
The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.
Diabetes Mellitus, Type 2
Virtual screening of plant derived compounds for aldose reductase inhibition using molecular docking.
Diabetes Mellitus, Type 2
Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro.
Diabetes Mellitus, Type 2
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]
Diabetic Angiopathies
Aldose reductase (AC)n gene polymorphism in Iranian patients with type 2 diabetic microangiopathy; a case-control study.
Diabetic Angiopathies
Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals.
Diabetic Angiopathies
Aldose reductase gene is associated with diabetic macroangiopathy in Japanese Type 2 diabetic patients.
Diabetic Angiopathies
Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients.
Diabetic Angiopathies
Diabetes-induced increases in vascular permeability and changes in granulation tissue levels of sorbitol, myo-inositol, chiro-inositol, and scyllo-inositol are prevented by sorbinil.
Diabetic Angiopathies
Effect of an aldose reductase inhibitor on type IV collagen production by human endothelial cells cultured in high glucose.
Diabetic Angiopathies
Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
Diabetic Angiopathies
Microangiopathy in diabetes mellitus: I. Causes, prevention and treatment.
Diabetic Angiopathies
Potential Role of Gene Regulator NFAT5 in the Pathogenesis of Diabetes Mellitus.
Diabetic Angiopathies
Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
Diabetic Angiopathies
Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Diabetic Angiopathies
The effect of aldose reductase inhibition by JMC-2004 on hyperglycemia-induced endothelial dysfunction.
Diabetic Angiopathies
[Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor]
Diabetic Nephropathies
(AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.
Diabetic Nephropathies
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
Diabetic Nephropathies
AKR1B10 is induced by hyperglycaemia and lipopolysaccharide in patients with diabetic nephropathy.
Diabetic Nephropathies
Aldose reductase and the role of the polyol pathway in diabetic nephropathy.
Diabetic Nephropathies
Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
Diabetic Nephropathies
Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy.
Diabetic Nephropathies
Aldose reductase gene expression is increased in diabetic nephropathy.
Diabetic Nephropathies
Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus.
Diabetic Nephropathies
Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus.
Diabetic Nephropathies
Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients.
Diabetic Nephropathies
Aldose reductase in the etiology of diabetic complications: 2. Nephropathy.
Diabetic Nephropathies
Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
Diabetic Nephropathies
Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.
Diabetic Nephropathies
Aldose reductase inhibition, glomerular metabolism, and diabetic nephropathy.
Diabetic Nephropathies
Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.
Diabetic Nephropathies
Aldose reductase inhibitors and diabetic kidney disease.
Diabetic Nephropathies
Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgf?1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
Diabetic Nephropathies
Aldose reductase, glomerular metabolism, and diabetic nephropathy.
Diabetic Nephropathies
Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor.
Diabetic Nephropathies
Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus.
Diabetic Nephropathies
AR C-106T gene polymorphism and diabetic nephropathy in the Eastern Asians with T2DM: A meta-analysis including 2120 subjects.
Diabetic Nephropathies
Association between (AC)n dinucleotide repeat polymorphism at the 5'-end of the aldose reductase gene and diabetic nephropathy: a meta-analysis.
Diabetic Nephropathies
Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients.
Diabetic Nephropathies
Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients.
Diabetic Nephropathies
C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control.
Diabetic Nephropathies
C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus.
Diabetic Nephropathies
Cyclocarya paliurus extract alleviates diabetic nephropathy by inhibiting oxidative stress and aldose reductase.
Diabetic Nephropathies
Diabetic nephropathy is associated with the 5'-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes.
Diabetic Nephropathies
Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes.
Diabetic Nephropathies
Diabetic nephropathy--prevention and treatment.
Diabetic Nephropathies
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Diabetic Nephropathies
Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
Diabetic Nephropathies
DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGF?1 signaling.
Diabetic Nephropathies
Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy.
Diabetic Nephropathies
Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats.
Diabetic Nephropathies
Effects of aldose reductase inhibitors on renal blood flow parameters in patients with early diabetic nephropathy.
Diabetic Nephropathies
Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathy.
Diabetic Nephropathies
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.
Diabetic Nephropathies
Gene expression and identification of gene therapy targets in diabetic nephropathy.
Diabetic Nephropathies
Genetic deficiency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice.
Diabetic Nephropathies
Glomerular changes in diabetes mellitus.
Diabetic Nephropathies
Glucose transporters of the glomerulus and the implications for diabetic nephropathy.
Diabetic Nephropathies
High glucose induction of DNA-binding activity of the transcription factor NFkappaB in patients with diabetic nephropathy.
Diabetic Nephropathies
Identification of a renal-specific oxido-reductase in newborn diabetic mice.
Diabetic Nephropathies
Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestat.
Diabetic Nephropathies
Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats.
Diabetic Nephropathies
Is rs759853 polymorphism in promoter of aldose reductase gene a risk factor for diabetic nephropathy? A meta-analysis.
Diabetic Nephropathies
Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Diabetic Nephropathies
Novel insights in the treatment of diabetic nephropathy.
Diabetic Nephropathies
Polymorphism in the 5'-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes.
Diabetic Nephropathies
Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase.
Diabetic Nephropathies
Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.
Diabetic Nephropathies
Role of aldose reductase in the high glucose induced expression of fibronectin in human mesangial cells.
Diabetic Nephropathies
Short Report : TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Diabetic Nephropathies
The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes.
Diabetic Nephropathies
The 5'-end polymorphism of the aldose reductase gene is not associated with diabetic nephropathy in Caucasian type I diabetic patients.
Diabetic Nephropathies
The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
Diabetic Nephropathies
The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
Diabetic Nephropathies
The effects of aldose reductase inhibitors in diabetic nephropathy.
Diabetic Nephropathies
The localisation of sorbitol pathway activity in the rat renal cortex and its relationship to the pathogenesis of the renal complications of diabetes mellitus.
Diabetic Nephropathies
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Diabetic Nephropathies
The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus.
Diabetic Nephropathies
Variants in the gene encoding aldose reductase (AKR1B1) and diabetic nephropathy in American Indians.
Diabetic Nephropathies
WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling.
Diabetic Nephropathies
Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy.
Diabetic Nephropathies
[Effect of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients]
Diabetic Nephropathies
[Effects of Shendan Jianyi Capsule on aldose reductase activity of kidney in diabetic rats]
Diabetic Nephropathies
[Progress in research of aldose reductase inhibitors in traditional medicinal herbs]
Diabetic Nephropathies
[The role of cellular glucose transporters in pathogenesis of diabetic nephropathy]
Diabetic Nephropathies
[The role of genetic studies in finding the etiopathogenesis of diabetes mellitus]
Diabetic Neuropathies
3-Mercapto-5H-1,2,4-Triazino[5,6-b]Indole-5-Acetic Acid (Cemtirestat) Alleviates Symptoms of Peripheral Diabetic Neuropathy in Zucker Diabetic Fatty (ZDF) Rats: A Role of Aldose Reductase.
Diabetic Neuropathies
A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
Diabetic Neuropathies
A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
Diabetic Neuropathies
A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
Diabetic Neuropathies
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Diabetic Neuropathies
A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
Diabetic Neuropathies
A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing.
Diabetic Neuropathies
A spontaneously immortalized Schwann cell line from aldose reductase-deficient mice as a useful tool for studying polyol pathway and aldehyde metabolism.
Diabetic Neuropathies
Advanced Diabetic Neuropathy: A Point of no Return?
Diabetic Neuropathies
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Diabetic Neuropathies
Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Diabetic Neuropathies
Aldose reductase inhibition for diabetic neuropathy.
Diabetic Neuropathies
Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
Diabetic Neuropathies
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
Diabetic Neuropathies
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Diabetic Neuropathies
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.
Diabetic Neuropathies
Aldose reductase inhibitors in clinical practice. Preliminary studies on diabetic neuropathy and retinopathy.
Diabetic Neuropathies
Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.
Diabetic Neuropathies
Aldose reductase inhibitors: the end of an era or the need for different trial designs?
Diabetic Neuropathies
Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy.
Diabetic Neuropathies
Aldose reductase structures: implications for mechanism and inhibition.
Diabetic Neuropathies
Aldose reductase, still a compelling target for diabetic neuropathy.
Diabetic Neuropathies
Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage.
Diabetic Neuropathies
Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat.
Diabetic Neuropathies
An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
Diabetic Neuropathies
Anti-platelet action of GU-7, a 3-arylcoumarin derivative, purified from glycyrrhizae radix.
Diabetic Neuropathies
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Diabetic Neuropathies
Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
Diabetic Neuropathies
Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Diabetic Neuropathies
Characterization of a novel aldose reductase inhibitor, TAT, and its effects on streptozotocin-induced diabetic neuropathy in rats.
Diabetic Neuropathies
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
Diabetic Neuropathies
Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
Diabetic Neuropathies
Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Diabetic Neuropathies
Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
Diabetic Neuropathies
Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
Diabetic Neuropathies
Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Diabetic Neuropathies
Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Diabetic Neuropathies
Decreased endoneurial fluid electrolytes in normal rat sciatic nerve after aldose reductase inhibition.
Diabetic Neuropathies
Diabetic neuropathy in db/db mice develops independently of changes in ATPase and aldose reductase. A biochemical and immunohistochemical study.
Diabetic Neuropathies
Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats: effect of an aldose reductase inhibitor, TAT.
Diabetic Neuropathies
Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment.
Diabetic Neuropathies
Diabetic neuropathy.
Diabetic Neuropathies
Diabetic peripheral neuropathy.
Diabetic Neuropathies
Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Diabetic Neuropathies
Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Diabetic Neuropathies
Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years.
Diabetic Neuropathies
Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy.
Diabetic Neuropathies
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
Diabetic Neuropathies
Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Diabetic Neuropathies
Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
Diabetic Neuropathies
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
Diabetic Neuropathies
Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat.
Diabetic Neuropathies
Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
Diabetic Neuropathies
Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat.
Diabetic Neuropathies
Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Diabetic Neuropathies
Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Diabetic Neuropathies
Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study.
Diabetic Neuropathies
Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Diabetic Neuropathies
Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
Diabetic Neuropathies
Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
Diabetic Neuropathies
Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
Diabetic Neuropathies
Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Diabetic Neuropathies
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Diabetic Neuropathies
Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
Diabetic Neuropathies
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
Diabetic Neuropathies
Emerging drugs for diabetic neuropathy.
Diabetic Neuropathies
Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.
Diabetic Neuropathies
Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Diabetic Neuropathies
Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.
Diabetic Neuropathies
Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation.
Diabetic Neuropathies
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Diabetic Neuropathies
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective.
Diabetic Neuropathies
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Diabetic Neuropathies
Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
Diabetic Neuropathies
Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Diabetic Neuropathies
Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines.
Diabetic Neuropathies
Fidarestat improves cardiomyocyte contractile function in db/db diabetic obese mice through a histone deacetylase Sir2-dependent mechanism.
Diabetic Neuropathies
Fidarestat. Sanwa Kagaku/NC Curex/Sankyo.
Diabetic Neuropathies
Further clinical studies with an aldose reductase inhibitor in diabetic neuropathy.
Diabetic Neuropathies
Galactose neuropathy. Structural changes evaluated by nuclear magnetic resonance spectroscopy.
Diabetic Neuropathies
Galactosemic neuropathy in transgenic mice for human aldose reductase.
Diabetic Neuropathies
Green synthesis of silver nanoparticles by Nigella sativa extract alleviates diabetic neuropathy through anti-inflammatory and antioxidant effects.
Diabetic Neuropathies
I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Diabetic Neuropathies
LC-MS/MS method for the quantification of aldose reductase inhibitor - epalrestat and application to pharmacokinetic study.
Diabetic Neuropathies
Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
Diabetic Neuropathies
Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Diabetic Neuropathies
Lower limb problems in diabetic patients. What are the causes? What are the remedies?
Diabetic Neuropathies
Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
Diabetic Neuropathies
Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor.
Diabetic Neuropathies
Neurophysiological variables and fibrinolysis in insulin-dependent diabetes treated with an aldose reductase inhibitor or placebo. A double-blind randomized study.
Diabetic Neuropathies
Neuroprotective Effect of Epalrestat on Hydrogen Peroxide-Induced Neurodegeneration in SH-SY5Y Cellular Model.
Diabetic Neuropathies
Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy.
Diabetic Neuropathies
One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
Diabetic Neuropathies
Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
Diabetic Neuropathies
Pathogenesis of diabetic neuropathy--do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?
Diabetic Neuropathies
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
Diabetic Neuropathies
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Diabetic Neuropathies
Pharmacologic intervention in axonal excitability: in vivo assessment of nodal persistent sodium currents in human neuropathies.
Diabetic Neuropathies
Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
Diabetic Neuropathies
Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats.
Diabetic Neuropathies
Polyol pathway and diabetic neuropathy: selective preventive effects of an aldose reductase inhibitor in experimental diabetic neuropathy.
Diabetic Neuropathies
Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
Diabetic Neuropathies
Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
Diabetic Neuropathies
Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
Diabetic Neuropathies
Pyridine nucleotide redox abnormalities in diabetes.
Diabetic Neuropathies
Reactive, degenerative, and proliferative Schwann cell responses in experimental galactose and human diabetic neuropathy.
Diabetic Neuropathies
Recent advances in the management of diabetic distal symmetrical polyneuropathy.
Diabetic Neuropathies
Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
Diabetic Neuropathies
Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
Diabetic Neuropathies
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Diabetic Neuropathies
Role of glucosamine in development of diabetic neuropathy independent of the aldose reductase pathway.
Diabetic Neuropathies
Short Report : TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Diabetic Neuropathies
Sorbitol, myo-inositol and sodium-potassium ATPase in diabetic peripheral nerve.
Diabetic Neuropathies
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Diabetic Neuropathies
Studies of aldose reductase using neuronal cell culture and ligated rat sciatic nerve.
Diabetic Neuropathies
Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats.
Diabetic Neuropathies
Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene.
Diabetic Neuropathies
The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
Diabetic Neuropathies
The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents.
Diabetic Neuropathies
The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
Diabetic Neuropathies
The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus.
Diabetic Neuropathies
The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy.
Diabetic Neuropathies
The involvement of aldose reductase in alterations to neurotrophin receptors and neuronal cytoskeletal protein mRNA levels in the dorsal root ganglion of streptozotocin-induced diabetic rats.
Diabetic Neuropathies
The pathogenesis and prevention of diabetic neuropathy and nephropathy.
Diabetic Neuropathies
The pathology of diabetic neuropathy and the effects of aldose reductase inhibitors.
Diabetic Neuropathies
The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Diabetic Neuropathies
The time to develop treatments for diabetic neuropathy.
Diabetic Neuropathies
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Diabetic Neuropathies
Tolrestat improves nerve regeneration after crush injury in streptozocin-induced diabetic rats.
Diabetic Neuropathies
Tolrestat pharmacokinetics in rat peripheral nerve.
Diabetic Neuropathies
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Diabetic Neuropathies
Transgenic mice overexpressing aldose reductase in Schwann cells show more severe nerve conduction velocity deficit and oxidative stress under hyperglycemic stress.
Diabetic Neuropathies
Transition metals and polyol pathway in the development of diabetic neuropathy in rats.
Diabetic Neuropathies
Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
Diabetic Neuropathies
Treatment of diabetic neuropathy with inhibitors of the aldose reductase enzyme.
Diabetic Neuropathies
Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function.
Diabetic Neuropathies
Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach.
Diabetic Neuropathies
Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
Diabetic Neuropathies
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity.
Diabetic Neuropathies
[Aldose reductase inhibitors in diabetic neuropathy]
Diabetic Neuropathies
[Correction of diabetic neuropathies using aldose reductase inhibitors and pikamilon]
Diabetic Neuropathies
[Diabetes mellitus and its complications in Japan. Polyol pathway and diabetic neuropathy: selective preventive effect of aldose reductase inhibitor on the experimental diabetic neuropathy]
Diabetic Neuropathies
[Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)]
Diabetic Neuropathies
[Diabetic neuropathy].
Diabetic Neuropathies
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]
Diabetic Neuropathies
[Inhibition effect of epalrestat on rat lens osmotic expansion]
Diabetic Neuropathies
[Protective Effect of Epalrestat against Oxidative Stress-induced Cytotoxicity].
Diabetic Neuropathies
[Role of the polyol pathway in the occurrence of degenerative complications of diabetes]
Diabetic Neuropathies
[Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?]
Diabetic Retinopathy
A non-invasive, multi-target approach to treat diabetic retinopathy.
Diabetic Retinopathy
A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes.
Diabetic Retinopathy
A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group.
Diabetic Retinopathy
A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Diabetic Retinopathy
A systematic meta-analysis of genetic association studies for diabetic retinopathy.
Diabetic Retinopathy
Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.
Diabetic Retinopathy
Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians.
Diabetic Retinopathy
Aldose Reductase / Polyol Inhibitors For Diabetic Retinopathy.
Diabetic Retinopathy
Aldose reductase activity in retinal and cerebral microvessels and cultured vascular cells.
Diabetic Retinopathy
Aldose reductase and diabetic retinopathy.
Diabetic Retinopathy
Aldose reductase C-106T gene polymorphism is associated with diabetic retinopathy in Japanese patients with type 2 diabetes.
Diabetic Retinopathy
Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility.
Diabetic Retinopathy
Aldose reductase in the diabetic eye. XLIII Edward Jackson memorial lecture.
Diabetic Retinopathy
Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
Diabetic Retinopathy
Aldose Reductase Inhibition Prevents Endotoxin-Induced Inflammatory Responses in Retinal Microglia.
Diabetic Retinopathy
Aldose reductase, diabetes, and thickening of the retinal inner limiting membrane.
Diabetic Retinopathy
Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Diabetic Retinopathy
An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.
Diabetic Retinopathy
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Diabetic Retinopathy
An aldose reductase intragenic polymorphism associated with diabetic retinopathy.
Diabetic Retinopathy
Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects.
Diabetic Retinopathy
Association between Aldose Reductase Gene C(-106)T Polymorphism and Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
Diabetic Retinopathy
Association of aldose reductase gene (AKR1B1) polymorphism with diabetic retinopathy.
Diabetic Retinopathy
Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.
Diabetic Retinopathy
Association of c(-106)t polymorphism in aldose reductase gene with diabetic retinopathy in chinese patients with type 2 diabetes mellitus.
Diabetic Retinopathy
Association of retinopathy with a microsatellite at 5' end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes.
Diabetic Retinopathy
Association of the Aldose Reductase-106TT Genotype with Increased Risk for Diabetic Retinopathy in the Chinese Han Population: An Updated Meta-Analysis.
Diabetic Retinopathy
Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy.
Diabetic Retinopathy
Bioinformatics analysis of diabetic retinopathy using functional protein sequences.
Diabetic Retinopathy
C(-106)T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy.
Diabetic Retinopathy
Calcium dobesilate in the treatment of diabetic retinopathy.
Diabetic Retinopathy
Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
Diabetic Retinopathy
Current and future pharmacological intervention for diabetic retinopathy.
Diabetic Retinopathy
Current progress in clinical trials of aldose reductase inhibitors in Japan.
Diabetic Retinopathy
Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation.
Diabetic Retinopathy
Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.
Diabetic Retinopathy
Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes.
Diabetic Retinopathy
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Diabetic Retinopathy
Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
Diabetic Retinopathy
Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175.
Diabetic Retinopathy
DW1029M, a novel botanical drug candidate, inhibits advanced glycation end product formation, rat lens aldose reductase activity, and TGF?1 signaling.
Diabetic Retinopathy
Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats.
Diabetic Retinopathy
Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Diabetic Retinopathy
Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial.
Diabetic Retinopathy
Efficacy of treatment after measurable diabeticlike retinopathy in galactose-fed rats.
Diabetic Retinopathy
Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant.
Diabetic Retinopathy
Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Diabetic Retinopathy
Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
Diabetic Retinopathy
Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy.
Diabetic Retinopathy
Functional genomic studies of aldo-keto reductases.
Diabetic Retinopathy
Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats.
Diabetic Retinopathy
High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
Diabetic Retinopathy
In vitro retinal and erythrocyte polyol pathway regulation by hormones and an aldose reductase inhibitor.
Diabetic Retinopathy
Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process.
Diabetic Retinopathy
Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2.
Diabetic Retinopathy
Length rather than a specific allele of dinucleotide repeat in the 5' upstream region of the aldose reductase gene is associated with diabetic retinopathy.
Diabetic Retinopathy
Meta-analysis of the association between aldose reductase gene (CA)n microsatellite variants and risk of diabetic retinopathy.
Diabetic Retinopathy
Neuroprotective effects of oleuropein on retina photoreceptors cells primary culture and olive leaf extract and oleuropein inhibitory effects on aldose reductase in a diabetic model: Meriones shawi.
Diabetic Retinopathy
NIH conference. Aldose reductase and complications of diabetes.
Diabetic Retinopathy
Novel transgenic mouse models develop retinal changes associated with early diabetic retinopathy similar to those observed in rats with diabetes mellitus.
Diabetic Retinopathy
On the pathogenesis of diabetic retinopathy.
Diabetic Retinopathy
On the pathogenesis of diabetic retinopathy. A 1990 update.
Diabetic Retinopathy
Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus.
Diabetic Retinopathy
Polymorphisms of Aldose Reductase (ALR2) Regulatory Gene are Risk Factors for Diabetic Retinopathy in Type-2 Diabetes Mellitus Patients in Bali, Indonesia.
Diabetic Retinopathy
Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus.
Diabetic Retinopathy
Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.
Diabetic Retinopathy
Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors.
Diabetic Retinopathy
Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.
Diabetic Retinopathy
Relationship between aldose reductase enzyme and the signaling pathway of protein kinase C in the in vitro diabetic retinopathy model.
Diabetic Retinopathy
Role of aldose reductase in diabetes-induced retinal microglia activation.
Diabetic Retinopathy
Screening for and managing diabetic retinopathy: current approaches.
Diabetic Retinopathy
Short Report : TreatmentLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Diabetic Retinopathy
Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model.
Diabetic Retinopathy
Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy.
Diabetic Retinopathy
Targeting the retinal microcirculation to treat diabetic sight problems.
Diabetic Retinopathy
Taxifolin Shows Anticataractogenesis and Attenuates Diabetic Retinopathy In STZ-Diabetic Rats via Suppression of Aldose Reductase, Oxidative Stress and MAPK Signaling Pathway.
Diabetic Retinopathy
The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes.
Diabetic Retinopathy
The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents.
Diabetic Retinopathy
The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy.
Diabetic Retinopathy
The effect of total lignans from Fructus Arctii on Streptozotocin-induced diabetic retinopathy in Wistar rats.
Diabetic Retinopathy
The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.
Diabetic Retinopathy
The effects of an aldose reductase inhibitor upon the sorbitol pathway, fructose-1-phosphate and lactate in the retina and nerve of streptozotocin-diabetic rats.
Diabetic Retinopathy
The effects of elevated glucose on Na+/K(+)-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay.
Diabetic Retinopathy
The inhibitory effect of Isoflavones isolated from Caesalpinia pulcherrima on aldose reductase in STZ induced diabetic rats.
Diabetic Retinopathy
The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
Diabetic Retinopathy
The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient.
Diabetic Retinopathy
The Relationship between Aldose reductase C-106T polymorphism and Diabetic retinopathy?An Updated Meta-analysis.
Diabetic Retinopathy
Tonicity-responsive enhancer binding protein regulates the expression of aldose reductase and protein kinase C ? in a mouse model of diabetic retinopathy.
Diabetic Retinopathy
Z-2 aldose reductase allele and diabetic retinopathy in India.
Diabetic Retinopathy
[Association study between diabetic retinopathy and aldose reductase gene polymorphism in Tunisians]
Diabetic Retinopathy
[Prevention of pericyte ghost formation in retinal capillaries by aldose reductase inhibitor in galactose-fed dogs with diabetic retinopathy]
Diabetic Retinopathy
[Role of aldose reductase in the progression of diabetic retinopathies]
Diabetic Retinopathy
[The biochemical mechanism in vitro of pericyte drop-out in diabetic retinopathy]
Diabetic Retinopathy
[What is the etiology of diabetic retinopathy?]
Digestive System Neoplasms
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Drug Hypersensitivity
Detoxifying Enzymes at the Cross-Roads of Inflammation, Oxidative Stress, and Drug Hypersensitivity: Role of Glutathione Transferase P1-1 and Aldose Reductase.
Dyslipidemias
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Dyslipidemias
Therapeutic interventions for nephropathy in type I diabetes mellitus.
Endometrial Neoplasms
AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Endometrial Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Endometrial Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Endometrial Neoplasms
Data on expression of genes involved in estrogen and progesterone action, inflammation and differentiation according to demographic, histopathological and clinical characteristics of endometrial cancer patients.
Endometrial Neoplasms
Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Endometrial Neoplasms
Fibrates in the chemical action of daunorubicin.
Endometrial Neoplasms
STAR and AKR1B10 are down-regulated in high-grade endometrial cancer.
Endometriosis
Aldo-keto reductase activity after diethylhexyl phthalate exposure in eutopic and ectopic endometrial cells.
Erectile Dysfunction
Erythrocyte aldose reductase correlates with erectile dysfunction in diabetic patients.
Erectile Dysfunction
[Is it possible to prevent andrological complications in the diabetic patient?]
Essential Hypertension
Aldose reductase C-106T polymorphism is associated with the risk of essential hypertension.
Essential Hypertension
Racial difference in aldose reductase C-106T genetic polymorphism and association with essential hypertension.
Eye Diseases
Aldose reductase expression as a risk factor for cataract.
Eye Diseases
Exclusion of aldose reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease.
Fatty Liver
Elevated fructose and uric acid via aldose reductase contribute to experimental and human alcoholic liver disease.
Fatty Liver
Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10.
Fatty Liver
Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease.
Fatty Liver
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
Fatty Liver
The Inhibition of Aldose Reductase Accelerates Liver Regeneration through Regulating Energy Metabolism.
Fatty Liver
The Role of AKR1B10 in Physiology and Pathophysiology.
Fatty Liver
Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.
Focal Nodular Hyperplasia
Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Galactosemias
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Galactosemias
Analysis of sorbitol, galactitol, and myo-inositol in lens and sciatic nerve by high-performance liquid chromatography.
Galactosemias
Changes of some biochemical parameters of the lens in galactose-treated weaned rats with and without vitamin E therapy.
Galactosemias
Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.
Galactosemias
Diabetic cataracts and flavonoids.
Galactosemias
Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats.
Galactosemias
Effect of galactose diet removal on the progression of retinal vessel changes in galactose-fed dogs.
Galactosemias
Effect of the isoflavone genistein against galactose-induced cataracts in rats.
Galactosemias
Fluorometric studies on the blood-retinal barrier in experimental animals.
Galactosemias
Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
Galactosemias
Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor.
Galactosemias
Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
Galactosemias
Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia: prevention by the aldose reductase inhibitor sorbinil.
Galactosemias
Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
Galactosemias
Reversal of galactose cataract with Sorbinil in rats.
Galactosemias
Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
Galactosemias
Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase.
Galactosemias
Synthesis and evaluation of novel aldose reductase inhibitors: Effects on lens protein kinase Cgamma.
Galactosemias
The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
Galactosemias
Time-dependent aspects of osmolyte changes in rat kidney, urine, blood and lens with sorbinil and galactose feeding.
Galactosemias
Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationship to pentosidine cross-links.
Gastrointestinal Diseases
AKR1B10 in gastrointestinal diseases.
Gastrointestinal Neoplasms
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
Gastroparesis
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Glaucoma
Keeping an eye on vision: new tools to preserve sight and quality of life. A roundtable discussion, Part 2.
Glaucoma
Transcriptional profiling analysis predicts potential biomarkers for glaucoma: HGF, AKR1B10 and AKR1C3.
Glioma
Adipocyte proteome and secretome influence inflammatory and hormone pathways in glioma.
Glomerulonephritis
[Effect of aldose reductase expression by transforming growth factor-beta1 on rat mesangial cell]
Glomerulonephritis, Membranous
Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.
Glomerulonephritis, Membranous
Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy.
Glycosuria
Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Heart Arrest
Proteomics approach to examine the cardiotoxic effects of Nemopilema nomurai Jellyfish venom.
Heart Failure
Amelioration of acute kidney injury in lipopolysaccharide-induced systemic inflammatory response syndrome by an aldose reductase inhibitor, fidarestat.
Heart Failure
Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Hepatitis
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Hepatitis
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Hepatitis B
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Hepatitis B
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Hepatitis B, Chronic
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Hepatitis B, Chronic
Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.
Hepatitis C
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Hepatitis C
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Hepatitis C, Chronic
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Hepatitis, Chronic
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Hepatitis, Chronic
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Herpes Zoster
Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.
Herpes Zoster
Physiological functions and hormonal regulation of mouse vas deferens protein (AKR1B7) in steroidogenic tissues.
HIV Infections
Short-term feeding of baicalin inhibits age-associated NF-kappaB activation.
Hyperalgesia
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Hyperalgesia
Different effects of two aldose reductase inhibitors on nociception and prostaglandin E.
Hyperalgesia
Effect of Tinospora cordifolia on experimental diabetic neuropathy.
Hyperalgesia
Mechanical hyperalgesia in rat models of systemic and local hyperglycemia.
Hyperalgesia
Pathogenesis of spinally mediated hyperalgesia in diabetes.
Hyperalgesia
Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
Hyperalgesia
Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine.
Hyperalgesia
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Hyperglycemia
A non-invasive, multi-target approach to treat diabetic retinopathy.
Hyperglycemia
A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat.
Hyperglycemia
A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
Hyperglycemia
Activation of aldose reductase by nonenzymatic glycosylation.
Hyperglycemia
Activation of aldose reductase from human tissues.
Hyperglycemia
Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase.
Hyperglycemia
Aldose reductase activity and glucose-related opacities in incubated lenses from dogs and cats.
Hyperglycemia
Aldose reductase and its inhibition in the control of diabetic complications.
Hyperglycemia
Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
Hyperglycemia
Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals.
Hyperglycemia
Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy.
Hyperglycemia
Aldose reductase inhibition in the treatment of diabetic neuropathy: where are we in 2004?
Hyperglycemia
Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca.
Hyperglycemia
Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta.
Hyperglycemia
Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF-alpha in human lens epithelial cells.
Hyperglycemia
Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages.
Hyperglycemia
Aldose reductase mediates the mitogenic signals of cytokines.
Hyperglycemia
Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-?1/mTOR pathway.
Hyperglycemia
Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgf?1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice.
Hyperglycemia
Anti-diabetic effects of Ganoderma lucidum.
Hyperglycemia
Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?
Hyperglycemia
Association study of sorbitol dehydrogenase -888G>C polymorphism with type 2 diabetic retinopathy in Caucasian-Brazilians.
Hyperglycemia
Comparative study of peripheral neuropathy and nerve regeneration in NOD and ICR diabetic mice.
Hyperglycemia
Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Hyperglycemia
Cytoprotective mechanism of action of curcumin against cataract.
Hyperglycemia
Damage to the crystalline lens in infants of diabetic mothers: a pathology so far neglected?
Hyperglycemia
Design synthesis and evaluation of novel aldose reductase inhibitors: The case of indolyl-sulfonyl-phenols.
Hyperglycemia
Development of coumarin-thiosemicarbazone hybrids as aldose reductase inhibitors: Biological assays, molecular docking, simulation studies and ADME evaluation.
Hyperglycemia
Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase.
Hyperglycemia
Diabetic kidney disease; review of the current knowledge.
Hyperglycemia
Diabetic retinopathy and pregnancy.
Hyperglycemia
Diarylmethanon, bromophenol and diarylmethane compounds: Discovery of potent aldose reductase, ?-amylase and ?-glycosidase inhibitors as new therapeutic approach in diabetes and functional hyperglycemia.
Hyperglycemia
Differential regulation of aldose reductase expression during macrophage polarization depends on hyperglycemia.
Hyperglycemia
Early involvement of central nervous system in type I diabetic patients.
Hyperglycemia
Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma.
Hyperglycemia
Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Hyperglycemia
Effect of hyperglycemia on sorbitol and myo-inositol content of cultured rat conceptus: failure of aldose reductase inhibitors to modify myo-inositol depletion and dysmorphogenesis.
Hyperglycemia
Effect of hyperglycemia on sorbitol and myo-inositol content of cultured rat conceptus: prevention of dysmorphogenesis with aldose reductase inhibitors and myo-inositol.
Hyperglycemia
Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation.
Hyperglycemia
Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sorbitol concentrations in 75 g oral glucose tolerance tests.
Hyperglycemia
Effects of high glucose concentrations and epalrestat on sorbitol and myo-inositol metabolism in cultured rabbit aortic smooth muscle cells.
Hyperglycemia
Effects of ONO-2235, an aldose reductase inhibitor, on muscarinic receptors and contractile response of the urinary bladder in rats with streptozotocin-induced diabetes.
Hyperglycemia
Effects of osmotic stress and hyperglycemia on aldose reductase gene expression in human renal proximal tubule cells.
Hyperglycemia
Enzymes inhibitors from natural sources with antidiabetic activity: A review.
Hyperglycemia
Epalrestat prevents the decrease in gastric mucosal blood flow and protects the gastric mucosa in streptozotocin diabetic rats.
Hyperglycemia
Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
Hyperglycemia
Extraction and identification of three major aldose reductase inhibitors from Artemisia montana.
Hyperglycemia
Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil.
Hyperglycemia
Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.
Hyperglycemia
Glutathione depletion in the lens of galactosemic and diabetic rats.
Hyperglycemia
Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells.
Hyperglycemia
Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway.
Hyperglycemia
Inhibition of phosphatidylinositol synthase by glucose in human retinal pigment epithelial cells.
Hyperglycemia
Involvement of hyperglycemia in the development of platelet procoagulant response: the role of aldose reductase and platelet swelling.
Hyperglycemia
Mechanism of capsaicin inhibition of aldose reductase activity.
Hyperglycemia
New pharmacologic approaches to treating diabetic retinopathy.
Hyperglycemia
NIH conference. Aldose reductase and complications of diabetes.
Hyperglycemia
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
Hyperglycemia
Pathogenesis of diabetic nephropathy.
Hyperglycemia
Pathogenesis of diabetic neuropathy--do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?
Hyperglycemia
Pathological mechanisms involved in diabetic neuropathy: can we slow the process?
Hyperglycemia
Permeability changes at blood-retinal barrier in diabetes and effect of aldose reductase inhibition.
Hyperglycemia
Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.
Hyperglycemia
Phenolic compounds inhibit the aldose reductase enzyme from the sheep kidney.
Hyperglycemia
Polyol pathway and RAGE: a central metabolic and signaling axis in diabetic complications.
Hyperglycemia
Possible involvement of facilitated polyol pathway in augmentation of intimal hyperplasia in rabbits with alloxan-induced hyperglycemia.
Hyperglycemia
Potential use of aldose reductase inhibitors to prevent diabetic complications.
Hyperglycemia
Prophylactic role of arjunolic acid in response to streptozotocin mediated diabetic renal injury: activation of polyol pathway and oxidative stress responsive signaling cascades.
Hyperglycemia
Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Hyperglycemia
Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors.
Hyperglycemia
Reduction of basement membrane thickening in diabetic cat retina by sulindac.
Hyperglycemia
Reduction of Glut1 in the Neural Retina But Not the RPE Alleviates Polyol Accumulation and Normalizes Early Characteristics of Diabetic Retinopathy.
Hyperglycemia
Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor.
Hyperglycemia
Role of aldose reductase in diabetes-induced retinal microglia activation.
Hyperglycemia
Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract.
Hyperglycemia
Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol.
Hyperglycemia
Screening for and managing diabetic retinopathy: current approaches.
Hyperglycemia
Semi-quantitation of mRNA by polymerase chain reaction. Levels of oxidative defense enzymes and aldose reductase in rat lenses cultured in hyperglycemic or oxidative medium.
Hyperglycemia
The activity of aldose reductase is elevated in diabetic mouse heart.
Hyperglycemia
The effect of insulin and aldose reductase inhibition on the phosphate metabolism of streptozotocin-diabetic rat lens.
Hyperglycemia
The effect of oxidants on biomembranes and cellular metabolism.
Hyperglycemia
The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes.
Hyperglycemia
The effects of elevated glucose on Na+/K(+)-ATPase of cultured bovine retinal pigment epithelial cells measured by a new nonradioactive rubidium uptake assay.
Hyperglycemia
The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat.
Hyperglycemia
The relationship between aldose reductase gene C106T polymorphism and the severity of retinopathy in Type 2 diabetic patients: A case-control study.
Hyperglycemia
Time-dependent aspects of osmolyte changes in rat kidney, urine, blood and lens with sorbinil and galactose feeding.
Hyperglycemia
Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats.
Hyperglycemia
Transcriptome Profiles Using Next-Generation Sequencing Reveal Liver Changes in the Early Stage of Diabetes in Tree Shrew (Tupaia belangeri chinensis).
Hyperglycemia
Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
Hyperglycemia
Uptake of myo-inositol by early-somite rat conceptus. Transport kinetics and effects of hyperglycemia.
Hyperglycemia
Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.
Hyperglycemia
Vitamin K1 prevents diabetic cataract by inhibiting lens aldose reductase 2 (ALR2) activity.
Hyperglycemia
[Two forms of aldose reductase in erythrocytes from patients with insulin-dependent diabetes mellitus]
Hyperlipidemias
Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
Hypertension
Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity.
Hypertension
Fluorometric studies on the blood-retinal barrier in experimental animals.
Hypertension, Pulmonary
Endotoxin causes pulmonary hypertension by upregulating smooth muscle endothelin type-B receptors: role of aldose reductase.
Hypertriglyceridemia
Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis.
Hypesthesia
Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats.
Hypesthesia
Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway.
Hypoglycemia
Aldose reductase inhibitory activity of compounds from Zea mays L.
Hypoglycemia
Inhibition of aldose reductase by phenylethanoid glycoside isolated from the seeds of Paulownia coreana.
Hypoglycemia
Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity.
Hypoglycemia
Inhibitory effects of Zingiber officinale Roscoe derived components on aldose reductase activity in vitro and in vivo.
Hypotension, Orthostatic
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Idiopathic Pulmonary Fibrosis
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Infections
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Infections
Bacteroides fragilis Enterotoxin Upregulates Intercellular Adhesion Molecule-1 in Endothelial Cells via an Aldose Reductase-, MAPK-, and NF-{kappa}B-Dependent Pathway, Leading to Monocyte Adhesion to Endothelial Cells.
Infections
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Infections
Identification of unique or elevated levels of kernel proteins in aflatoxin-resistant maize genotypes through proteome analysis.
Infections
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Infections
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Insulin Resistance
Effects of S-Allylcysteine on Biomarkers of the Polyol Pathway in Rats with Type 2 Diabetes.
Insulin Resistance
Euonymus alatus: A Review on Its Phytochemistry and Antidiabetic Activity.
Insulin Resistance
Potential Role of Gene Regulator NFAT5 in the Pathogenesis of Diabetes Mellitus.
Insulin Resistance
[The experimental study of Radix Puerariae inhibiting glycation in rats induced by D-galactose]
Keloid
The aldo-keto reductase AKR1B10 is upregulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease.
Kidney Diseases, Cystic
Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
Kidney Failure, Chronic
Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes.
l-iditol 2-dehydrogenase deficiency
Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-derived human aldose reductase and sorbitol dehydrogenase deficiency.
l-iditol 2-dehydrogenase deficiency
[Effects of transgenic human aldose reductase and sorbitol dehydrogenase deficiency on diabetes complications]
Laryngeal Neoplasms
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Leishmaniasis, Visceral
A glutathione-specific aldose reductase of Leishmania donovani and its potential implications for methylglyoxal detoxification pathway.
Leprosy
Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction.
Leprosy, Multibacillary
Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction.
Leprosy, Paucibacillary
Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction.
Leukemia, Myeloid
NADPH-dependent reductases and polyol formation in human leukemia cell lines.
Leukoplakia
Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex.
Liver Cirrhosis
Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.
Liver Cirrhosis
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Liver Cirrhosis
Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Liver Cirrhosis
Proteomic Analysis of Niemann-Pick Type C Hepatocytes Reveals Potential Therapeutic Targets for Liver Damage.
Liver Cirrhosis
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Liver Diseases
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Liver Diseases
Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.
Liver Diseases
Elevated fructose and uric acid via aldose reductase contribute to experimental and human alcoholic liver disease.
Liver Diseases
Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10.
Liver Diseases
Inhibition of aldose reductase ameliorates ethanol?induced steatosis in HepG2 cells.
Liver Diseases
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Liver Diseases
Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease.
Liver Diseases
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
Liver Diseases
The Role of AKR1B10 in Physiology and Pathophysiology.
Liver Diseases, Alcoholic
Aldose Reductase Inhibitors of Plant Origin in the Prevention and Treatment of Alcoholic Liver Disease: A Minireview.
Liver Diseases, Alcoholic
Elevated fructose and uric acid via aldose reductase contribute to experimental and human alcoholic liver disease.
Liver Diseases, Alcoholic
Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines.
Liver Neoplasms
Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Liver Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Liver Neoplasms
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Liver Neoplasms
Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Liver Neoplasms
Overexpression of aldose reductase in liver cancers may contribute to drug resistance.
Liver Neoplasms
Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study.
Liver Neoplasms
SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer.
Liver Neoplasms
[Effects of AKR1B10 gene silence on the growth and gene expression of HCC cell line MHCC97H.].
Lung Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Lung Neoplasms
AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer.
Lung Neoplasms
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
Lung Neoplasms
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
Lung Neoplasms
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Lung Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Lung Neoplasms
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Lung Neoplasms
Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Lung Neoplasms
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Lung Neoplasms
Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Lung Neoplasms
Fibrates in the chemical action of daunorubicin.
Lung Neoplasms
Finding Genes Discriminating Smokers from Non-smokers by Applying a Growing Self-organizing Clustering Method to Large Airway Epithelium Cell Microarray Data.
Lung Neoplasms
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Lung Neoplasms
Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10.
Lung Neoplasms
Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Lung Neoplasms
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Lung Neoplasms
Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma.
Lung Neoplasms
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Lung Neoplasms
Screening and identification of lung cancer metastasis-related genes by suppression subtractive hybridization.
Lung Neoplasms
Smoking-induced Up-regulation of AKR1B10 Expression in the Airway Epithelium of Healthy Individuals.
Lung Neoplasms
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Lung Neoplasms
Systems biology analysis of publicly available transcriptomic data reveals a critical link between AKR1B10 gene expression, smoking and occurrence of lung cancer.
Lung Neoplasms
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Lung Neoplasms
[Transcription TIMP3, DAPk1 and AKR1B10 genes in squamous cell lung cancer]
Lymphatic Metastasis
AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy.
Lymphatic Metastasis
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Lymphatic Metastasis
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Lymphatic Metastasis
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Lymphatic Metastasis
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Lymphatic Metastasis
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Lymphatic Metastasis
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Lymphoma, B-Cell
Overexpression of Aldose Reductase Render Mouse Hepatocytes More Sensitive to Acetaminophen Induced Oxidative Stress and Cell Death.
Melanoma
Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI.
Melanoma, Experimental
Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
Melanoma, Experimental
Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI.
Metabolic Diseases
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Metabolic Diseases
Effect of the isoflavone genistein against galactose-induced cataracts in rats.
Metabolic Syndrome
A Pharmacological Update of Ellagic Acid.
Microaneurysm
Amelioration of diabetes-like retinal changes in galactose-fed dogs.
Microaneurysm
Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor.
Microaneurysm
Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175.
Microaneurysm
Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.
Microaneurysm
Quantitative analysis of retinal vessel changes in galactose-fed dogs.
Microaneurysm
[What is the etiology of diabetic retinopathy?]
Mouth Neoplasms
Gedunin abrogates aldose reductase, PI3K/Akt/mToR, and NF-?B signaling pathways to inhibit angiogenesis in a hamster model of oral carcinogenesis.
Muscular Diseases
Polyol pathway-related skeletal muscle contractile and morphological abnormalities in diabetic rats.
Muscular Dystrophies
Chicken muscle aldose reductase: purification, properties and relationship to other chicken aldo/keto reductases.
Myocardial Infarction
Aldose reductase: a novel target for cardioprotective interventions.
Myocardial Infarction
Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins.
Myocardial Ischemia
Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury.
Myocardial Reperfusion Injury
Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism.
Nasopharyngeal Carcinoma
AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-?B axis in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Nasopharyngeal Neoplasms
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasm Metastasis
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Neoplasm Metastasis
AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy.
Neoplasm Metastasis
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Neoplasm Metastasis
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Neoplasm Metastasis
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Neoplasm Metastasis
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
Neoplasm Metastasis
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Neoplasm Metastasis
Inhibition of aldose reductase prevents colon cancer metastasis.
Neoplasm Metastasis
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasm Metastasis
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Neoplasm Metastasis
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Neoplasms
Accumulation and spatial location of aldose reductase mRNA in a lens tumor of an alpha A-crystallin/SV40 T antigen transgenic mouse line.
Neoplasms
ACTH and PRL sensitivity of highly differentiated cell lines obtained by adrenocortical targeted oncogenesis.
Neoplasms
Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.
Neoplasms
Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis.
Neoplasms
AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Neoplasms
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Neoplasms
AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
Neoplasms
AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-?B axis in nasopharyngeal carcinoma.
Neoplasms
AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
Neoplasms
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Neoplasms
AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer.
Neoplasms
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Neoplasms
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Neoplasms
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Neoplasms
AKR1B10 protects against UVC-induced DNA damage in breast cancer cells.
Neoplasms
AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.
Neoplasms
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
Neoplasms
Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.
Neoplasms
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Neoplasms
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Neoplasms
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Neoplasms
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Neoplasms
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Neoplasms
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Neoplasms
Aldo-keto reductase family 1, member B10 is secreted through a lysosome-mediated non-classical pathway.
Neoplasms
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Neoplasms
Aldo-Keto Reductases 1B in Adrenal Cortex Physiology.
Neoplasms
Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Neoplasms
Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels.
Neoplasms
Aldo-Keto Reductases Mediated Cytotoxicity of 2-Deoxyglucose: A Novel Anticancer Mechanism.
Neoplasms
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Neoplasms
Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
Neoplasms
Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells.
Neoplasms
Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.
Neoplasms
Ameliorative effects of thymoquinone against eye lens changes in streptozotocin diabetic rats.
Neoplasms
Analysis of the anticancer activity of curcuminoids, thiotryptophan and 4-phenoxyphenol derivatives.
Neoplasms
Anti-diabetic potential of alkaloid rich fraction from Capparis decidua on diabetic mice.
Neoplasms
Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-?B and MAPK pathways.
Neoplasms
Association of candidate gene polymorphisms with diabetic retinopathy in Chinese patients with type 2 diabetes.
Neoplasms
Author's reply to: AKR1B10 and its emerging role in tumor carcinogenesis and as a cancer biomarker.
Neoplasms
Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling.
Neoplasms
Biostatistics mining associated method identifies AKR1B10 enhancing hepatocellular carcinoma cell growth and degenerated by miR-383-5p.
Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Neoplasms
CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.
Neoplasms
Cellular senescence bypass screen identifies new putative tumor suppressor genes.
Neoplasms
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Neoplasms
Cisplatin and platinum drugs at the molecular level. (Review).
Neoplasms
Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors.
Neoplasms
Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Neoplasms
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Neoplasms
Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions.
Neoplasms
Diabetic retinopathy: Validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort.
Neoplasms
Diallyl sulfide protects against N-nitrosodiethylamine-induced liver tumorigenesis: role of aldose reductase.
Neoplasms
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Neoplasms
Effect of rutin on retinal VEGF, TNF-?, aldose reductase, and total antioxidant capacity in diabetic rats: molecular mechanism and ocular pharmacokinetics.
Neoplasms
Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes.
Neoplasms
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
Neoplasms
Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Neoplasms
Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
Neoplasms
Epidermal Growth Factor Induces Tumor Marker AKR1B10 Expression through Activator Protein-1 Signaling in Hepatocellular Carcinoma Cells.
Neoplasms
Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells.
Neoplasms
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Neoplasms
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Neoplasms
Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Neoplasms
Fibrates in the chemical action of daunorubicin.
Neoplasms
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
Neoplasms
Gedunin, A Neem Limonoid in Combination With Epalrestat Inhibits Cancer Hallmarks By Attenuating Aldose Reductase-Driven Oncogenic Signaling In SCC131 Oral Cancer Cells.
Neoplasms
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Neoplasms
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Neoplasms
Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde.
Neoplasms
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Neoplasms
Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
Neoplasms
Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Neoplasms
Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity.
Neoplasms
Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Neoplasms
Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response.
Neoplasms
In silico designing of novel inhibitors for triple inhibition of Aldose Reductase, Aldose Reductase like protein 1, and Aldehyde Reductase.
Neoplasms
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Neoplasms
Induction of aldose reductase gene expression in LEC rats during the development of the hereditary hepatitis and hepatoma.
Neoplasms
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Neoplasms
Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.
Neoplasms
Inhibition of aldose reductase prevents colon cancer metastasis.
Neoplasms
Inhibition of human aldose reductase-like protein (AKR1B10) by ?- and ?-mangostins, major components of pericarps of mangosteen.
Neoplasms
Involvement of nuclear factor kappaB in up-regulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol-13-acetate in HeLa cells.
Neoplasms
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Neoplasms
Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway.
Neoplasms
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Neoplasms
Novel aldose reductase inhibitors: a patent survey (2006--present).
Neoplasms
Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Neoplasms
Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Neoplasms
Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha.
Neoplasms
Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Neoplasms
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Neoplasms
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Neoplasms
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Neoplasms
Overexpression of aldose reductase in human cancer tissues.
Neoplasms
Phenolic glycosides and other constituents from the bark of Magnolia officinalis.
Neoplasms
Phorbol ester up-regulates aldose reductase expression in A549 cells: a potential role for aldose reductase in cell cycle modulation.
Neoplasms
Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Neoplasms
Potential of AKR1B10 as a Biomarker and Therapeutic Target in Type 2 Leprosy Reaction.
Neoplasms
Prognostic Significance of 14-3-3?, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
Neoplasms
Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.
Neoplasms
Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma.
Neoplasms
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Neoplasms
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Neoplasms
Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics.
Neoplasms
QSAR-based rational discovery of novel substituted-4'-iminospiro[indoline-3,3'-[1,2,5]thiadiazolidinyl]-2-one 1',1'-dioxide with potent in vitro anticancer activity.
Neoplasms
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Neoplasms
Quantitative Evaluation of Aldo-keto Reductase Expression in Hepatocellular Carcinoma (HCC) Cell Lines.
Neoplasms
Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.
Neoplasms
Regulation of aldo-keto reductase AKR1B10 gene expression: Involvement of transcription factor Nrf2.
Neoplasms
Regulation of aldo-keto-reductase family 1 B10 by 14-3-3? and their prognostic impact of hepatocellular carcinoma.
Neoplasms
Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.
Neoplasms
Selective Inhibition of Human AKR1B10 by n-Humulone, Adhumulone and Cohumulone Isolated from Humulus lupulus Extract.
Neoplasms
Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Neoplasms
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Neoplasms
Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Neoplasms
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma.
Neoplasms
Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study.
Neoplasms
STAR and AKR1B10 are down-regulated in high-grade endometrial cancer.
Neoplasms
Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10.
Neoplasms
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Neoplasms
Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008.
Neoplasms
Structural Determinants of the Selectivity of 3-Benzyluracil-1-acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10.
Neoplasms
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Neoplasms
Studies on the alkaloids of the bark of Magnolia officinalis: isolation and on-line analysis by HPLC-ESI-MS(n).
Neoplasms
Substrate Specificity, Inhibitor Selectivity and Structure-Function Relationships of Aldo-Keto Reductase 1B15: A Novel Human Retinaldehyde Reductase.
Neoplasms
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Neoplasms
Systems biology analysis of publicly available transcriptomic data reveals a critical link between AKR1B10 gene expression, smoking and occurrence of lung cancer.
Neoplasms
Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Neoplasms
Targeting aldose reductase for the treatment of cancer.
Neoplasms
The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.
Neoplasms
The aldo-keto reductases (AKRs): Overview.
Neoplasms
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Neoplasms
The Role of AKR1B10 in Physiology and Pathophysiology.
Neoplasms
Treatment of cancer cells with chemotherapeutic drugs results in profound changes in expression of genes encoding aldehyde-metabolizing enzymes.
Neoplasms
Treatment with NADPH oxidase inhibitor apocynin alleviates diabetic neuropathic pain in rats.
Neoplasms
Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex.
Neoplasms
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: Implications for inhibitor binding and selectivity.
Neoplasms
[Abnormal expression of genes that regulate retinoid metabolism and signaling in non-small-cell lung cancer].
Neoplasms
[Downregulation of AKR1B10 gene expression in colorectal cancer]
Neoplasms
[Expression of genes involved in retinoic acid biosynthesis in human gastric cancer].
Neoplasms
[Proteomic analysis of morphine rabbit myocardium with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry]
Neoplasms
[Transcription TIMP3, DAPk1 and AKR1B10 genes in squamous cell lung cancer]
Neuralgia
Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives.
Neuralgia
Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
Neuralgia
Phosphorylation of c-Jun N-terminal kinase (JNK) in sensory neurones of diabetic rats, with possible effects on nerve conduction and neuropathic pain: prevention with an aldose reductase inhibitor.
Neurilemmoma
Polyol pathway and protein kinase C activity of rat Schwannoma cells.
Neuroaxonal Dystrophies
Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy.
Neuroaxonal Dystrophies
Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats.
Neuroblastoma
Cloning and expression of human aldose reductase.
Neuroblastoma
Effect of fructose supplementation on sorbitol accumulation and myo-inositol metabolism in cultured neuroblastoma cells exposed to increased glucose concentrations.
Neuroblastoma
Effect of increased glucose levels on Na+/K+-pump activity in cultured neuroblastoma cells.
Neuroblastoma
Upregulation of cellular glutathione by 3H-1,2-dithiole-3-thione as a possible treatment strategy for protecting against acrolein-induced neurocytotoxicity.
Neuroinflammatory Diseases
Aldose reductase inhibitors attenuate ?-amyloid-induced TNF-? production in microlgia via ROS-PKC-mediated NF-?B and MAPK pathways.
Neurologic Manifestations
Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
Non-alcoholic Fatty Liver Disease
Aldose reductase is involved in the development of murine diet-induced nonalcoholic steatohepatitis.
Non-alcoholic Fatty Liver Disease
Elevated fructose and uric acid via aldose reductase contribute to experimental and human alcoholic liver disease.
Non-alcoholic Fatty Liver Disease
Glycyrrhetinic acid attenuates disturbed vitamin a metabolism in non-alcoholic fatty liver disease through AKR1B10.
Non-alcoholic Fatty Liver Disease
Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor ?.
Non-alcoholic Fatty Liver Disease
Natural aldose reductase inhibitor: A potential therapeutic agent for non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Non-alcoholic Fatty Liver Disease
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.
Non-alcoholic Fatty Liver Disease
The Role of AKR1B10 in Physiology and Pathophysiology.
Non-alcoholic Fatty Liver Disease
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.
Obesity
Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE).
Obesity
High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition.
Optic Nerve Diseases
Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process.
Optic Nerve Diseases
The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.
Osteoporosis
The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5?-reductase type 2.
Pancreatic Neoplasms
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Parkinson Disease
Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson's disease.
Parkinson Disease
Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose.
Pelvic Inflammatory Disease
Aldose Reductase Inhibitor Engeletin Suppresses Pelvic Inflammatory Disease by Blocking the Phospholipase C/Protein Kinase C-Dependent/NF-?B and MAPK Cascades.
Periodontitis
Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats.
Periodontitis
Efficacy of Structurally-Diverse Aldose Reductase Inhibitors on Experimental Periodontitis in Rats.
Peripheral Nerve Injuries
Antinociceptive effect of the novel compound OT-7100 in a diabetic neuropathy model.
Peripheral Nerve Injuries
Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway.
Peripheral Nervous System Diseases
3-Mercapto-5H-1,2,4-Triazino[5,6-b]Indole-5-Acetic Acid (Cemtirestat) Alleviates Symptoms of Peripheral Diabetic Neuropathy in Zucker Diabetic Fatty (ZDF) Rats: A Role of Aldose Reductase.
Peripheral Nervous System Diseases
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
Peripheral Nervous System Diseases
Aldose reductase gene polymorphisms and peripheral nerve function in patients with type 2 diabetes.
Peripheral Nervous System Diseases
Aldose reductase inhibition: studies with alrestatin.
Peripheral Nervous System Diseases
Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
Peripheral Nervous System Diseases
Association of aldose reductase gene polymorphism (C-106T) in susceptibility of diabetic peripheral neuropathy among north Indian population.
Peripheral Nervous System Diseases
Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function.
Peripheral Nervous System Diseases
Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
Peripheral Nervous System Diseases
Clinical trial of an aldose reductase inhibitor in diabetic neuropathy.
Peripheral Nervous System Diseases
Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
Peripheral Nervous System Diseases
Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Preliminary report.
Peripheral Nervous System Diseases
Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
Peripheral Nervous System Diseases
Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
Peripheral Nervous System Diseases
Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine.
Peripheral Nervous System Diseases
Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
Peripheral Nervous System Diseases
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Peripheral Nervous System Diseases
How does glucose generate oxidative stress in peripheral nerve?
Peripheral Nervous System Diseases
Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients.
Peripheral Nervous System Diseases
Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Peripheral Nervous System Diseases
Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats.
Peripheral Nervous System Diseases
New pharmacologic approaches to treating diabetic retinopathy.
Peripheral Nervous System Diseases
Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
Peripheral Nervous System Diseases
Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
Peripheral Nervous System Diseases
Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
Peripheral Nervous System Diseases
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Peripheral Nervous System Diseases
The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Peripheral Nervous System Diseases
The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
The time to develop treatments for diabetic neuropathy.
Peripheral Nervous System Diseases
Thoracic polyradiculopathy--abdominal wall swelling and sensory symptoms in diabetes mellitus.
Peripheral Nervous System Diseases
Treatment for diabetic peripheral neuropathy: What have we learned from animal models?
Peripheral Nervous System Diseases
Triglyceride-lowering effect of the aldose reductase inhibitor cemtirestat-another factor that may contribute to attenuation of symptoms of peripheral neuropathy in STZ-diabetic rats.
Peripheral Nervous System Diseases
WITHDRAWN: Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy.
Peripheral Nervous System Diseases
[Examination of questionnaire items regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of this disorder - influence on treatment course]
Peripheral Nervous System Diseases
[Pharmacological effects of Gosha-jinki-gan-ryo extract: effects on experimental diabetes]
Peripheral Nervous System Diseases
[Progress in research of aldose reductase inhibitors in traditional medicinal herbs]
Peripheral Nervous System Diseases
[Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes]
Peripheral Nervous System Diseases
[Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients]
Pneumonia
Novel role for aldose reductase in mediating acute inflammatory responses in the lung.
Polyneuropathies
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Polyneuropathies
Diabetic neuropathy: pathogenesis and therapy.
Polyneuropathies
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.
Polyneuropathies
Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy.
Polyneuropathies
Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Polyneuropathies
Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Polyneuropathies
Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
Polyneuropathies
Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
Polyneuropathies
Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.
Polyneuropathies
Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
Polyneuropathies
[Diabetic neuropathy. Current concepts on etiopathogenesis, diagnosis, and treatment]
Polyradiculopathy
Thoracic polyradiculopathy--abdominal wall swelling and sensory symptoms in diabetes mellitus.
Potassium Deficiency
Potassium depletion modulates aldose reductase mRNA in rat renal inner medulla.
Pre-Eclampsia
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Precancerous Conditions
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Pressure Ulcer
Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy.
Prostatic Hyperplasia
AKR1B10 expression in benign prostatic hyperplasia and its related mechanism.
Prostatic Neoplasms
Network-based analysis of prostate cancer cell lines reveals novel marker gene candidates associated with radioresistance and patient relapse.
Proteinuria
Aldose reductase inhibition by ponalrestat (statil) does not prevent proteinuria in long-term diabetic rats.
Proteinuria
Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat.
Proteinuria
Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor.
Proteinuria
Functional and structural alterations of the glomerular permeability barrier in experimental galactosemia.
Proteinuria
Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats.
Proteinuria
The polyol pathway, sorbinil, and renal dysfunction.
Proteinuria
Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus.
Psoriasis
Combined Transcriptomic Analysis Revealed AKR1B10 Played an Important Role in Psoriasis through the Dysregulated Lipid Pathway and Overproliferation of Keratinocyte.
Pulmonary Fibrosis
Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat.
Renal Insufficiency
Association of glomerulopathy with the 5'-end polymorphism of the aldose reductase gene and renal insufficiency in type 2 diabetic patients.
Renal Insufficiency, Chronic
Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
Renal Insufficiency, Chronic
Differential expression of proteins from cultured endothelial cells exposed to uremic versus normal serum.
Reperfusion Injury
Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore.
Reperfusion Injury
Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury.
Reperfusion Injury
Central role for aldose reductase pathway in myocardial ischemic injury.
Reperfusion Injury
Effects of aldose reductase inhibitors on antioxidant defense in rat and rabbit liver.
Reperfusion Injury
Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina.
Reperfusion Injury
The Aldose Reductase Inhibitor Fidarestat Suppresses Ischemia-Reperfusion-Induced Inflammatory Response in Rat Retina.
Reperfusion Injury
The Inhibition of Aldose Reductase Attenuates Hepatic Ischemia-Reperfusion Injury Through Reducing Inflammatory Response.
Retinal Degeneration
[The NADP.H-cytochrome C reductase and aldose reductase activities in the retina, cerebral cortex and liver of healthy rats and of those with hereditary retinal degeneration in the early postnatal development period]
Retinal Degeneration
[The role of iron ions in regulating aldose reductase activity in the cerebral cortex and retina in health rats and rats with hereditary retinal degeneration]
Retinal Neovascularization
An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Retinopathy of Prematurity
Deficiency of aldose reductase attenuates inner retinal neuronal changes in a mouse model of retinopathy of prematurity.
Rhinitis, Allergic
Prevention of Allergic Rhinitis by Aldose Reductase Inhibition in a Murine Model.
Sarcoma, Experimental
Purification and properties of aldose reductase and aldehyde reductase from EHS tumor cells.
Sensation Disorders
Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
Sepsis
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Sepsis
Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis.
Sepsis
Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition.
Sepsis
Non-acidic bifunctional benzothiazole-based thiazolidinones with antimicrobial and aldose reductase inhibitory activity as a promising therapeutic strategy for sepsis.
Sepsis
Novel aldose reductase inhibitors: a patent survey (2006--present).
Skin Diseases
Identification and characterization of functional antioxidant response elements in the promoter of the aldo-keto reductase AKR1B10 gene.
Skin Diseases
The Role of AKR1B10 in Physiology and Pathophysiology.
Small Cell Lung Carcinoma
Smoking-induced Up-regulation of AKR1B10 Expression in the Airway Epithelium of Healthy Individuals.
Spinal Cord Injuries
Aldose Reductase Regulates Microglia/Macrophages Polarization Through the cAMP Response Element-Binding Protein After Spinal Cord Injury in Mice.
Squamous Cell Carcinoma of Head and Neck
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Squamous Cell Carcinoma of Head and Neck
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Starvation
AKR1B10 negatively regulates autophagy through reducing GAPDH upon glucose starvation in colon cancer.
Starvation
Inhibition of aldose reductase activity stimulates starvation induced autophagy and clears aldehyde protein adducts.
Stomach Neoplasms
Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Stomach Neoplasms
AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy.
Stomach Neoplasms
AKR1B10, a good prognostic indicator in gastric cancer.
Stomach Neoplasms
Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early-stage gastric cancer.
Stomach Neoplasms
[Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Stroke
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Thrombosis
Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?
Thyroiditis
NADPH-dependent reductases in dog thyroid: comparison of a third enzyme "glyceraldehyde reductase" to dog thyroid aldehyde reductase.
Tongue Neoplasms
Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response.
Urinary Bladder Neoplasms
Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.
Urinary Bladder, Overactive
Oxidative modification of mitochondrial integrity and nerve fiber density in the ischemic overactive bladder.
Uterine Cervical Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Uterine Cervical Neoplasms
Fibrates in the chemical action of daunorubicin.
Uterine Cervical Neoplasms
The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.
Uterine Cervical Neoplasms
The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.
Uterine Diseases
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases.
Uterine Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Uterine Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Uterine Neoplasms
Fibrates in the chemical action of daunorubicin.
Uveitis
Aldo-Keto Reductases: Multifunctional Proteins as Therapeutic Targets in Diabetes and Inflammatory Disease.
Uveitis
Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.
Uveitis
Aldose reductase inhibition prevents endotoxin-induced uveitis in rats.
Uveitis
Amelioration of experimental autoimmune uveoretinitis by aldose reductase inhibition in Lewis rats.
Uveitis
Inhibition of ocular aldose reductase by a new benzofuroxane derivative ameliorates rat endotoxic uveitis.
Varicose Veins
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Vascular System Injuries
[Epidemiology, pathogenesis and therapy of diabetic retinopathy and maculopathy]
Vasculitis
Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis.
Virus Diseases
Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C virus infection.
Vision Disorders
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model.
Vitreous Hemorrhage
[Pathophysiology of diabetic retinopathy and nephropathy]
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00029
1-butyl-2-[[(4-oxo-3,4-dihydroquinazolin-2-yl)methyl]sulfanyl]-1H-benzimidazole-5-sulfonamide
Homo sapiens
pH 6.6, temperature not specified in the publication
0.0012
2-[(4-fluorobenzyl)[(2-fluorophenyl)sulfonyl]amino]-N-[2-(3-fluorophenyl)ethyl]acetamide
Homo sapiens
pH 6.6, temperature not specified in the publication
0.00126
methyl 3-methyl-2-([2-nitro-4-(trifluoromethyl)phenyl]amino)butanoate
Homo sapiens
pH 6.6, temperature not specified in the publication
0.001
N-tert-butyl-2-(2-chloro-6-methoxy-4-([(3-methyl-5-sulfanyl-4H-1,2,4-triazol-4-yl)amino]methyl)phenoxy)acetamide
Homo sapiens
pH 6.6, temperature not specified in the publication
0.0033
(17alpha)-17-hydroxyandrost-4-en-3-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
7.3
(1H-indol-1-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
2.87
(2,3-dihydrocyclopenta[b]indol-4(1H)-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.001932
(2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
Homo sapiens
30°C, pH 6.2
0.00334
(2-oxo-8-phenyl-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
Homo sapiens
30°C, pH 6.2
0.000138
(2-oxo-8-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid
Homo sapiens
30°C, pH 6.2
0.2572
(2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one
Homo sapiens
-
pH 7.0, 37°C
0.04141
(2R)-1-[(benzyloxy)carbonyl]-2,3-dihydro-1H-indole-2-carboxylic acid
Homo sapiens
-
0.00037
(2S)-7,4'-dihydroxy-5-methoxy-8-(gamma,gamma-dimethylallyl)-flavanone
Homo sapiens
-
-
0.00043
(3-methyl-1-oxo-5-phenylpyrimido[4,5-c]quinolin-2(1H)-yl)acetic acid
Homo sapiens
pH 7.5, 25°C
0.097
(3-sulfanyl-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
2.24
(3-[[(2-fluorophenyl)methyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
4.06
(3-[[2-oxo-2-(2,4,6-trimethylanilino)ethyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.0244
(4-hydroxy-3-methoxyphenyl)acetonitrile
Homo sapiens
-
IC50: 0.0244 mM
0.0634
(4-hydroxy-3-methoxyphenyl)methamine
Homo sapiens
-
IC50: 0.0634 mM
0.0414
(4-hydroxyphenyl)(6-hydroxypyrazin-2-yl)methanone
Homo sapiens
-
isolated from red ascidian Botryllus leachi, pyrazine derivative, IC50: 0.0414 mM
0.0214
(4-hydroxyphenyl)[4-(4-hydroxyphenyl)-1H-imidazol-2-yl]methanone
Homo sapiens
-
isolated from red ascidian Botryllus leachi, imidazole derivative, IC50: 0.0214 mM
11.46
(4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indol-5-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.019
(5Z)-3-chloro-4-(3,5-dibromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.019 mM
0.0008
(5Z)-3-chloro-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-4-(4-hydroxyphenyl)furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.0008 mM
0.02
(5Z)-4-(3,5-dibromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.020 mM
0.013
(5Z)-4-(3-bromo-4-hydroxyphenyl)-3-chloro-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.013 mM
0.048
(5Z)-4-(3-bromo-4-hydroxyphenyl)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.048 mM
0.017
(5Z)-4-(3-bromo-4-hydroxyphenyl)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-chlorofuran-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.017 mM
0.057
(5Z)-5-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-4-(4-hydroxyphenyl)furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.057 mM
0.046
(5Z)-5-[(3-bromo-4-hydroxyphenyl)methylidene]-3-chloro-4-(4-hydroxyphenyl)furan-2(5H)-one
Homo sapiens
-
isolated from ascidians Ritterella rubra and Synoicum blochmanni, IC50: 0.046 mM
2.75
(6H-indolo[2,3-b]quinoxalin-6-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
9.95
(7H-indolo[2',3':5,6][1,2,4]triazino[2,3-a]benzimidazol-7-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.33
(8-methyl-3-[[2-oxo-2-(propylamino)ethyl]sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.019
(E)-3-(5-(3-nitrophenyl)furan-2-yl)acrylic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0203
(Z)-2-(5-biphenyl-4-ylmethylene-2,4-dioxothiazolidin-3-yl)-N-hydroxyacetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.00734
(Z)-2-[5-(4-benzyloxybenzylidene)-2,4-dioxothiazolidin-3-yl]-N-hydroxyacetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.00652
(Z)-2-[5-(4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.0042
(Z)-N-hydroxy-2-(5-naphthalen-1-ylmethylene-2,4-dioxothiazolidin-3-yl)acetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.0127
(Z)-N-hydroxy-2-[2,4-dioxo-5-(3-phenoxybenzylidene)-thiazolidin-3-yl]acetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.00367
(Z)-N-hydroxy-2-[2,4-dioxo-5-(4-phenoxybenzylidene)-thiazolidin-3-yl]acetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.00179
(Z)-N-hydroxy-2-[5-(4-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetamide
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.07764
([2-[(4-methoxy-1-methyl-1H-indazol-3-yl)amino]-2-oxoethyl]sulfanyl)acetic acid
Homo sapiens
-
0.0111
1'-(4-fluorobenzene-1-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
Homo sapiens
pH 6.2, 33°C
0.00375
1'-(5-chlorothiophene-2-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
Homo sapiens
pH 6.2, 33°C
0.00776
1-(4-fluorophenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.00253
1-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.00872
1-(4-methylphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.00478
1-(5-chlorothiophen-2-yl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.008
1-O-Galloyl-beta-D-glucose
Homo sapiens
pH and temperature not specified in the publication
0.012
17alpha-estradiol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.003
17beta-estradiol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.03561
2,1,3-benzoxadiazol-5-yl 5-chlorothiophene-2-sulfonate
Homo sapiens
-
0.5271
2,2'-[sulfonylbis(benzene-4,1-diyliminomethylylidene)]dipropanedinitrile
Homo sapiens
-
4.41
2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione
Homo sapiens
pH and temperature not specified in the publication
0.0303
2-(3,4-dimethoxyphenyl)-ethanoic acid
Homo sapiens
-
IC50: 0.0303 mM
0.0185
2-(4-hydroxy-3-methoxyphenyl)ethanoic acid
Homo sapiens
-
derived from ginger rhizom, Zingiber officinale, IC50: 0.0185 mM, suppresses nt only sorbitol accumulation in human erythrocytes
0.0192
2-(4-hydroxy-3-methoxyphenyl)ethanol
Homo sapiens
-
derived from ginger rhizom, Zingiber officinale, IC50: 0.0192 mM, suppresses sorbitol accumulation in human erythrocytes
0.0265
2-amino-4-oxo-3,4-dihydropteridine-7-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.00086
2-oxo-3-(3,4,5-trihydroxyphenoxy)-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00757
2-oxo-3-(3,4,5-trimethoxyphenoxy)-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00857
2-oxo-3-phenoxy-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0251
2-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]-4-phenylbutanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.00162
3'-(4-fluorobenzene-1-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
Homo sapiens
pH 6.2, 33°C
0.00491
3'-(5-chlorothiophene-2-sulfonyl)spiro[fluorene-9,4'-imidazolidine]-2',5'-dione
Homo sapiens
pH 6.2, 33°C
0.4812
3,4-dinitro-2,5-bis(phenylsulfanyl)thiophene
Homo sapiens
-
0.127
3,5-dichlorosalicylic acid
Homo sapiens
ALR2 in 50 mM potassium phosphate (pH 6.2)
53.54
3-(1H-indol-1-yl)propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0765
3-(2,4-dihydroxyphenyl)-5-hydroxy-7-methoxy-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
Homo sapiens
-
pH 7.0, 37°C
0.022
3-(2-phenylthiazole-4-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.00031
3-(3,4-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00568
3-(3,4-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00236
3-(3,5-dihydroxy-4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000087
3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0043
3-(3,5-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00453
3-(3-hydroxy-4,5-dimethoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0025
3-(3-hydroxy-4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00285
3-(3-hydroxy-5-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00768
3-(4-fluorophenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.283
3-(4-hydroxy-3-methoxyphenyl)propanol
Homo sapiens
-
IC50: 0.283 mM
0.00012
3-(4-hydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00268
3-(4-methoxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00831
3-(4-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.00353
3-(4-methylphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.1073
3-(4-nitrophenyl)-2-[(phenylsulfonyl)amino]propanoic acid
Homo sapiens
-
0.0019 - 0.014
3-(5-(3-(trifluormethyl)phenyl)thiophene-2-yl)propanoic acid
0.003
3-(5-(3-acetylphenyl)furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.016
3-(5-(3-aminophenyl)furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0068
3-(5-(3-methoxyphenyl)furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0054
3-(5-(3-methoxyphenyl)thiophene-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0057
3-(5-(3-methylphenyl)furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0049
3-(5-(3-methylphenyl)thiophene-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.004
3-(5-(3-methylsulfonyl)phenylfuran-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.00026
3-(5-(3-nitrophenyl)furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.00017
3-(5-(3-nitrophenyl)thiophene-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.002
3-(5-(3-trifluormethyl)phenylfuran-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.00047
3-(5-chlorothiophen-2-yl)-1,3-diazaspiro[4.5]decane-2,4-dione
Homo sapiens
pH 6.2, 33°C
0.016
3-(5-phenylfuran-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0053
3-(5-phenylthiophene-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.031
3-(5-pyridine-2-yl-furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.019
3-(5-pyridine-3-yl-furan-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.03108
3-benzyl-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl 4-methylbenzenesulfonate
Homo sapiens
-
0.2808
3-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-4H-chromen-4-one
Homo sapiens
-
pH 7.0, 37°C
19.85
3-[3-[(diethylamino)methyl]-1H-indol-1-yl]propanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.197
4-(4-hydroxy-3-methoxyphenyl)-2-butanone
Homo sapiens
-
IC50: 0.197 mM
0.642
4-(4-hydroxy-3-methoxyphenyl)butanol
Homo sapiens
-
IC50: 0.642 mM
0.0031
4-(5-(3-methylphenyl)thiophene-2-yl)butanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0064
4-(5-phenylthiophene-2-yl)butanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0016
4-androsten-17beta-ol-3-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0005
4-androstene-3,17-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.273
4-hydroxy-3-methoxyphenol
Homo sapiens
-
IC50: 0.273 mM
0.0244
4-hydroxy-3-methoxyphenyl methanol
Homo sapiens
-
IC50: 0.0244 mM
0.0041
4-oxo-4-(5-(3-methylphenyl)thiophene-2-yl)butanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0065
4-oxo-4-(5-phenylthiophen-2-yl)butanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.0025
4-pregenene-21-ol-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.017
4-pregnene-11beta,17alpha,21-triol-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.005
4-pregnene-11beta,21-diol-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0022
4-pregnene-17alpha,21-diol-3,11,20-trione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.022
4-pregnene-18-al-11beta,21-diol-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0255
4-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]butanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.00119 - 0.00392
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
0.1762
4-[5,7-dimethoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl]benzene-1,3-diol
Homo sapiens
-
pH 7.0, 37°C
0.1306
4-[7-hydroxy-5-methoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl]benzene-1,3-diol
Homo sapiens
-
pH 7.0, 37°C
0.0011
5-androsten-3beta-ol-17-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00023
5-cholenic acid-3beta-ol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0853
5-oxo-3-phenyl-5-(quinolin-2-ylamino)pentanoic acid
Homo sapiens
-
0.0117
5-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]pentanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0057
5alpha-Androstan-17alpha-ol-3-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00051
5alpha-androstan-17beta-ol-3-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0027
5alpha-Androstan-3alpha-ol-17-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00032
5alpha-Androstan-3beta-ol-17-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00039
5alpha-androstane-3,17-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0046
5alpha-androstane-3alpha,17beta-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00052
5alpha-Androstane-3beta,17beta-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.000064
5alpha-cholanic acid-3beta-ol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0005
5alpha-pregnan-3beta-ol-20-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00037
5alpha-pregnane-21-ol-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00044
5alpha-pregnane-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0042
5beta-androstan-17beta-ol-3-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0048
5beta-Androstan-3alpha-ol-17-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00033
5beta-androstan-3beta-ol-17-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0021
5beta-androstane-3,17-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0016
5beta-androstane-3beta,17beta-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.04
5beta-cholan-24-ol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.000052
5beta-cholanic acid
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.018
5beta-cholanic acid methyl ester
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00011
5beta-cholanic acid-3-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00021
5beta-cholanic acid-3alpha,12alpha-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00026
5beta-cholanic acid-3alpha,6alpha-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0022
5beta-cholanic acid-3alpha,7alpha,12alpha-triol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0011
5beta-cholanic acid-3alpha,7alpha-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00078
5beta-cholanic acid-3alpha,7beta-diol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00012
5beta-cholanic acid-3alpha-ol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.000027
5beta-cholanic acid-3beta-ol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00055
5beta-Pregnan-3alpha-ol-20-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00044
5beta-Pregnan-3beta-ol-20-one
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00078
5beta-pregnane-3,20-dione
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.000056
6-bromo-3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000023
6-chloro-3-(3,5-dihydroxyphenoxy)-2-oxo-1,8-naphthyridine-1(2H)-carboxylic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00402
6-[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino]hexanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.00079
8-lavandulylkaempferol
Homo sapiens
-
-
0.001
8-methoxy-N-[(1S)-2-methyl-1-(5-phenyl-1H-imidazol-2-yl)propyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000731
8-methoxy-N-[(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000899
8-methoxy-N-[[5-(4-methoxyphenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.003
bezafibrate
Homo sapiens
-
noncompetitive, IC50: 0.003 mM, recombinant enzyme
0.0007
butein
Homo sapiens
-
in 0.1 M sodium phosphate buffer (pH 6.2)
0.00086
ciprofibrate
Homo sapiens
-
competitive, IC50: 0.00086 mM, recombinant enzyme
0.0012
Clofibric acid
Homo sapiens
-
noncompetitive, IC50: 0.0012 mM, recombinant enzyme
0.1873
coptisine
Homo sapiens
-
in 100 mM sodium phosphate buffer (pH 6.2)
0.00045
desmethylanhydroicaritin
Homo sapiens
-
-
0.000045 - 0.0013
epalrestat
0.1681
epiberberine
Homo sapiens
-
in 100 mM sodium phosphate buffer (pH 6.2)
0.025
estriol
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.0016
estrone
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00056
fenofibrate
Homo sapiens
-
competitive, IC50: 0.00056 mM, recombinant enzyme
0.000026 - 0.033
fidarestat
0.0525
folic acid
Homo sapiens
pH and temperature not specified in the publication
0.0065
gemfibrozil
Homo sapiens
-
noncompetitive, IC50: 0.0065 mM, recombinant enzyme
0.0071
glycochenodeoxycholic acid
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.00071
glycolithocholic acid
Homo sapiens
in 0.1 M potassium phosphate, pH 7.4, at 25°C
0.1542
groenlandicine
Homo sapiens
-
in 100 mM sodium phosphate buffer (pH 6.2)
0.00928
indomethacin
Homo sapiens
pH 6.2, temperature not specified in the publication, ALR2
0.0275
isoliquiritigenin
Homo sapiens
-
pH 7.0, 37°C
0.00027
kuraridin
Homo sapiens
-
-
0.00085
kushenol E
Homo sapiens
-
-
0.000005 - 0.027
lidorestat
0.0219
liquiritigenin
Homo sapiens
-
pH 7.0, 37°C
0.0006
lukianol B
Homo sapiens
-
IC50: 0.0006 mM
0.00028
minalrestat
Homo sapiens
ALR2 in 50 mM potassium phosphate (pH 6.2)
0.0175
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-beta-alanine
Homo sapiens
pH and temperature not specified in the publication
0.0124
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-alanine
Homo sapiens
pH and temperature not specified in the publication
0.069
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-isoleucine
Homo sapiens
pH and temperature not specified in the publication
0.0617
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-leucine
Homo sapiens
pH and temperature not specified in the publication
0.046
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-phenylalanine
Homo sapiens
pH and temperature not specified in the publication
0.0292
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-serine
Homo sapiens
pH and temperature not specified in the publication
0.216
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-tyrosine
Homo sapiens
pH and temperature not specified in the publication
0.0834
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)-L-valine
Homo sapiens
pH and temperature not specified in the publication
0.00197
N-(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)glycine
Homo sapiens
pH and temperature not specified in the publication
0.00367
N-cyclopropyl-N-[cyclopropyl(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.003072
N-cyclopropyl-N-[cyclopropyl(5-phenyl-1H-imidazol-2-yl)methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000222
N-cyclopropyl-N-[cyclopropyl[5-(pyridin-3-yl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000146
N-cyclopropyl-N-[cyclopropyl[5-(pyridin-3-yl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.009
N-galloyl beta-D-glucopyranosylamine
Homo sapiens
pH and temperature not specified in the publication
0.00022
N-[(1S)-1-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-methylpropyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000771
N-[(1S)-1-[5-(4-bromophenyl)-1H-imidazol-2-yl]-2-methylpropyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.00429
N-[(1S)-2-methyl-1-(5-phenyl-1H-imidazol-2-yl)propyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.002122
N-[(5-phenyl-1H-imidazol-2-yl)methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000732
N-[[5-(4-bromophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000091
N-[[5-(4-bromophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000337
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl](cyclopropyl)methyl]-N-cyclopropyl-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000031
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl](cyclopropyl)methyl]-N-cyclopropyl-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000114
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000065
N-[[5-(4-chlorophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.00042
N-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000071
N-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-8-methoxy-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.000275
N-[[5-(4-methoxyphenyl)-1H-imidazol-2-yl]methyl]-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 6.2, 30°C
0.0241
N2-(2-methylaminobenzoyl)tetrahydro-1H-pyrido[3,4-b]indol-1-one
Homo sapiens
-
pH not specified in the publication, temperature not specified in the publication
0.0026
naringenin
Homo sapiens
pH 6.2, 25°C
0.16
piplartine
Homo sapiens
-
pH 7.4, 37°C
0.0387
pyrazolo[5,1-c][1,2,4]benzotriazin-8-yl dimethylcarbamate
Homo sapiens
-
0.00254 - 0.027
quercetin
0.0106
semilicoisoflavone B
Homo sapiens
-
pH 6.2, 37°C
0.00141 - 0.0036
sorbinil
0.0013
sulfuretin
Homo sapiens
-
in 0.1 M sodium phosphate buffer (pH 6.2)
0.000374
sulindac
Homo sapiens
pH 6.2, temperature not specified in the publication, ALR2
0.000279
sulindac sulfide
Homo sapiens
pH 6.2, temperature not specified in the publication, ALR2
0.000367
sulindac sulfone
Homo sapiens
pH 6.2, temperature not specified in the publication, ALR2
0.00239
Tolmetin
Homo sapiens
pH 6.2, temperature not specified in the publication, ALR2
0.00026
Tolrestat
Homo sapiens
ALR2 in 50 mM potassium phosphate (pH 6.2)
0.00006
zopolrestat
Homo sapiens
-
competitive, IC50: 0.00006 mM, recombinant enzyme
0.0426
[(2-amino-4-oxo-3,4-dihydropteridine-7-carbonyl)amino](phenyl)acetic acid
Homo sapiens
pH and temperature not specified in the publication
3.46
[(5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.000308
[2-oxo-8-[(E)-2-phenylethenyl]-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
13.76
[3-(2,2-dimethylpropanoyl)-1H-indol-1-yl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.00018
[3-(2,4-dihydroxyphenyl)-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00087
[3-(2,5-dihydroxyphenyl)-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000007 - 0.1
[3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
30.14
[3-[(diethylamino)methyl]-1H-indol-1-yl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
42.16
[3-[(dimethylamino)methyl]-2-methyl-1H-indol-1-yl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.00016
[3-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0001
[3-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00019
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00021
[3-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0001
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00006
[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
34.52
[3-[(morpholin-4-yl)methyl]-1H-indol-1-yl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
2.05
[3-[(propan-2-yl)sulfanyl]-5H-[1,2,4]triazino[5,6-b]indol-5-yl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
46.48
[3-[(pyrrolidin-1-yl)methyl]-1H-indol-1-yl]acetic acid
Homo sapiens
pH and temperature not specified in the publication
0.00098
[3-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-6-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00085
[3-[2-(4-hydroxy-3-methoxyphenyl)ethyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00051
[3-[2-(4-hydroxyphenyl)ethyl]-7-methoxy-2-oxoquinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.0002
[5-(3-carboxymethoxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
Homo sapiens
ALR2, pH 6.7, temperature not specified in the publication
0.00066
[5-(3-hydroxy-4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl]acetic acid
Homo sapiens
ALR2, pH 6.7, temperature not specified in the publication
0.0002
[5-(4-bromophenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.00019
[5-(4-chlorophenyl)-1-oxo-3-propylpyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.00012
[5-(4-chlorophenyl)-3-ethyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.00041
[5-(4-chlorophenyl)-3-ethyl-9-fluoro-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.00021
[5-(4-chlorophenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.00035
[5-(4-chlorophenyl)-9-fluoro-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.000012 - 0.1012
[6-ethyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
0.0194
[6-hydroxy-3-(4-hydroxyphenoxy)pyrazin-2-yl](4-hydroxyphenyl)methanone
Homo sapiens
-
isolated from red ascidian Botryllus leachi, pyrazine derivative, IC50: 0.0194 mM
0.00027
[6-methoxy-2-oxo-3-(2,4,6-trihydroxyphenyl)quinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.000008 - 0.1
[6-methyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
0.00017
[7-methoxy-2-oxo-3-(2,4,6-trihydroxyphenyl)quinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00092
[7-methoxy-2-oxo-3-[(E)-2-phenylethenyl]quinoxalin-1(2H)-yl]acetic acid
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00105
[8-(4-formylphenyl)-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000774
[8-(4-methoxyphenyl)-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000167
[8-[(E)-2-(4-fluorophenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000188
[8-[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000082
[8-[(E)-2-(4-hydroxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000208
[8-[(E)-2-(4-methoxyphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.00022
[8-[(E)-2-(4-methylphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000262
[8-[(E)-2-(4-nitrophenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.00017
[8-[(E)-2-(4-tert-butylphenyl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.000281
[8-[(E)-2-([1,1'-biphenyl]-4-yl)ethenyl]-2-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl]acetic acid
Homo sapiens
30°C, pH 6.2
0.00026
[9-fluoro-5-(4-methoxyphenyl)-3-methyl-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
Homo sapiens
pH 7.5, 25°C
0.05887
[[(4-methylphenyl)sulfonyl](2-thiophen-2-ylethyl)amino]acetic acid
Homo sapiens
-
additional information
additional information
Homo sapiens
-
gallic acid IC50: 0.0973 mg/ml, p-coumaric acid IC50: 0.1623 mg/ml, syringic acid IC50: 0.1721 mg/ml, trans-cinnamic acid IC50: 0.0681 mg/ml, p-catechuic acid IC50: 0.0427 mg/ml, quercetin IC50: 0.02523 mg/ml (in 50 mM sodium potassium phosphate buffer (pH 6.0) containing 5 mM beta-mercaptoethanol, 0.7 M NADPH, 0.4 M Li2SO4, and 2.5 mM of DL-glyceraldehyde)
-
0.0019
3-(5-(3-(trifluormethyl)phenyl)thiophene-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.014
3-(5-(3-(trifluormethyl)phenyl)thiophene-2-yl)propanoic acid
Homo sapiens
in sodium phosphate buffer (100 mM, pH 6.2)
0.00119
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
Homo sapiens
-
0.00392
4-[3-(5-oxo-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-6-yl)-1,2,4-oxadiazol-5-yl]butanoic acid
Homo sapiens
-
0.01
curcumin
Homo sapiens
pH 6.0, 30°C, ALR2
0.03
curcumin
Homo sapiens
pH 7.0, 37°C, AKR1B10
0.000045
epalrestat
Homo sapiens
pH 6.2, 30°C
0.0000665
epalrestat
Homo sapiens
pH and temperature not specified in the publication
0.000089
epalrestat
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00009
epalrestat
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00011
epalrestat
Homo sapiens
pH 6.2, temperature not specified in the publication, ALR2
0.00028
epalrestat
Homo sapiens
-
-
0.0013
epalrestat
Homo sapiens
-
in 0.1 M sodium phosphate buffer (pH 6.2)
0.000026
fidarestat
Homo sapiens
pH 7.0, 25°C, recombinant detagged enzyme
0.0018
fidarestat
Homo sapiens
pH 7.0, 25°C, recombinant detagged enzyme
0.033
fidarestat
Homo sapiens
pH 7.0, 25°C, recombinant detagged wild-type enzyme
0.000005
lidorestat
Homo sapiens
-
ALR2, pH not specified in the publication, temperature not specified in the publication
0.027
lidorestat
Homo sapiens
-
ALR1, pH not specified in the publication, temperature not specified in the publication
0.00254
quercetin
Homo sapiens
-
-
0.00592
quercetin
Homo sapiens
ALR2 in 50 mM potassium phosphate (pH 6.2)
0.0127
quercetin
Homo sapiens
-
pH 7.0, 37°C
0.027
quercetin
Homo sapiens
-
IC50: 0.027 mM
0.00141
sorbinil
Homo sapiens
in 0.25 M potassium phosphate buffer pH 6.8, at 37°C
0.0021
sorbinil
Homo sapiens
-
competitive, IC50: 0.0021 mM, recombinant enzyme
0.0036
sorbinil
Homo sapiens
-
orally active inhibitor, IC50: 0.0036 mM
0.000007
[3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
Homo sapiens
-
ALR2, pH not specified in the publication, temperature not specified in the publication
0.1
[3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
Homo sapiens
-
above, ALR1, pH not specified in the publication, temperature not specified in the publication
0.000012
[6-ethyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
Homo sapiens
-
ALR2, pH not specified in the publication, temperature not specified in the publication
0.1012
[6-ethyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
Homo sapiens
-
above, ALR1, pH not specified in the publication, temperature not specified in the publication
0.000008
[6-methyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
Homo sapiens
-
ALR2, pH not specified in the publication, temperature not specified in the publication
0.1
[6-methyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acid
Homo sapiens
-
above, ALR1, pH not specified in the publication, temperature not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.1.1.21 aldose reductase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
